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DUPUYTREN’S DISEASE: Measure. Compare. Predict?  
 
1. In carefully selected patients, percutaneous needle aponeurotomy and Collagenase 
injection can be just as effective as limited fasciectomy at reducing contractures 
within the first 3 months of treatment. (this thesis)   
2. Propensity score analyses enable investigators to make valid inferences about the 
comparative effectiveness of treatments for Dupuytren’s disease using real-world 
data. (this thesis) 
3. People with Dupuytren’s contracture care about the appearance of their hand, and 
so should providers if they seek to improve satisfaction. (this thesis) 
4. Open surgery is still the closest thing to a cure for Dupuytren’s contracture. (this 
thesis) 
5. Although the number of procedures a surgeon performs for Dupuytren’s disease 
influences outcomes, patient factors matter more. (this thesis) 
6. Studies comparing surgical techniques for Dupuytren’s disease should account for 
the expertise of the surgeons in order to minimize the risk of bias. (this thesis) 
7. Surgeons should not fear the eccentricity of lipofilling or Collagenase as a treatment 
for Dupuytren’s contracture, for every treatment now accepted was once eccentric.  
8. Despite the large number of studies describing outcomes of treatments for 
Dupuytren’s disease, little high-quality evidence is available to guide decision-
making between these treatments. 
9. “In all affairs, including the treatment of Dupuytren’s disease, it’s a healthy thing now 
and then to hang a question mark on the things you have long taken for granted.” 
Adaptation from B. Russell, mathematician and Nobel laureate. (1)  
10. “Basic research efforts are needed to fully unravel the pathogenesis of Dupuytren’s 
disease and offer the greatest promise to find a cure.” Adaptation from G. Dolmans 
and P. Werker et al. (2) 
11. “Most people use statistics like a drunk man uses a lamp post; more for support than 
illumination.” A.E. Housman, classicist and poet. (3) 
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Introduction 
Dupuytren’s disease is a chronic, mostly progressive, debilitating disease of the palmar 
and digital fascial structures of the hand.1 It is characterized by the nodular thickening 
and contracture of these structures. Patients experience varying degrees of functional 
impairment and diminished quality-of-life2, depending on how the disease has manifested 
itself. The search for better treatments for the disease has both challenged and attracted 
clinicians and scientists over the past decades.3 
 
Epidemiology 
Dupuytren’s disease occurs in people from various ethnicities.4 Prevalence, however, is 
highest among those of northern European ancestry. Historically, the disease has 
therefore been referred to as a Nordic as well as a Viking’s disease.5 Overall prevalence 
estimates range from 2 to 22% in study populations in the Netherlands, which vary 
depending on the definition of disease and geographical location sampled.6 Incidence 
increases with advancing age and men are six times more often affected than women.7 
Genetic and environmental risk factors have both been identified for Dupuytren’s 
disease.8 Studies have suggested an autosomal dominant inheritance pattern with 
variable penetrance.9 Risk factors that have been reported include repetitive trauma, 
epilepsy, smoking, diabetes and alcoholism.10 These relations, however, were generally 
weak, suggesting that they exacerbate an underlying genetic predisposition rather than 
being an independent risk factor for developing the disease.1 
 
History 
Contrary to common belief, Guillaume Dupuytren was not the first to describe the 
disease. Instead it was probably Felix Plater who did so in 1614 in Observationum in 
Hominis affectibus. Herein, he described a role of the palmar fascia in the development 
of the observed contractures.15 Guillaume Dupuytren did, however, provide one of the 
most thorough descriptions of the disease during a series of lectures at Hotel-Dieu, 
Paris, in December 5th, 1831. He reported a case with contractures affecting his ring and 
little fingers whom he treated with what now would be considered an open 
fasciotomy approach. It is believed that, in part, these lectures and subsequent reports 
Introduction 
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on the disease increased awareness for the disease, eventually resulting the disease to 
be named after him instead of Felix Plater. 
 
Anatomy and disease manifestation 
The superficial and deep fascias of the palm provide a firm but mobile framework for the 
soft tissues of the palm to adhere to. In Dupuytren’s disease, the normal superficial 
palmar fascia (palmar aponeurosis) transforms to thickened pathologic cords. This is the 
result of the contractile forces generated by myofibroblasts and deposition of Collagen 
type I and III.11 In contrast, the deep fascia is not involved.  
The formation of nodules and lumps that develop into fibrotic cords, which can 
then lead to contractures over time, characterizes the natural course of disease: this 
progression is pathognomonic (Figure 1). A diagnosis is usually made when patients 
present somewhere along this disease spectrum. The earliest clinical signs, however, are 
dimpling and pits in the palmar skin, which precedes nodule formation. Although pits, 
nodules, and cords form anywhere from finger tip to as proximal as the wrist crease, 
they usually occur in the ulnar region of the palm.12 While complaints associated with 
these pits and nodules include tightness and/or discomfort to pressure at the palm of the 
hand, they typically are pain free.  
	
Figure 1. The characteristic disease progression in Dupuytren’s disease from nodules into cords, 
which then lead to contractures. Source: Patientplus.info.  
With disease progression, longitudinal and (spiral) cords develop mostly from the 
palm that extend into the fingers. The ring and little fingers are most commonly involved. 
Although the course of the digital cords can vary substantially, they mostly do not extend 
past the midphalanx. Usually, the MCP joint becomes affected first, followed by the PIP 
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joint. Alternatively, nodules can form just proximal to the PIP joint creating isolated PIP 
contractures. As a result, patients complain about limitations in daily activities such as 
difficulty in shaking hands, fitting a hand into a pocket, and grasping objects.2,13,14 
 Several lesions and conditions are associated with Dupuytren’s disease, including 
“knuckle pad’s”, Garrod’s nodules and Peyronie’s (penile fibromatosis) and Ledderhose’s 
disease (plantar fibromatosis). Penile fibromatosis is found in a small percentage of 
patients with Dupuytren’s disease (1-3%) and presents as a painless plaque on the dorsum 
of the penis. Plantar fibromatosis is slightly more common (5-20%) and presents as 
nodular thickening of skin of the arch of the foot without contracture of the toes. These 
conditions, however, are beyond the scope of this thesis.   
 
Indications  
Current treatment of Dupuytren’s disease aims to restore hand function and to improve 
disability by reducing the degree of contracture and deformity. Unfortunately, a curative 
therapy has yet to be found. Indications and timing for treatment depend primarily on 
the extent of functional impairment, the degree of contracture, and the joints involved. 
For example, accepted indications for surgery include contracture of 30 degrees at the 
MCP joint level and, for most providers, any degree of contracture at the PIP joint level 
that causes functional impairment. The joint collateral ligaments shorten easily at the PIP 
joint level. Specific additional contractures include small finger abduction contracture, 
and first-web adduction contractures. 
 Absolute contraindications for treatment do no exist. Treatment outcomes are 
poor for longstanding PIP joint contractures. Such cases may require other interventions 
such as arthrolysis, arthrodesis or sometimes even amputation in the most advanced 
cases. Severe tobacco use, previous surgery with or without neurovascular injury, and 
use of anticoagulants increases the risks of treatment, but are considered relative 
contraindications at our centers. 
 
Treatment 
A wide array of treatments for Dupuytren’s contracture exist that may be categorized 
into non-operative, injection, and surgical interventions. Surgery has been the mainstay 
Introduction 
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of treatment because it provides the most long lasting corrections.16 However, all 
existing treatments including surgery are fraught with complications, disease recurrence 
and extension.  
Surgery is typically divided into aponeurotomy (i.e. fasciotomy) and 
aponeurectomy (i.e. fasciectomy) techniques. In aponeurotomy or fasciotomy (Figure 2), 
pathologic tissue and cords are weakened, perforated, and/or divided without actually 
removing any tissue. Fasciotomy or aponeurotomy is mostly performed percutaneously 
but can also be performed through an open approach.17 In fasciectomy or 
aponeurectomy, extensive palmar and digital dissection is performed and the diseased 
fascia is removed. Various fasciectomy techniques differ depending on the extent to 
which the tissue is removed as well as how the skin is managed. Although many 
variations in the two techniques exist,  two of the most popular techniques are 
percutaneous needle aponeurotomy or fasciotomy (PNA) and limited fasciectomy (LF, 
Figure 3).18  
 
Figure 2. Percutaneous needle aponeurotomy/fasciotomy. Source: Patientplus.info. 
                                       Figure 3. Limited fasciectomy. Source: Patientplus.info. 
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Compared with LF, PNA is far less invasive and involves the division of pathologic cords 
at two or more levels under local anesthesia. Traditionally, PNA is considered most 
suitable for mild to moderate contractures at the MCP joint level. Experienced providers, 
however, have dared to travel more distal and found that it can also effectively treat PIP 
contractures. PNA’s largest drawback is that contractures tend to recur more rapidly 
after treatment.16 The only randomized clinical trial comparing PNA with LF found a 85% 
recurrence rate at 5 years compared with 21% for LF.16 In LF, macroscopically abnormal 
tissue is removed in the palm and fingers as mentioned previously. As normal appearing 
fascial structures are still left behind, the risk for disease recurrence remains but is much 
lower. Treatment is under regional of general anesthesia and with the use of an arm 
tourniquet. Fasciectomy can be used to treat the mildest to most severe forms of 
Dupuytren’s contracture. For contractures at the PIP joint and severe cases, it continues 
to be the mainstay of treatment.19  
Injection treatment for Dupuytren’s disease goes back to 1952, when 
corticosteroids were proposed and used as a postoperative adjunct.20 To date, steroid 
injections are considered to have a limited role in the treatment of a painful nodule but 
does not have any efficacy in terms of reducing contractures. The idea of injecting 
enzymes that target and degrade pathologic Dupuytren’s tissue dates back to 1907. 
Hueston reported promising results using a mixture of hyaluronidase, trypsin, and 
xylocaine.21 However, treatment using such non-specific enzymes became unpopular 
because of serious adverse effects including  tendon ruptures and severe neurovascular 
injury. More recently, Collagenase Clostridium Histolyticum (CCH) has emerged as a 
“non-surgical” treatment for Dupuytren’s contracture (Figure 4).22 In CCH, which 
selectively disintegrates collagen, a small volume of collagenase solution is injected into 
the pathologic cord, thereby weakening the treated areas to allow subsequent rupture. 
Over the past years, multiple placebo-controlled randomized clinical trials have 
demonstrated the efficacy and safety of injectable CCH.4,23-30  
Introduction 
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Current issues 
Although Dupuytren’s disease has been treated for over many decades using various 
techniques, it continues to present a challenge for anyone who treats these patients. 
Since the first description of the disease, clinicians and researchers have sought to 
increase our understanding of its etiology, natural course, and explored various methods 
of treatment. Although much progress has been made, the wide array of existing 
treatments highlights the lack of a single ideal treatment that can fully meet the needs of 
each individual patient. In this thesis, we sought to address a number issues we regarded 
as the most controversial from a clinical perspective.  
The first issue relates to the fact that, while many previous studies have reported 
the outcomes of each of the previously mentioned treatments individually, a wide range 
of assessment methods and different definitions for outcomes are used.31 This severely 
impairs the ability to make meaningful comparisons between different treatments – 
some investigators even consider comparison of outcomes across invidivual studies to be 
impossible. A recent Cochrane review on surgery of Dupuytren’s contracture even 
concluded that “Currently, insufficient evidence is available to show the relative 
superiority of different surgical procedures.” Head-to-head comparisons of treatments 
not only helps to fully elucidate their unique pros and cons, but are essential for 
delineating the optimal position of each treatment in the management of Dupuytren’s 
disease. As such, the need for well-designed comparative studies is clear. 
A second issue relates to our incomplete understanding of the patient perspective 
in patients with Dupuytren’s disease. Traditionally, interventional studies have used 
objective measures such as the degree of residual contracture, incidence of 
Figure 4. Injection with Collagenase 
Clostridium Histolyticum. Source: 
Patientplus.info. 
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each individual patient. In this thesis, we sought to address a number issues we regarded 
as the most controversial from a clinical perspective.  
The first issue relates to the fact that, while many previous studies have reported 
the outcomes of each of the previously mentioned treatments individually, a wide range 
of assessment methods and different definitions for outcomes are used.31 This severely 
impairs the ability to make meaningful comparisons between different treatments – 
some investigators even consider comparison of outcomes across invidivual studies to be 
impossible. A recent Cochrane review on surgery of Dupuytren’s contracture even 
concluded that “Currently, insufficient evidence is available to show the relative 
superiority of different surgical procedures.” Head-to-head comparisons of treatments 
not only helps to fully elucidate their unique pros and cons, but are essential for 
delineating the optimal position of each treatment in the management of Dupuytren’s 
disease. As such, the need for well-designed comparative studies is clear. 
A second issue relates to our incomplete understanding of the patient perspective 
in patients with Dupuytren’s disease. Traditionally, interventional studies have used 
objective measures such as the degree of residual contracture, incidence of 
Figure 4. Injection with Collagenase 
Clostridium Histolyticum. Source: 
Patientplus.info. 
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complications and rates of disease recurrence to gauge their efficacy.14 Although these 
provider-centric outcomes probably determine the extent to which patients are satisfied, 
they do not substitute a direct evaluation of patient reported satisfaction and outcomes. 
In the current patient-oriented health care system, patient satisfaction is increasingly 
used as a indicator for the quality of care delivered.32-40 Although this outcome measure 
seems particularly well suited for the evaluation of treatments for Dupuytren’s 
disease, the factors that determine why some patients are satisfied with their outcome 
while others are not remain poorly understood. Research in this area will increase our 
understanding of how patients view their treatments, and may offer unique perspectives 
on the definition of therapeutic success.  
A third issue has to do with the fact that existing treatments are still being 
updated and improved upon. In an attempt to combine the best characteristics of the 
existing treatments, Hovius and Khouri pioneered a surgical procedure that combines an 
extensive form of percutaneous needle release with autologous fat grafting: extensive 
percutaneous aponeurotomy with lipofilling (or in short ‘PALF’).41 Early results of a 
randomized, single-blinded, clinical trial comparing PALF with LF were promising, 
indicating comparable 1-year results in terms of residual contracture.42 However, whether 
this hybrid technique offers results that are just as long-lasting as those from open 
surgery remains an exciting question that has yet to be answered.  
The last issue addressed in this thesis is the considerable variation in treatment 
outcomes across individual patients and what factors influence this variation. Outcomes 
of surgical procedures in Dupuytren’s disease depend on which specific procedure is 
employed, but may also depend on who and how often he or she has performed the 
procedure in the past. For certain major surgical procedures, studies have demonstrated 
clear associations between the number of these procedures a surgeon performs on an 
annual basis (surgeon annual procedure volume) and subsequent outcomes.43-47 
Whether this also the case for Dupuytren’s surgery,  and if so to what extent is currently 
unknown. Insight into what factors may be modified to improve the outcomes of 
Dupuytren’s disease treatment, including surgeon volume, may help to identify 
strategies for improving outcomes. Importantly, the answer to this question also helps to 
inform the current debate regarding who should operate patients with Dupuytren’s 
disease and who not. 
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Efficacy or effectiveness? 
The gap between research and practice is well known. Efficacy is the extent to which a 
(surgical) intervention does more good than harm under ideal circumstances48,49. In 
contrast, effectiveness is the extent to which a (surgical) intervention does more good 
than harm when provided under usual circumstances of health care practice. Variability 
and imperfections in health care delivery explain that the results achieved in 
effectiveness studies (broadly generalizable across populations and settings) 
sometimes do not mirror those seen in efficacy studies (controlled, complex, and more 
standardized). Generally, there is much more known about the efficacy of treatments 
than their effectiveness in the real world. As such, recent reports have highlighted the 
gap between efficacy and effectiveness research as well as the pivotal role of 
observational studies to help bridge this gap. 
 
General aims and outline 
The first aim of this thesis is to examine the comparative effectiveness of LF, PNA and 
CCH – three treatments that have already been demonstrated to be efficacious (Part I). 
The second aim is to examine LF from the patient perspective by using patient 
satisfaction as the primary outcome (Part II). A third aim is to examine the long-term 
efficacy of PALF and compare it with that of LF (Part III). The fourth and last aim is to 
clarify the extent to which the number of procedures a surgeon performs annually for 
Dupuytren’s disease is associated with his or her surgical outcomes (Part IV). This thesis 
is therefore structured accordingly as seen on the next page. 
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Part I. Comparative Effectiveness 
PNA vs. LF. It has been more than a decade since the only randomized trial to date 
was published that compared the efficacy of PNA and LF.18 In the next chapter 
(Chapter 2), the aim was to compare the real-world effectiveness of both treatments 
because the results of such a comparison can support patients in their decision-
making. 
 
CCH vs. LF. CCH is now considered an efficacious and safe treatment for Dupuytren’s 
contracture.50 The aim in Chapter 3 was to compare CCH with LF in terms of both 
objective and subjective outcomes. A secondary aim was to validate propensity score 
matching as a tool that enables valid comparisons between two treatments for 
Dupuytren’s disease using observational data.51 
 
CCH vs. PNA. In Chapter 4, our aim was to compare CCH with PNA because of 
proposed similarities and characteristics between the two treatments. Our secondary 
aim was to focus on possible differences between the two minimally invasive 
treatments in terms of impact on specific domains in hand-function as well as objective 
outcomes such as degree of contracture and complications. 
 
Part II. Patient Satisfaction  
In Chapter 5, we sought to examine patient satisfaction with hand function after 
surgical fasciectomy for Dupuytren’s contracture and determined which preoperative 
patient- and disease-specific factors predicted this satisfaction. 
 
Part III. Long-Term Comparative Efficacy of PALF 
In Chapter 6, the aim was to report the long-term results of a randomized, controlled, 
single-blinded clinical trial comparing the efficacy of PALF with LF.42 
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Part IV. Volume and Outcomes  
In Chapter 7, we aimed to clarify the possible relations between annual surgeon 
procedure volume and three important objective outcomes of Dupuytren’s surgery 
among a group of fully practicing hand-surgeons. 
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Part IV. Volume and Outcomes  
In Chapter 7, we aimed to clarify the possible relations between annual surgeon 
procedure volume and three important objective outcomes of Dupuytren’s surgery 
among a group of fully practicing hand-surgeons. 
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Abstract 
Background: Percutaneous needle aponeurotomy is a less invasive surgical alternative to 
limited fasciectomy for Dupuytren's contracture, but appeared less efficacious in a 
previous randomized clinical trial. This study compared the effectiveness of both 
techniques in contemporary clinical practice. 
Methods: The authors evaluated prospectively gathered data from all patients who were 
treated with percutaneous needle aponeurotomy or limited fasciectomy between 2011 
and 2014 at six hand surgery practice sites in The Netherlands. The degree of total active 
extension deficit, Michigan Hand Outcomes Questionnaire subscores, and complications 
evaluated at 6 to 12 weeks after treatment were compared after propensity score-based 
inverse-probability weighting to account for the differences in baseline characteristics 
between the treatment groups. 
Results: After inverse-probability weighting, 78 percutaneous needle aponeurotomy 
patients and 103 limited fasciectomy patients remained with similar characteristics (88 
percent Tubiana grade I or II). The degree of total residual extension deficit at follow-up 
was similar between the weighted groups (percutaneous needle aponeurotomy, 21 
degrees; limited fasciectomy, 18 degrees; p = 0.330). Furthermore, percutaneous needle 
aponeurotomy was associated with a lower mild complication rate (percutaneous needle 
aponeurotomy, 5.2 percent; limited fasciectomy, 24.3 percent; p < 0.001) and larger 
increases in the subdomain scores of satisfaction (p < 0.001), work performance (p < 
0.001), activities of daily living (p = 0.009), and overall hand function (p = 0.001). 
Conclusions: This multicenter observational study found that, among patients with mildly 
to moderately affected digits, percutaneous needle aponeurotomy reduced contractures 
as effectively as limited fasciectomy does in clinical practice. Furthermore, percutaneous 
needle aponeurotomy provided a more rapid functional recovery and had a lower rate of 
mild complications. 
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Introduction 
Although novel techniques for treating Dupuytren’s contracture, such as collagenase 
injection1, have emerged, surgery remains the mainstay of treatment. Two of the most 
commonly used surgical techniques are Limited Fasciectomy (LF) and Percutaneous 
Needle Aponeurotomy (PNA). LF continues to be the most established technique for 
proximal interphalangeal joint (PIP) contractures and advanced cases. PNA is an 
accepted surgical alternative to LF that seeks to minimize complications and morbidity. 
Questions, however, persist regarding the comparative effectiveness of PNA and 
LF. Numerous studies have described the results for each technique separately but 
recent reviews of these studies have underscored the complexity of making meaningful 
comparisons because of differences in study populations and definitions for outcomes.2-4 
To date, there has been one randomized clinical trial comparing PNA and LF.5 In this 
study, PNA resulted in 18% less reduction in total passive extension deficit evaluated at 6 
weeks postoperatively, primarily due to PNA’s inferior efficacy for advanced cases.  As a 
consequence, the authors concluded that PNA seemed particularly useful for treating 
patients with mild to moderate disease.  
As of this writing, nearly a decade has past since the publication of the 
abovementioned trial, which should have allowed sufficient time to pass for its findings 
to disseminate into contemporary practice. This study compared the effectiveness of 
PNA and LF using prospectively gathered data from 6 different hand surgery practice 
sites in the Netherlands.  
2Chapter 2	
	 26	
 
Abstract 
Background: Percutaneous needle aponeurotomy is a less invasive surgical alternative to 
limited fasciectomy for Dupuytren's contracture, but appeared less efficacious in a 
previous randomized clinical trial. This study compared the effectiveness of both 
techniques in contemporary clinical practice. 
Methods: The authors evaluated prospectively gathered data from all patients who were 
treated with percutaneous needle aponeurotomy or limited fasciectomy between 2011 
and 2014 at six hand surgery practice sites in The Netherlands. The degree of total active 
extension deficit, Michigan Hand Outcomes Questionnaire subscores, and complications 
evaluated at 6 to 12 weeks after treatment were compared after propensity score-based 
inverse-probability weighting to account for the differences in baseline characteristics 
between the treatment groups. 
Results: After inverse-probability weighting, 78 percutaneous needle aponeurotomy 
patients and 103 limited fasciectomy patients remained with similar characteristics (88 
percent Tubiana grade I or II). The degree of total residual extension deficit at follow-up 
was similar between the weighted groups (percutaneous needle aponeurotomy, 21 
degrees; limited fasciectomy, 18 degrees; p = 0.330). Furthermore, percutaneous needle 
aponeurotomy was associated with a lower mild complication rate (percutaneous needle 
aponeurotomy, 5.2 percent; limited fasciectomy, 24.3 percent; p < 0.001) and larger 
increases in the subdomain scores of satisfaction (p < 0.001), work performance (p < 
0.001), activities of daily living (p = 0.009), and overall hand function (p = 0.001). 
Conclusions: This multicenter observational study found that, among patients with mildly 
to moderately affected digits, percutaneous needle aponeurotomy reduced contractures 
as effectively as limited fasciectomy does in clinical practice. Furthermore, percutaneous 
needle aponeurotomy provided a more rapid functional recovery and had a lower rate of 
mild complications. 
 
PNA vs. LF 
	
 27	
Introduction 
Although novel techniques for treating Dupuytren’s contracture, such as collagenase 
injection1, have emerged, surgery remains the mainstay of treatment. Two of the most 
commonly used surgical techniques are Limited Fasciectomy (LF) and Percutaneous 
Needle Aponeurotomy (PNA). LF continues to be the most established technique for 
proximal interphalangeal joint (PIP) contractures and advanced cases. PNA is an 
accepted surgical alternative to LF that seeks to minimize complications and morbidity. 
Questions, however, persist regarding the comparative effectiveness of PNA and 
LF. Numerous studies have described the results for each technique separately but 
recent reviews of these studies have underscored the complexity of making meaningful 
comparisons because of differences in study populations and definitions for outcomes.2-4 
To date, there has been one randomized clinical trial comparing PNA and LF.5 In this 
study, PNA resulted in 18% less reduction in total passive extension deficit evaluated at 6 
weeks postoperatively, primarily due to PNA’s inferior efficacy for advanced cases.  As a 
consequence, the authors concluded that PNA seemed particularly useful for treating 
patients with mild to moderate disease.  
As of this writing, nearly a decade has past since the publication of the 
abovementioned trial, which should have allowed sufficient time to pass for its findings 
to disseminate into contemporary practice. This study compared the effectiveness of 
PNA and LF using prospectively gathered data from 6 different hand surgery practice 
sites in the Netherlands.  
Chapter 2	
	 28	
Methods 
This is a retrospective study of data from a consortium of 6 hand surgery practice sites. 
Data were gathered in a registry that was developed for research and quality 
improvement purposes, and included a wide range of patient and treatment 
characteristics. Patient characteristics included age, gender, comorbidities, bilateral and 
recurrent disease, and family history. Treatment characteristics included the technique 
used, digits treated and the joint levels affected. Our institutional review board approved 
the study protocol and waived the requirement for informed consent due to the 
retrospective nature of the study. 
For this study, all patients who underwent PNA or LF between October 2011 and 
March 2014 at one of the practice sites were identified. We restricted our analyses to 
patients with available pre-operative data on the degree of contracture. There were no 
significant differences in the characteristics of patients with and without data available. 
In addition, we excluded patients with thumb contractures, isolated MP contractures 
with less than 20 degrees of contracture who were treated for other purposes than 
functional disability, and those with a concomitant hand condition or simultaneously 
undergoing another procedure (e.g. carpal tunnel release) on the treated side to prevent 
confounding of outcome assessments. Patients treated for recurrent disease were 
included if they met all other criteria. 
 
Treatments 
Treatments were performed by one of the 17 hand surgeons of the practice sites through 
shared decision-making.  
LF was performed in an operating theatre with tourniquet exsanguination and 
loupe magnification under axillary block or general anesthesia. Cords were excised after 
Bruner type or longitudinal incisions with Z-plasties. Care was taken to prevent injury to 
the digital neurovascular bundles. Compressive dressings were applied for 2 weeks. All 
patients were offered a supervised program of hand therapy with instructed use of 
removable night splints for 3 months. 
PNA was performed under local anesthesia. Cords were released using 25 gauge 
needles at as many levels as possible in the palm and fingers. Patients were instructed to 
report paresthesias to avoid nerve injury. After release, the treated digit was extended 
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with a progressive force to maximize contracture reduction. Patients were encouraged 
to flex and extend their fingers immediately following treatment and to restart normal 
use of their hands after 24 hours. Patients were offered identical rehabilitation and 
splinting programs as patients undergoing LF.   
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Outcomes 
The primary outcome was the degree of total residual extension deficit. Certified hand-
therapists examined patients before and at visits occurring between 6 and 12 weeks after 
surgery. The degree of extension deficit was assessed using a finger goniometer by 
summing up the degree of active extension deficit at the MP, PIP and DIP joint levels for 
each affected digit. Hyperextension at the individual joints was defined as 0 degrees to 
prevent underestimation of extension deficit. To increase comparability between 
patients with single versus multiple digit involvement, we used data from the digit that 
was most severely affected at baseline (e.g. highest total extension deficit). 
The impact of PNA and LF on patient-reported hand function was assessed using 
the Michigan Hand Questionnaire (MHQ). The MHQ is a self-reported 37-item hand-
specific assessment tool evaluating 6 aspects of hand function for each hand separately: 
overall hand function, ability to perform activities in daily life (ADL), work performance, 
aesthetics, pain and satisfaction. It is thoroughly developed and well-validated for 
Dupuytren’s disease.6-8 Scores range from 0(poorest function) to 100(best function). 
Because functional restoration was considered the primary treatment objective, we 
excluded all pain outcomes from our analysis. Only the outcomes pertaining to the 
treated side were considered. 
Treatment-related complications were prospectively documented and classified 
into a mild (neuropraxia, skin fissure, scar and wound healing sequelae) and a serious 
category (nerve laceration, uncorrectable contracture, wound infection requiring 
antibiotic treatment, arterial laceration, tendon rupture, cold intolerance, palmar or 
digital hematoma). 
 
Statistical analyses 
Sample size 
Sample-size calculations showed that a total number of 144 patients (72 each group) 
would provide 85% power (β=0.15, α=0.05) to detect a 5° difference in total extension 
deficit between the treatment groups with the use of two-sided tests.  
 
Adjustment for between-group differences in baseline characteristics 
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We anticipated differences in the baseline characteristics between the PNA and LF 
groups because we expected LF to be the preferred treatment for advanced cases. Such 
differences in the factors that influence the treatment decision between both 
treatments threaten the validity of a comparison due to treatment selection bias. 
Propensity score analyses provide a statistical approach for investigators to minimize this 
form of bias by accounting for the differences in such factors, given that there are 
patients who are suitable candidates for both techniques.9-11 The assumption that there 
are PNA patients who could have been treated with LF and vice versa is likely met, as 
decisions often depend on patient preference.12 In the present study, the propensity 
score is defined as the probability of undergoing PNA based on factors influencing the 
decision between LF and PNA, including age, primary or recurrent disease, the number of 
digits affected, the joint levels affected and the degree of extension deficit at these 
joints. To calculate this probability (propensity score), we used multivariate logistic 
regression modeling with the pretreatment factors as independent variables and 
treatment technique as the dependent variable. To minimize the risk of further bias13,14, 
we also included possible confounders of the relation between treatment and outcomes, 
including gender15, diabetes, smoking status, bilateral and familial history of the disease.  
As PNA and LF were the two treatments available, the probability of receiving LF 
is 1 minus the probability of undergoing PNA (inverse probability) and vice versa. Patients 
with a high-probability of undergoing LF would therefore have a low-probability of 
undergoing PNA and vice versa. By weighting patients based on the inverse of their 
propensity score, patients with a similar probability of undergoing PNA and LF receive 
more weight while those with a high-probability of undergoing either treatment receive 
less weight. Consequently, patients with similar baseline characteristics are weighted 
more than those with dissimilar characteristics, thus resulting in more balanced 
treatment groups.  
Propensity-score based inverse probability weighting was used as the primary 
method to account for the between-group differences. To verify whether the groups 
were indeed more balanced afterwards, we compared the groups before and after this 
approach. As compared with propensity-score based matching approaches, inverse 
probability weighting minimizes the exclusion of patients, thereby increasing the ability 
to generalize from the results.13,14  
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Comparison of outcomes 
Baseline characteristics were compared using Pearson chi-square tests for 
categorical variables and Student’s t-tests for continuous variables. To compare the 
degree of total residual contracture and MHQ scores at follow-up among the treatment 
groups, we used repeated measures analyses of variance with the treatment group as a 
between-subjects factor. To compare complication rates of mild and serious 
complications, we used using Pearson chi-square or Fisher’s exact tests.  
To test the robustness of our findings, we performed additional sensitivity 
analyses using data from patients in the PNA and LF groups who did not have severe PIP 
contractures (defined as >40 degrees extension deficit).16 This approach assumes that 
having a severe PIP contracture is the only factor influencing the decision between NA 
and LF that should be accounted for. Descriptive statistics are presented as percentages 
for categorical variables and as means ±SD for continuous variables. Significance 
thresholds were set at p≤0.05. 
PNA vs. LF 
	
 33	
Results 
There were a total of 368 patients who underwent PNA (25%) or LF (75%) for Dupuytren’s 
contracture between 2011 and 2014. After applying the eligibility criteria, 293 patients 
remained to form the study sample. Of these, 78 patients (27%) underwent PNA and 215 
patients (73%) underwent LF (Figure 1).	 
 
Table 1 shows the baseline characteristics of the study sample before and after inverse 
probability weighting. Before weighting, PNA patients had, on average, fewer affected 
digits, 14° less total extension deficit, less advanced PIP joint contractures, and were 
more likely to have primary disease, demonstrating that LF was the preferred technique 
for advanced cases. The PNA group also had relatively more women.  
Figure 1. Patient selection flowchart. PNA; Percutaneous needle aponeurotomy, LF; Limited fasciectomy. 
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Table 1. Baseline characteristics before and after inverse probability weighting, by 
treatment group.* 
 Not Weighted Weighted 
PNA 
(N=78) 
LF 
(N=215) 
p  PNA 
(N=78) 
LF 
(N=103) 
p  
Demographics 
 Age –yrs. 
 Male gender –% 
 Diabetes –% 
 Current smoker –% 
 
65±8 
68 
18 
14 
 
63±9 
81 
8 
14 
 
0.103 
0.014 
0.014 
0.974 
 
65±8 
68 
18 
14 
 
65±8 
72 
10 
10 
 
0.837 
0.571 
0.106 
0.361 
Disease Characteristics 
 Bilateral disease –% 
 Recurrent disease –% 
 Positive family history –% 
 No. digits affected 
  1 –% 
  2 –% 
  >2 –% 
 
47 
19 
49 
 
64 
23 
13 
 
57 
36 
47 
 
45 
29 
26 
 
0.157 
0.006 
0.792 
0.009 
 
 
47 
19 
49 
 
64 
23 
13 
 
52 
28 
53 
 
60 
28 
12 
 
0.592 
0.166 
0.533 
0.600 
 
Outcomes 
 Extension deficit† –
degrees 
  Total 
  MP joint level 
  PIP joint level 
  DIP joint level 
 
 
60±28 
38±29 
19±19 
3±8 
 
 
74±37 
25±25 
41±28 
7±12 
 
 
0.003 
<0.001 
<0.001 
0.001 
 
 
60±28 
38±29 
19±19 
3±8 
 
 
62±26 
40±24 
19±22 
3±9 
 
 
0.702 
0.740 
0.957 
0.736 
* Plus-minus values are means ±SD. 
† Values are reported for all joints. 
PNA, Percutaneous Needle Aponeurotomy; LF, Limited Fasciectomy; MP, 
metacarpophalangeal; PIP, proximal interphalangeal; DIP, distal interphalangeal; SD, 
standard deviation.  
 
After inverse probability weighting, all baseline characteristics were well-balanced 
among the treatment groups (Table 1). This was in part due to 112 LF patients (52%) with 
such a high probability of receiving LF that they received a weight of zero in further 
analyses (Figure 1). These patients, as compared with the other weighted patients, had, 
on average, 21 degrees more total extension deficit preoperatively, more advanced PIP 
and DIP contractures, and 8 degrees worse residual contracture postoperatively, further 
demonstrating that LF was used for patients with advanced disease and the need to 
account for such differences. 
Among the weighted treatment groups, the mean age was 65 years. The majority 
of digits involved (88%) were Tubiana grade I (<45°) or grade II (45°-90°), 10% grade III 
(90°-135°) and 2% grade IV (>135°). The majority of digits had isolated MP contractures 
(42%) or contractures of both the MP and the PIP joint (37%). Eleven percent of digits had 
PNA vs. LF 
	
 35	
an isolated PIP contracture. The remaining digits had a DIP contracture combined with an 
affected PIP joint (6%), MP joint (2%) or a contracture spanning all three joints (3%).  
All patients in the weighted groups had follow-up data available on the degree of 
total residual extension deficit and complications. The average follow-up duration was 10 
weeks (range, 6–12 weeks) and similar between groups (P=0.891). Sixty-seven percent of 
the PNA patients as compared to 83% of the LF patients completed the MHQ at follow-up 
with no differences in the baseline characteristics between those who did and did not 
complete the MHQ.  
 
Residual contracture 
Among the weighted treatment groups, the degree of total residual extension deficit at 
follow-up was not significantly different (PNA, 20° vs. LF, 18°; Figure 2A), which 
corresponded with an improvement from baseline of 66% (39°) for PNA and 71% (43°) for 
LF (Figure 2B).  
 
	
Figure 2. Degree of total contracture (total active extension deficit) in the weighted PNA and LF 
groups at baseline and follow-up (A). Means and standard errors are plotted. Corresponding 
improvement in contracture expressed in absolute degrees and percentual improvement from 
baseline (B). PNA; Percutaneous needle aponeurotomy, LF; Limited fasciectomy. 
 
When separately evaluating MP from PIP contractures, the degree of residual extension 
deficit was not significantly different among the weighted groups for neither the 
affected MP joints (PNA, 10° vs. LF, 8°; Figure 3A) nor affected PIP joints (PNA, 18° vs. LF, 
13°; Figure 3B).  
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Table 1. Baseline characteristics before and after inverse probability weighting, by 
treatment group.* 
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PNA 
(N=78) 
LF 
(N=215) 
p  PNA 
(N=78) 
LF 
(N=103) 
p  
Demographics 
 Age –yrs. 
 Male gender –% 
 Diabetes –% 
 Current smoker –% 
 
65±8 
68 
18 
14 
 
63±9 
81 
8 
14 
 
0.103 
0.014 
0.014 
0.974 
 
65±8 
68 
18 
14 
 
65±8 
72 
10 
10 
 
0.837 
0.571 
0.106 
0.361 
Disease Characteristics 
 Bilateral disease –% 
 Recurrent disease –% 
 Positive family history –% 
 No. digits affected 
  1 –% 
  2 –% 
  >2 –% 
 
47 
19 
49 
 
64 
23 
13 
 
57 
36 
47 
 
45 
29 
26 
 
0.157 
0.006 
0.792 
0.009 
 
 
47 
19 
49 
 
64 
23 
13 
 
52 
28 
53 
 
60 
28 
12 
 
0.592 
0.166 
0.533 
0.600 
 
Outcomes 
 Extension deficit† –
degrees 
  Total 
  MP joint level 
  PIP joint level 
  DIP joint level 
 
 
60±28 
38±29 
19±19 
3±8 
 
 
74±37 
25±25 
41±28 
7±12 
 
 
0.003 
<0.001 
<0.001 
0.001 
 
 
60±28 
38±29 
19±19 
3±8 
 
 
62±26 
40±24 
19±22 
3±9 
 
 
0.702 
0.740 
0.957 
0.736 
* Plus-minus values are means ±SD. 
† Values are reported for all joints. 
PNA, Percutaneous Needle Aponeurotomy; LF, Limited Fasciectomy; MP, 
metacarpophalangeal; PIP, proximal interphalangeal; DIP, distal interphalangeal; SD, 
standard deviation.  
 
After inverse probability weighting, all baseline characteristics were well-balanced 
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When separately evaluating MP from PIP contractures, the degree of residual extension 
deficit was not significantly different among the weighted groups for neither the 
affected MP joints (PNA, 10° vs. LF, 8°; Figure 3A) nor affected PIP joints (PNA, 18° vs. LF, 
13°; Figure 3B).  
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Figure 3. Degree of contracture (active extension deficit) for affected MCP (A) and affected PIP (B) 
joints in weighted PNA and LF groups at baseline and follow-up. Means and standard errors are 
plotted. MCP; metacarpophalangeal, PIP; proximal interphalangeal, PNA; percutaneous needle 
aponeurotomy, LF; Limited fasciectomy. 
 
Patient-reported outcomes 
Significantly larger improvements in the MHQ subscore of satisfaction, work 
performance, ADL, and overall hand function were found in the weighted PNA group as 
compared with the weighted LF group (Figure 4). However, the hand appearance 
subscore showed a similar improvement.	 
 
 
Figure 4. Change in MHQ scores in the weighted PNA and LF groups at follow-up from baseline. 
Asterisks (*) denote significant differences among the adjusted treatment groups. PNA; 
percutaneous needle aponeurotomy, LF; Limited fasciectomy. 
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Complications 
Table 2 compares complication rates among the weighted groups. Although the rate for 
serious complications did not significantly differ among the groups (PNA, 2.6% vs. LF, 
1.7%), mild complications occurred significantly less frequently after PNA than after LF 
(PNA, 5.2% vs. LF, 24.3%).  
 
Table 2. Complications rates in the inverse probability weighted PNA and LF 
groups.* 
Complication PNA (N=78) LF (N=103) P value 
Serious 
 Nerve Laceration 
 Uncorrectable contracture  
 Wound infection  
 Arterial Laceration 
 Tendon Rupture 
 Cold Intolerance 
 Hematoma 
 Extensive edema 
Mild 
 Neuropraxia  
 Scar sequelae 
 Skin Fissure 
 Wound healing 
 
1.3 
1.3 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
 
2.6 
0.0 
2.6 
0.0 
 
0.0 
0.0 
1.3 
0.0 
0.0 
0.0 
0.0 
0.4 
 
17.4 
4.9 
0.0 
1.9 
0.579 
 
 
 
 
 
 
 
 
 
 
 
 
<0.001 
* Values are percentages. 
PNA, Percutaneous Needle Aponeurotomy; LF, Limited Fasciectomy. 
 
Recurrence subgroup  
Comparing only patients who were treated for recurrent disease among the weighted 
groups, there was no significant difference in the baseline degree of total extension 
deficit. The degree of total residual extension deficit at follow-up was also not 
significantly different between the recurrence subgroups (PNA, 24° vs. LF, 18°; P=0.101). 
 
Sensitivity analyses  
Sensitivity analyses performed using data from 65 PNA and 95 LF patients without severe 
PIP contractures yielded similar results for the outcome comparisons. However, the two 
groups differed in several baseline characteristics, indicating that inverse probability 
weighting achieved more balance and thus more precise inferences about the treatment 
effects.  
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Recurrence subgroup  
Comparing only patients who were treated for recurrent disease among the weighted 
groups, there was no significant difference in the baseline degree of total extension 
deficit. The degree of total residual extension deficit at follow-up was also not 
significantly different between the recurrence subgroups (PNA, 24° vs. LF, 18°; P=0.101). 
 
Sensitivity analyses  
Sensitivity analyses performed using data from 65 PNA and 95 LF patients without severe 
PIP contractures yielded similar results for the outcome comparisons. However, the two 
groups differed in several baseline characteristics, indicating that inverse probability 
weighting achieved more balance and thus more precise inferences about the treatment 
effects.  
Chapter 2	
	 38	
Discussion 
Interest in comparative effectiveness research has exploded in recent years, because the 
results from such studies may better reflect real-world practice than those obtained by 
strictly controlled clinical trials.17,18 The purpose of this multicenter study was to compare 
the effectiveness of PNA and LF for treating Dupuytren’s contracture in contemporary 
clinical practice. We found that both techniques provided a similar degree of contracture 
reduction among patients who have mild to moderately affected digits. These findings 
were similar when separately evaluating affected MP joints from affected PIP joints. 
However, PNA was associated with larger improvements in most MHQ subscores and a 
significantly lower rate of mild complications. 
Despite that PNA has become an accepted treatment for Dupuytren’s 
contracture, questions persist regarding its effectiveness as compared with LF. To date, 
there has been one randomized clinical trial comparing the efficacy of the two 
treatments.5 In this trial, PNA achieved 18 percent less reduction in total passive 
extension deficit than LF assessed at 6 weeks postoperatively. However, subgroup 
analyses indicated that this difference was primarily due to PNA’s inferior results for 
more advanced cases, while similar results were found for those graded as Tubiana I and 
II. Hence, the authors concluded that PNA seemed particular useful as a treatment for 
patients with mild to moderately severe contractures. The similar degree of contracture 
reduction achieved among the two treatment groups in this study consisting of primarily 
(88%) of Tubiana grade I and II patients demonstrates that PNA was indeed used to treat 
patients with less advanced disease at the practice sites involved, and appeared as 
effective as LF at reducing contractures in contemporary practice.  
The evaluation of changes in MHQ subscores following treatment allowed 
comparison of the early impact of PNA and LF on different aspects of hand function. 
Larger improvements in the subscores of overall hand function, satisfaction, work 
performance and ADL were found in the PNA group, which primarily shows that the 
technique restores hand function more rapidly than LF does and highlights its less 
invasive nature. The similar improvement in the subscore of hand appearance among the 
treatment groups suggests that both treatments help to address concerns patients may 
have about the appearance of their hand.19  
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The significantly lower rate of mild complications after PNA than after LF is 
consistent the findings of previous reports20 and related to the high rate of neuropraxia 
found in the LF group. With the exception of neuropraxia, all other complications were 
unique to each treatment group. Although the low incidence of complications in this 
study merits careful interpretation, this finding is in line the clinical observation that 
complications arise as a consequence of the nature of the technique. For example, the 
reported skin fissures are likely to have occurred because of the percutaneous and blind 
nature of PNA, whereas the scar and wound healing sequelae found in the LF group can 
be expected from any open surgical technique. Until sufficiently powered studies are 
performed directly comparing the risk profile of both techniques among comparable 
patients, we feel that both the differences in mild complication rates and the type of 
complications occurring after PNA and LF may be informative for patient counseling. 
 Strengths of this study include the of inverse probability weighting to account for 
the differences in baseline characteristics to minimize bias. This approach allowed 
comparison of the effectiveness of PNA and LF in actual clinical practice using data from 
6 practice sites that were prospectively gathered by therapists who had no knowledge of 
this study. Although both treatment groups were well-balanced after inverse probability 
weighting, however, the possibility remains for unobserved confounding factors to have 
influenced our findings, such as patients’ genetic constitution.21 Another limitation was 
that a substantial proportion of patients who underwent LF for advanced PIP and DIP 
joint contractures were not weighted in the analyses, thus our findings do not apply to 
such patients. 
The largest drawback of this study is its short follow-up duration. Although this 
allowed for a comparison of short-term outcomes, recurrence rates may be just as 
important to patients when selecting between treatments.12 Considering that PNA has 
become the preferred technique for less severe cases in contemporary practice, there is 
a need for long-term studies assessing whether the previously reported 64% higher 
recurrence rate at 5 years as compared with LF is still accurate.22 
The present study provides information that may be used to help Dupuytren’s 
disease patients and clinicians decide between PNA and LF. It shows that PNA, in the 
short-term, reduces mild to moderately affected digits as effective as LF does in routine 
practice, confirming recent recommendations that PNA has most value as a first-line 
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treatment.23,24 Furthermore, PNA provided a faster functional recovery and had a lower 
rate of mild complications. Besides an evaluation of treatments, this study highlights 
inverse probability weighting as a useful and feasible tool in assessing the comparative 
effectiveness of different treatment techniques for Dupuytren’s disease.25  
This approach could be of increasing importance considering the expanding number of 
treatment strategies for Dupuytren’s disease, many of which may never be compared to 
each other in randomized clinical trials. 
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Abstract 
Background: Controversy exists about the relative effectiveness of injectable collagenase 
(collagenase clostridium histolyticum) and limited fasciectomy in the treatment of 
Dupuytren's contracture. The authors compared the effectiveness of both techniques in 
actual clinical practice. 
 
Methods: This study evaluated all subjects treated with collagenase clostridium 
histolyticum or limited fasciectomy for metacarpophalangeal and/or proximal 
interphalangeal joint contractures between 2011 and 2014 at seven practice sites. The 
authors compared the degree of residual contracture (active extension deficit), Michigan 
Hand Outcomes Questionnaire scores, and adverse events at follow-up visits occurring 
between 6 and 12 weeks after surgery or the last injection with the use of propensity 
score matching. 
 
Results: In 132 matched subjects who were treated with collagenase (n = 66) or 
fasciectomy (n = 66), the degree of residual contracture at follow-up for affected 
metacarpophalangeal joints was not significantly different (13 degrees versus 6 degrees; 
p = 0.095) and affected proximal interphalangeal joints had significantly worse residual 
contracture in the collagenase group compared with those in the fasciectomy group (25 
degrees versus 15 degrees; p = 0.010). Collagenase subjects experienced fewer serious 
adverse events than did fasciectomy subjects and reported larger improvements in the 
Michigan Hand Outcomes Questionnaire subscores evaluating satisfaction with hand 
function, activities of daily living, and work performance. 
 
Conclusion: This propensity score-matched study showed that collagenase clostridium 
histolyticum was not significantly different from limited fasciectomy in reducing 
metacarpophalangeal joint contractures, whereas proximal interphalangeal joint 
contractures showed slightly better reduction following limited fasciectomy. Collagenase 
provided a more rapid recovery of hand function than did fasciectomy and was 
associated with fewer serious adverse events. 
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Introduction 
Dupuytren’s disease is an incurable fibro-proliferative disease involving the palmar fascia 
of the hand. Abnormal deposition of collagen initially leads to the formation of palpable 
palmar nodules. As the disease progresses, cords typically develop that cause flexion 
contractures at the affected finger joints. Ultimately, these contractures can severely 
impair hand function and diminish quality of life.1 
Collagenase Clostridium Histolyticum (CCH), which selectively disintegrates 
collagen, is a recently popularized enzymatic treatment option for Dupuytren’s 
contracture.2 The technique involves the injection of a small volume of collagenase 
solution into the pathologic cord(s), thus weakening the treated areas to allow for 
subsequent rupture by manipulation of the contracted finger. While several large clinical 
trials have demonstrated the efficacy2 (N=308) and safety3 (N=587) of the injections, 
these studies were placebo-controlled4, and therefore do not provide evidence on the 
relative effectiveness of CCH and the available surgical techniques.  
Limited fasciectomy (LF) remains the most widely accepted surgical standard of 
care for Dupuytren’s disease. As of this writing, few studies have directly compared LF 
with CCH: the only two comparative studies we are aware of reported that the two 
techniques were similar in reducing joint contractures.5,6 However, these studies had 
relatively small sample sizes (N=46 in the largest study), which may have precluded the 
authors from finding significant differences due to limited statistical power. Another 
weakness inherent to such observational studies relates to the risk of confounding by 
indication. Since the choice of performing CCH and LF is partly influenced by patient and 
clinical characteristics, such as diathesis factors, the severity of the disease, and the joint 
levels involved, these should be accounted for to ensure valid comparisons between 
treatment groups. 
The purpose of this study was to directly compare the early clinical results of CCH 
and LF while minimizing the risk of confounding by indication bias with the use of 
propensity score matching. Propensity score matching is a statistical approach that 
allows investigators to account for a large number of observed confounding variables, 
and is particularly useful in circumstances where randomized treatment allocation is 
unfeasible or unethical.7 Since randomized clinical trials evaluating CCH versus LF are 
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currently lacking, this approach allowed for a timely comparison of the effectiveness of 
both techniques in reducing contractures and restoring hand function in actual clinical 
practice.8  
 
Methods 
After approval of the study by the Medical Ethics Committee of the Erasmus MC, all 
subjects with Dupuytren’s disease undergoing CCH and LF between August 2011 and 
March 2014 at 7 practice sites in the Netherlands were identified using a prospectively 
maintained database.  
Patient characteristics derived from this database were age, gender, hand dominance, 
and comorbidities. Disease specific characteristics included bilateral presence of the 
disease, primary versus recurrent disease, family history of Dupuytren’s disease. In case 
data were missing from the database, electronic health records were abstracted.  
Subjects with the diagnosis of Dupuytren’s disease, who were 18 years or older, 
and with the ability to complete the study questionnaires in Dutch were included in the 
study. Exclusion criteria included multiple finger involvement, concomitant hand 
conditions or interventions (e.g., carpal tunnel release) on the affected side, and the lack 
of baseline data on the degree of contracture. Subjects undergoing revision treatment 
for recurrent disease were included if other eligibility criteria were met. This study was 
conducted in accordance with the declaration of Helsinki. 
 
Treatments 
Treatments were performed as part of routine care by the hand surgeons of the 7 sites 
through shared decision-making. 
CCH was administered according to manufacturer instructions, without local 
anesthesia. Injections were limited to 0.25mL and 0.20 mL for MP and PIP joint 
contractures, respectively. Compressive dressings were applied afterwards. Treated 
fingers were manipulated after 24 to 72 hours to attempt rupturing of the weakened 
cords under local anesthesia. Up to 3 injections were offered at 4 week-intervals if 
subjects were dissatisfied with the achieved level of contracture correction but were not 
mandatory.  
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LF, which is the preferred technique for treating Dupuytren’s disease in the 
Netherlands9, was performed with tourniquet exsanguination and loupe magnification 
under axillary block or general anesthesia in an operating theatre. Cords were 
approached and excised after Bruner type or longitudinal incisions with Z-plasties. Care 
was taken to prevent injury to the digital neurovascular bundles. Compressive dressings 
were applied for 2 weeks. All patients were offered a similar supervised program of hand 
therapy with instructed use of removable night splints for 3 months. 
 
 
Outcome Assessments  
The primary outcome of this study was the degree of residual contracture assessed at 
follow-up visits occurring between six and twelve weeks after surgery or the last 
injection. Certified hand therapists performed goniometry to determine the degree of 
active extension deficit at baseline and follow-up according to a standardized 
assessment protocol. Hyperextension was classified as 0° to prevent underestimation of 
extension deficit. 
Secondary outcomes assessed included whether affected joints achieved clinical 
improvement (defined as a greater than 50% reduction from baseline contracture) 
adverse events, and self-reported hand function assessed using the Michigan Hand 
Outcomes Questionnaire (MHQ). The MHQ is a self-reported functioning scale consisting 
of 37 items evaluating 6 functional subdomains for each hand separately: overall hand 
function, ability to perform activities in daily life (ADL), work performance, aesthetics, 
pain and satisfaction with hand function. The MHQ has been rigorously designed and 
used for a variety of hand conditions10 including Dupuytren’s disease.11,12 Scores range 
from 0 (poorest function) to 100 (best function). Because functional restoration was 
considered the primary treatment objective, we excluded all pain outcomes from our 
analysis. Only the outcomes pertaining to the treated side were used. 
Adverse events were graded based on their severity into two categories: serious (non-
transient or requiring an intervention) and mild (transient or not requiring an 
intervention).  
Given the increasing clinical and policy implications of patient satisfaction data13, 
we performed a post-hoc analysis of the specific items that constitute the satisfaction 
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subdomain of the MHQ. These items examine satisfaction with overall hand function, 
finger motion, wrist motion, hand strength, and sensation, and are assessed using a 5-
point Likert scale, with possible answers ranging from “very satisfied” (1 point) to “very 
dissatisfied” (5 points). Subjects who rated their satisfaction as “very satisfied” (1 point) 
or “somewhat satisfied” (2 points) were classified as “satisfied” and all others as 
“dissatisfied”. 
 
Statistical Analysis 
Continuous variables were reported as means ±SD and categorical variables were 
summarized with the use of frequencies. Sample-size calculations revealed that a total 
number of 32 MP contractures (16 each group) and 70 PIP contractures (35 each group) 
would provide 80% power (β = 0.20, α = 0.05) to detect a 10° difference in residual 
contracture between the two treatment groups with the use of two-sided tests. 
Propensity score matching was used to minimize the risk of confounding by 
indication bias.14 The propensity score was defined as the probability of receiving CCH 
conditional on 8 baseline factors. We used logistic regression modeling to estimate a 
score for each subject with the treatment type as the independent variable and the 
following baseline variables as dependent variables: age, gender, family history of 
Dupuytren’s disease, bilateral involvement, recurrent disease, and the degree of 
contracture at the three joint levels. The scores were then used to match CCH subjects to 
LF subjects on a 1-to-1 basis using a nearest-neighbor algorithm while allowing for a 
matching tolerance width of 0.2SD of the logit of the propensity score. We excluded 
unmatchable subjects from further analysis. To examine whether the matching approach 
improved balance among the matched treatment groups, significance testing was 
performed.  
For joint contracture and MHQ outcomes, we used a mixed-models repeated 
measures approach to compare the change from baseline with least-square means and 
corresponding standard errors plotted graphically. An advantage is that this approach 
estimates missing values and accounts for the within-subject dependency of the 
repeated measures.15,16 Joint contracture was evaluated separately for affected MP and 
PIP joints.  
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Our primary outcome analysis included all affected joints. However, in some CCH 
subjects with two affected joints in the same finger one of the contractures was 
specifically treated with CCH (mostly MP) because the degree of contracture of the other 
affected joint was improved to such an extent that further injections were deemed 
unnecessary.2 To assess whether the inclusion of all affected joints in our analysis 
influenced our results, we performed a subgroup analysis of only the primary targeted 
joint contractures. 
The incidence of serious adverse events was compared between the groups using 
a Fisher’s exact test. Mild adverse events were not compared because many of these 
were considered to be CCH specific or a natural consequence of surgery.  
Significance thresholds were set at P<0.05. Statistical analyses were performed 
using R (version 2.14) and SPSS (version 20.0). 
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Results 
There were a total of 397 subjects with Dupuytren’s disease who were treated with CCH 
or LF by one of the 15 surgeons of the practice sites. To improve comparability among 
the two treatment groups, 36% of the subjects who underwent LF for contractures 
involving multiple fingers were excluded. After exclusion of another 9% of subjects due 
to the other criteria, there remained a total of 218 eligible subjects of whom 48% were 
treated with CCH and 52% with LF (Figure 1).		
	
	
Figure 1. Subject selection flowchart. Clostridium Collagenase Histolyticum; LF, Limited Fasciectomy; 
MHQ, Michigan Hand Outcomes Questionnaire.  
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Table 1 shows the baseline characteristics of the study sample before and after 
propensity score matching. Before matching, the CCH group had relatively milder PIP and 
DIP joint contractures but worse MP joint contractures. Additionally, the proportion of 
subjects treated for recurrent disease was smaller in the CCH group and the distribution 
of the involved fingers was different.  
 
Table 1. Baseline characteristics before and after propensity score matching, by treatment 
group.* 
 All Subjects Matched Subjects 
CCH  
(N=104) 
LF 
(N=114) 
p  CCH  
(N=66) 
LF 
(N=66) 
p 
Demographics 
 Age –yrs. 
 Male gender –% 
 Diabetes –% 
 Current tobacco use –% 
 
61±10 
80 
3 
9 
 
63±9 
81 
9 
16 
 
0.410 
0.868 
0.087 
0.090 
 
61±10 
82 
6 
8 
 
63±8 
76 
5 
15 
 
0.334 
0.394 
0.698 
0.170 
Disease Characteristics 
 Recurrent disease –% 
 Bilateral disease –% 
 Treated side is dominant –% 
 Positive family history Dd –% 
 Treated finger 
  Little –% 
  Ring –% 
  Other –% 
 
 26 
 85 
 58 
 54 
 
 48 
 37 
 15 
 
38 
83 
53 
60 
 
72 
24 
4 
 
0.063 
0.797 
0.453 
0.388 
0.003 
 
 
33 
89 
53 
59 
 
55 
33 
12 
 
30 
89 
61 
49 
 
61 
32 
8 
 
0.709 
1.000 
0.380 
0.222 
0.789 
 
Outcomes 
 Contracture† –degrees 
  MP joint  
  PIP joint 
  DIP joint 
 Total MHQ score (0-100) 
 
 
29±24 
22±25 
1±4 
75±14 
 
 
19±27 
44±27 
8±14 
74±15 
 
 
0.002 
<0.001 
<0.001 
0.844 
 
 
26±25 
27±26 
1±14 
77±13 
 
 
23±25 
33±25 
2±14 
75±14 
 
 
0.632 
0.221 
0.547 
0.545 
* Plus-minus values are means ±SD. 
† Values are reported for all joints. 
CCH, Collagenase Clostridium Histolyticum; LF, Limited Fasciectomy; Dd, Dupuytren’s disease. 
 
Using propensity scores, we were able to match 66 CCH subjects with mean 
baseline contractures of 39° degrees for 43 affected MP joints and 41° for 43 affected PIP 
joints to 66 LF subjects with mean baseline contractures of 39° degrees for 39 affected 
MP joints and 41° for 52 affected PIP joints with similar characteristics.  
Ninety-six percent of affected joints in the matched LF group had follow-up data 
available as compared to 80% in the matched CCH group. Follow-up duration for the 
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0.453 
0.388 
0.003 
 
 
33 
89 
53 
59 
 
55 
33 
12 
 
30 
89 
61 
49 
 
61 
32 
8 
 
0.709 
1.000 
0.380 
0.222 
0.789 
 
Outcomes 
 Contracture† –degrees 
  MP joint  
  PIP joint 
  DIP joint 
 Total MHQ score (0-100) 
 
 
29±24 
22±25 
1±4 
75±14 
 
 
19±27 
44±27 
8±14 
74±15 
 
 
0.002 
<0.001 
<0.001 
0.844 
 
 
26±25 
27±26 
1±14 
77±13 
 
 
23±25 
33±25 
2±14 
75±14 
 
 
0.632 
0.221 
0.547 
0.545 
* Plus-minus values are means ±SD. 
† Values are reported for all joints. 
CCH, Collagenase Clostridium Histolyticum; LF, Limited Fasciectomy; Dd, Dupuytren’s disease. 
 
Using propensity scores, we were able to match 66 CCH subjects with mean 
baseline contractures of 39° degrees for 43 affected MP joints and 41° for 43 affected PIP 
joints to 66 LF subjects with mean baseline contractures of 39° degrees for 39 affected 
MP joints and 41° for 52 affected PIP joints with similar characteristics.  
Ninety-six percent of affected joints in the matched LF group had follow-up data 
available as compared to 80% in the matched CCH group. Follow-up duration for the 
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treatment groups was on average 11 weeks (range, 6–12 weeks) and was not significantly 
different between groups.  
 
Joint Contracture  
For affected MP joints, the degree of residual contracture (CCH, 13° vs. LF, 6°; Figure 2A) 
at follow-up and the proportion of joints achieving clinical improvement (Figure 3) were 
not significantly different among the matched treatment groups.		
	
	
Figure 2. Degree of contracture for affected metacarpophalangeal (A) and proximal interphalangeal 
(B) joints in the matched collagenase injection and limited fasciectomy groups at baseline and 
follow-up. Least-square means and standard errors from a repeated measures model are plotted. 
	
	
Figure 3. Percentage of affected joints meeting clinical improvement defined as more than 50% 
improvement from baseline in the degree of contracture.  
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For affected PIP joints, however, the degree of residual contracture was 
significantly worse in the CCH group than in the LF group (CCH, 25° vs. LF, 15°; Figure 2B). 
In line with this, relatively fewer affected PIP joints achieved clinical improvement in the 
CCH group than in the LF group (Figure 3). 
 
Self-Reported Outcome 
MHQ (sub)scores at baseline were similar among the matched treatment groups. CCH 
subjects reported significantly larger improvements than did LF subjects in the MHQ 
subdomain scores assessing satisfaction, ADL and work performance (Figure 4).  
	
Figure 4. Change in MHQ scores in the matched collagenase injection and limited fasciectomy groups 
at follow-up as compared with baseline. Asterisks (*) denote significant differences between the 
matched treatment groups. 
 
The proportion of subjects who were satisfied with each of the items that make 
up the satisfaction subdomain of the MHQ was similar between the matched treatment 
groups at baseline. The proportion of subjects who were satisfied with their finger 
mobility and hand function had similarly increased at follow-up among the two treatment 
3Chapter 3	
	 52	
treatment groups was on average 11 weeks (range, 6–12 weeks) and was not significantly 
different between groups.  
 
Joint Contracture  
For affected MP joints, the degree of residual contracture (CCH, 13° vs. LF, 6°; Figure 2A) 
at follow-up and the proportion of joints achieving clinical improvement (Figure 3) were 
not significantly different among the matched treatment groups.		
	
	
Figure 2. Degree of contracture for affected metacarpophalangeal (A) and proximal interphalangeal 
(B) joints in the matched collagenase injection and limited fasciectomy groups at baseline and 
follow-up. Least-square means and standard errors from a repeated measures model are plotted. 
	
	
Figure 3. Percentage of affected joints meeting clinical improvement defined as more than 50% 
improvement from baseline in the degree of contracture.  
CCH vs. LF 
	
 53	
	
For affected PIP joints, however, the degree of residual contracture was 
significantly worse in the CCH group than in the LF group (CCH, 25° vs. LF, 15°; Figure 2B). 
In line with this, relatively fewer affected PIP joints achieved clinical improvement in the 
CCH group than in the LF group (Figure 3). 
 
Self-Reported Outcome 
MHQ (sub)scores at baseline were similar among the matched treatment groups. CCH 
subjects reported significantly larger improvements than did LF subjects in the MHQ 
subdomain scores assessing satisfaction, ADL and work performance (Figure 4).  
	
Figure 4. Change in MHQ scores in the matched collagenase injection and limited fasciectomy groups 
at follow-up as compared with baseline. Asterisks (*) denote significant differences between the 
matched treatment groups. 
 
The proportion of subjects who were satisfied with each of the items that make 
up the satisfaction subdomain of the MHQ was similar between the matched treatment 
groups at baseline. The proportion of subjects who were satisfied with their finger 
mobility and hand function had similarly increased at follow-up among the two treatment 
Chapter 3	
	 54	
groups. However, as compared with LF subjects, more CCH subjects were satisfied with 
their hand strength and sensation (Figure 5). 
 
 
		
 
 
 
 
 
 
 
 
 
	
 
 
 
 
Figure 5. The proportion of subjects who were satisfied with five specific items constituting the 
satisfaction subdomain of the Michigan Hand Questionnaire in the matched collagenase injection 
and limited fasciectomy groups at baseline and follow-up.  
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Adverse Events 
Table 2 lists the adverse events noted in the matched groups, graded by severity.  
Table 2. Adverse events, by matched treatment groups.* 
Adverse event CCH (N=66) LF (N=66) 
Serious 
 Tenosynovitis  
 Nerve Injury 
 Arterial Injury 
 Tendon Rupture 
 Cold Intolerance 
 CRPS 
Mild 
 Peripheral Edema 
 Contusion  
  Extensive 
  Mild 
 Pain in Extremity 
 Blood Blister 
 Skin Fissure 
 Paresthesia 
 Axillary Tenderness 
 Erythema 
 Wound Dehiscence 
 Pruritus 
 Lymphadenopathy 
 Neuropraxia 
 Flare Reaction 
 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
49 (74) 
42 (64) 
3 (5) 
39 (59) 
17 (26) 
9 (14) 
5 (8) 
3 (5) 
6 (9) 
3 (5) 
0 (0) 
3 (5) 
2 (3) 
0 (0) 
1 (2) 
 
3 (5) 
1 (2) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
0 (0) 
3 (5) 
n.a. 
n.a. 
2 (3) 
n.a. 
n.a. 
1 (2) 
0 (0) 
* Values are numbers (percentages). 
CRPS; Complex Regional Pain Syndrome; n.a. not assessed. 
 
All serious adverse events occurred after LF; three events of tenosynovitis requiring an 
intervention and one nerve injury were noted as compared with zero events after CCH 
(P=0.042). Arterial injuries, cold intolerance complaints and tendon ruptures were not 
seen in either of the matched groups.  
Three of the most frequently noted mild adverse events after CCH were 
peripheral edema (74%), contusion (64%), and extremity pain (26%).  
 
Subgroup Analysis of the Joints Affected by Recurrent Disease 
Evaluating only the joints affected by recurrent disease, we found no significant 
differences in the baseline degree of contracture among the matched treatment, 
although affected MP joints were on average 8° worse in the CCH subgroup than in the 
LF subgroup.  
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Subgroup Analysis of the Joints Affected by Recurrent Disease 
Evaluating only the joints affected by recurrent disease, we found no significant 
differences in the baseline degree of contracture among the matched treatment, 
although affected MP joints were on average 8° worse in the CCH subgroup than in the 
LF subgroup.  
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Comparison of these two groups showed that while the degree of residual 
contracture at follow-up was not significantly different for affected MP joints (CCH, 19° 
vs. LF, 10°; Figure 6A), affected PIP joints in the CCH subgroup were significantly worse as 
compared with those in the LF subgroup (CCH, 33° vs. LF, 22°; Figure 6B).  
 
Figure 6. Degree of contracture for metacarpophalangeal (A) and proximal interphalangeal (B) 
joints affected by recurrent disease in the matched collagenase injection and limited fasciectomy 
groups at baseline and follow-up. Least-square means and standard errors from a repeated 
measures model are plotted. 
 
Subgroup Analysis of Primary Targeted Joints 
Evaluation of only the joints that were specifically targeted with CCH also showed a 
similar degree of residual contracture as compared to all affected MP joints in the LF 
group (data not shown). However, the PIP joint contractures that were specifically 
targeted with CCH showed significantly worse residual contracture as compared with the 
LF group. 
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Discussion 
The aim of this study was to compare the effectiveness of CCH and LF while accounting 
for the baseline variables that contribute to treatment selection bias using propensity 
score matching.17 Our primary finding was that the degree of residual contracture in the 
two treatment groups was not significantly different for contractures at the MP joint 
level, while affected PIP joints showed a relatively small but significantly worse residual 
contracture in the CCH group as compared with the LF group. Nevertheless, subjects in 
the CCH group reported larger functional improvements than did LF subjects at early 
follow-up, and experienced fewer serious adverse events. 
Previous comparative studies on CCH have reported 10° of residual contracture for 
affected MP joints6,18 of and 23°-26° for affected PIP joints6,18 at early follow-up, which is 
similar to the 13° and 24° found in the present study. The 6° and 15° for affected MP and 
PIP joints found in our LF group is consistent with the 5° and 14° degrees reported at 6 
weeks follow-up by van Rijssen and colleagues.19 However, our finding that LF was 
superior to CCH for affected PIP joints contrasts the few available studies comparing the 
two techniques.5,6 Although one retrospective study found that LF achieved an average 
of 9° more contracture reduction after examining a total number of 24 affected PIP 
joints, this difference was not significant.18 The only other head-to-head study we are 
aware of, reported similar results after evaluating only 18 affected PIP joints.6 In contrast, 
the present study included more subjects with PIP joint involvement and was therefore 
more powered to detect significant differences. Another reason may lie in the fact that 
the two procedures differ fundamentally: CCH is a closed technique which relies on 
enzymatic fasciotomy, whereas an open technique such as LF allows for extensive 
excision of the cord and the performance of ancillary surgical efforts, such as the division 
of the collateral ligaments, check-rein ligaments and occasionally the release of the volar 
plate, to maximize joint correction. However, it should also be noted that the results of in 
the CCH group reflect the injection technique as recommended by the manufacturer, 
that is, injecting only in one part of the cord. Injection into multiple areas, as recently 
suggested by Murphy and colleagues, may translate into better results at the PIP joint 
level and should be explored in future investigations.8  
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As compared with those who underwent LF, CCH subjects reported larger 
functional improvements in the MHQ subdomains assessing ADL, work performance and 
satisfaction with hand function at follow-up. As a recent study reported a gradual 
improvement in MHQ scores in the first year following LF12, we believe that this finding 
primarily shows that hand function recovers more rapidly after CCH than after LF, which 
is consistent with what was previously reported by an observational study that used the 
DASH questionnaire5.  
This study has several limitations. While most previous reports evaluated only 
primary cases, our study included subjects with joints affected by primary as well as 
recurrent disease. Although our subgroup analysis of only the subjects with recurrent 
disease showed that the comparative effectiveness of the two techniques was similar to 
that of the overall groups, future studies with a larger number of recurrent cases are 
required to confirm these findings. Moreover, the relatively higher incidence of serious 
adverse events noted in the LF group warrants careful interpretation due to the small 
number of events, but is in line with a previous systematic review showing that CCH has a 
more favorable risk profile than LF.20 
Another concern is that our study only evaluated early clinical results, leaving 
uncertainty about the durability of these outcomes. However, we decided on this 
approach because, as of this writing, few studies have directly compared CCH to LF in 
terms of their associated risks and their effectiveness in reducing contractures and 
restoring hand function. Although studies have shown acceptable long-term outcomes 
for each technique separately, meaningful comparisons have proven to be challenging 
due to the heterogeneity of their study samples and the wide variety of endpoints 
used.21-24 Although there is some evidence suggesting that better original contracture 
corrections correspond to a lower risk of developing recurrence25-27, a comparison of the 
two techniques in terms of recurrence and revision rates is urgently needed to provide 
patients and providers with more nuanced information required to improve clinical 
decision-making.  
Finally, we acknowledge the inherent drawbacks of propensity score analyses. For 
example, our matching procedure only accounted for imbalance in observed variables 
whereas randomization, when properly conducted, would also account for the 
differences in possible hidden confounding factors such as patients’ genetic constitution. 
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It also resulted in the exclusion of a sizeable proportion of subjects with more 
comparatively more advanced PIP joint contractures in the LF group to whom the results 
of this study do not apply. 
Taken together, the findings of the present study suggest that CCH offers an 
alternative to LF for subjects with MP contractures and those with affected PIP joints 
who are willing to trade slightly better contracture correction for faster recovery of hand 
function and a lower risk of serious adverse events. Besides an evaluation of treatments, 
this study highlights the use of propensity-score matching methods for making 
inferences on the effectiveness of treatments for Dupuytren’s disease in actual clinical 
practice. Future head-to-head studies are required to delineate the long-term 
effectiveness of CCH and the established surgical techniques, particularly for those 
subjects with multiple finger involvement and advanced PIP contractures. 
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Abstract 
 
Background: Although the efficacy of collagenase clostridium histolyticum (CCH) 
injections has been demonstrated by randomized clinical trials, the relative effectiveness 
of CCH remains uncertain. Our aim was to compare the outcomes of CCH with those of 
percutaneous needle aponeurotomy (PNA) in daily clinical practice. 
 
Methods: We analyzed data from patients undergoing PNA or CCH between 2011 and 
2014 at 7 practice sites in the Netherlands. We examined the degree of improvement in 
contracture and adverse effects at 6-12 weeks after surgery or the last injection. 
Additionally, we invited patients to complete the Michigan Hand Questionnaire before 
and at 6-12 months follow-up. To minimize the risk of bias, we used propensity score 
matching. 
 
Results: Among 130 matched patients (93% Tubiana I or II) undergoing PNA (n = 46) and 
CCH (n = 84), improvement in contracture was similar: 26 degrees (65% improvement 
from baseline) for PNA versus 31 degrees (71%) for CCH for affected 
metacarpophalangeal joints (P = 0.163). This was 16 degrees (50% improvement) versus 17 
degrees (42%) for affected proximal interphalangeal joints (P = 0.395), respectively. No 
serious adverse effects occurred in either of the 2 treatment groups. Of the mild adverse 
effects, only skin fissures and sensory disturbances were seen in both groups. Through 1-
year follow-up, patients reported similar improvements in the overall Michigan Hand 
Questionnaire score (PNA 5.3 points versus CCH 4.9 points; P = 0.912). 
 
Conclusion: In patients with mild contractures (Tubiana I or II), CCH was as effective as 
PNA in reducing contractures. Both treatments were safe and improved hand function to 
a similar extent in daily practice. 
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Introduction 
Dupuytren’s disease is an incurable proliferative disorder of the palmar fascia, 
characterized by the development of palmar nodules and cords.1 Over time, the cords 
can contract and limit finger extension. Patients report a variable extent of functional 
impairment and diminished quality of life.2,3  
 Percutaneous needle aponeurotomy (PNA) and Collagenase Clostridium 
Histolyticum (CCH) have gained popularity as less-invasive treatment alternatives to 
limited fasciectomy – the current standard of care.4-7 With PNA, originally popularized by 
French rheumatologists, surgeons use a hypodermic needle to release cords at multiple 
levels after which the affected finger is extended to improve contracture. With CCH, 
which selectively dissolves collagen, a small volume of collagenase solution is injected 
into the cords. This weakens the treated areas, allowing for subsequent release through 
forceful manipulation. To date, two randomized clinical trials have compared the two 
techniques, both reporting that their efficacy is comparable.8,9 Nevertheless, the extent 
to which these results can be translated into clinical practice remains incompletely 
understood because the controlled conditions in such trials may not reflect clinical 
practice. Patients’ choices, selection and compliance with treatment regimens in trials 
can differ substantially from that in actual practice, resulting in a discrepancy in the 
results achieved in trials versus those in practice.10-12  
The aim of this study was to compare the outcomes of PNA and CCH in daily 
practice using data gathered at multiple practice sites in the Netherlands. We studied the 
impact of both treatments on the degree of contracture, different domains of hand 
function, and associated adverse effects.  
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Methods 
Study design 
This is a study of data compiled from two previous comparative studies4,13 performed 
between 2011 and 2014 at 7 hand surgery practice sites in the Netherlands, including one 
academic institution and a consortium of 6 dedicated hand surgery sites.  
Briefly, patients were eligible if they were adults with a diagnosis of primary or 
recurrent Dupuytren’s disease, underwent PNA or CCH, and had contractures affecting 
the MCP and/or PIP joints. Patients were excluded if they underwent treatment for a 
concomitant hand condition that could confound outcomes assessments (e.g. carpal 
tunnel release). For this study, we also excluded patients who underwent simultaneous 
treatment for multiple digits to increase comparability between the groups. Our local 
institutional review board exempted this study from formal review due to the 
retrospective nature of this study. 
 
Procedures 
Treatments were performed as part of standard clinical practice by the surgeons of the 
participating practice sites. Hence, treatment selection occurred through shared-decision 
making. 
PNA was performed under local anesthesia. Cords were released using 25 gauge 
needles at as many levels as possible in the palm and fingers. Patients were instructed to 
report paresthesias to avoid nerve injury. After release, the treated digit was extended 
with a progressive force to maximize correction. Patients were encouraged to flex and 
extend their digits immediately following treatment and to restart normal use of their 
hands after 24 hours.  
CCH was administered according to manufacturer instructions, without local 
anesthesia. Injections were limited to 0.25mL and 0.20 mL for MCP and PIP joint 
contractures, respectively. Afterwards, compressive dressings were applied. Treated 
digits were manipulated after 24 to 72 hours to attempt release of the weakened cords 
under local anesthesia. Up to 3 injections were offered at 4 week-intervals if patients 
were dissatisfied with the achieved level of correction but were not mandatory. All 
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patients were offered a similar rehabilitation and splinting program as patients 
undergoing PNA. 
 
Outcome measures  
The primary outcome was early improvement in degree of contracture. The degree of 
contracture (active extension deficit) was assessed by certified hand-therapists using a 
finger goniometer before treatment and at visits occurring between six to twelve weeks 
after surgery or the last injection. Any hyperextension was defined as 0° to prevent 
underestimation of total extension deficit. At the same visits, adverse effects were 
noted, which were divided based on their severity into two categories: serious (non-
transient or requiring an intervention) and mild (transient or not requiring an 
intervention).  
Lastly, we examined the impact of both treatments on different aspects of hand 
function using the Michigan Hand outcomes Questionnaire (MHQ).14 Because we 
assumed that some patients would require at least 6 months for full functional recovery 
after treatment, we asked patients to complete the MHQ before and between 6 months 
and 1 year after treatment. The MHQ consists of 37 items evaluating 6 subdomains for 
each hand separately: overall hand function, ability to perform activities in daily life 
(ADL), work performance, hand appearance, pain and satisfaction with hand function. 
The fact that the MHQ includes a subdomain assessing hand appearance increases its 
scope15 and makes it particularly well-suited for some patients with Dupuytren’s 
contracture.16,17 Scores range from 0 to 100 (with 100 indicating best hand performance). 
As this study was directed at assessing improvement in contracture rather than pain 
reduction, we excluded all pain-related outcomes. We only used the outcomes pertaining 
to the treated side. 
 
Propensity-score matching 
In practice, the choice between PNA versus CCH is not random but related to clinical 
factors, such as the degree of contracture and patient characteristics, as a consequence 
of differences in patient selection and preference. Therefore, we expected that the PNA 
and CCH groups would differ with respect to their baseline characteristics. To account for 
such differences that can otherwise threaten the validity of a comparison due to 
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treatment selection bias, we applied propensity score matching.18,19 This approach has 
been used previously to examine the comparative effectiveness of treatments for 
Dupuytren’s contracture, including PNA and CCH.4,13  
Propensity scores for the probability of undergoing CCH and PNA were developed 
using a logistic regression model with the following baseline characteristics as 
explanatory variables: age20, gender21, family history of the disease22, primary or 
recurrent disease23, the baseline degree of contracture24 at the MCP, PIP and DIP joint 
levels and which joints were affected25. These variables were included because they were 
considered related to 1) either the choice between CCH or PNA or 2) clinical outcomes. 
After calculating the individual scores, we attempted to match each patient from the 
PNA group with two patients from the CCH group with the closest propensity scores (i.e. 
who had the most similar characteristics) using a nearest-neighbor algorithm with 
replacement. We repeated this process until matches had been attempted for all 
patients from the PNA group. To examine whether propensity score matching improved 
similarity among the treatment groups, significance testing was performed before and 
after matching.  
 
Statistical analysis 
Sample size calculations estimated that a total 32 affected MCP joints (16 each group) 
and 70 proximal interphalangeal contractures (35 each group) would provide 80 percent 
power to detect a 10-degree difference in contracture between the two treatment 
groups with the use of two-sided tests.4 
 For improvement in contracture (both in percentage and in absolute degrees) and 
MHQ scores, we used Student t-tests to compare the change at follow-up from baseline 
between treatment groups with corresponding means and two standard errors plotted 
graphically. The proportion of joints with clinical improvement, defined as improvement 
of >50 percent in the degree of contracture, was compared with Chi-square tests. 
Outcomes were analyzed separately for affected MCP and PIP joints because results at 
the PIP joint are typically worse. Rates of adverse effects were compared using the Chi-
square or Fisher’s exact test if effects occurred in both treatment groups.  
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Continuous variables were reported as means ± SD and categorical variables with 
the use of frequencies. P-values of <0.05 were considered to indicate statistical 
significance. 
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Results 
Study sample 
There were a total of 183 patients of whom 79 underwent PNA and 104 CCH. After 
excluding 28 patients who were treated with PNA for multiple digits, a total of 155 
eligible patients remained: 51 underwent PNA and 104 underwent CCH (Figure 1.).  
 
Figure 1. Patient selection flowchart. CCH, Collagenase Clostridium Histolyticum; PNA, percutaneous 
needle aponeurotomy; LF, limited fasciectomy; PS, propensity score. 
 
	
 
Differences between the PNA and CCH groups before propensity score matching included that 
patients undergoing CCH were more often men, were, on average, younger, had less total 
extension deficit, and proportionally fewer affected MCP joints (Table 1. left).  
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Table 1. Characteristics of Clostridium Collagenase Histolyticum and percutaneous needle aponeurotomy 
treatment groups, before and after propensity-score based matching. 
 Unmatched Matched  
PNA (N=51) CCH (N=104) p  PNA (N=46) CCH (N=84) p  
Demographics 
 Age –yrs. 
 Men–% 
 Alcohol use –% 
 Current smoker –% 
 Epilepsy –% 
 
65±8 
65 
73 
18 
0 
 
61±10 
80 
59 
16 
2 
 
0.021 
0.050 
0.092 
0.839 
1.000 
 
63±8 
72 
72 
15 
0 
 
64±8 
75 
60 
18 
2 
 
0.466 
0.686 
0.232 
0.701 
0.539 
Disease characteristics 
 Tubiana –% 
   Grade I  
   Grade II 
   Grade III or IV 
 Recurrent disease –% 
 Positive family history –% 
 
 
33 
53 
14 
22 
43 
 
 
47 
45 
8 
26 
54 
 
0.315 
 
 
 
0.550 
0.210 
 
 
51 
45 
4 
22 
41 
 
 
42 
50 
6 
21 
48 
  
0.562 
 
 
 
0.840 
0.489 
Outcomes 
 Extension deficit –degrees 
  Total 
  MCP joint level 
   All joints 
   Affected joints –% 
  PIP joint level 
   All joints 
   Affected joints –% 
  DIP joint level 
   All joints 
   Affected joints –% 
 
 
62±30 
 
39±23 
90 
 
20±21 
63 
 
3±9 
14 
 
 
52±29 
 
29±24 
75 
 
22±25 
61 
 
1±4 
6 
 
 
0.053 
 
0.010 
0.026 
 
0.498 
0.795 
 
0.063 
0.093 
 
 
49±23 
 
31±21 
89 
 
17±19 
63 
 
1±5 
9 
 
 
54±30 
 
33±24 
81 
 
19±22 
57 
 
1±5 
7 
 
 
0.317 
 
0.518 
0.226 
 
0.546 
0.513 
 
0.966 
0.751 
* Plus-minus values are means ±SD. 
PNA, Percutaneous Needle Aponeurotomy; CCH, Collagenase Clostridium Histolyticum; MCP, 
metacarpophalangeal; PIP, proximal interphalangeal; DIP, distal interphalangeal; SD, standard deviation.  
	
This further highlights the need to account for these differences before comparing the 
two groups since all these factors have been previously found to influence outcomes.21-24 
At the same time, all remaining characteristics were not significantly different, showing 
that the indications for CCH and PNA were not substantially different at the participating 
sites. 
With the use of propensity scores, we were able to match 46 PNA patients to 84 
CCH patients who were similar in terms of their baseline degree of contracture and 
proportions of affected MCP joints (PNA, 34 degrees for 41 joints vs. CCH, 41 degrees for 
68 joints) and affected PIP joints (PNA, 30 degrees for 26 joints vs. CCH, 35 degrees for 
46 joints). All other characteristics were also similar between groups (Table 1. right).  
Among the matched treatment groups, the average degree of total extension 
deficit was 52 degrees. This corresponded to 93% of patients being graded as Tubiana I 
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33 
53 
14 
22 
43 
 
 
47 
45 
8 
26 
54 
 
0.315 
 
 
 
0.550 
0.210 
 
 
51 
45 
4 
22 
41 
 
 
42 
50 
6 
21 
48 
  
0.562 
 
 
 
0.840 
0.489 
Outcomes 
 Extension deficit –degrees 
  Total 
  MCP joint level 
   All joints 
   Affected joints –% 
  PIP joint level 
   All joints 
   Affected joints –% 
  DIP joint level 
   All joints 
   Affected joints –% 
 
 
62±30 
 
39±23 
90 
 
20±21 
63 
 
3±9 
14 
 
 
52±29 
 
29±24 
75 
 
22±25 
61 
 
1±4 
6 
 
 
0.053 
 
0.010 
0.026 
 
0.498 
0.795 
 
0.063 
0.093 
 
 
49±23 
 
31±21 
89 
 
17±19 
63 
 
1±5 
9 
 
 
54±30 
 
33±24 
81 
 
19±22 
57 
 
1±5 
7 
 
 
0.317 
 
0.518 
0.226 
 
0.546 
0.513 
 
0.966 
0.751 
* Plus-minus values are means ±SD. 
PNA, Percutaneous Needle Aponeurotomy; CCH, Collagenase Clostridium Histolyticum; MCP, 
metacarpophalangeal; PIP, proximal interphalangeal; DIP, distal interphalangeal; SD, standard deviation.  
	
This further highlights the need to account for these differences before comparing the 
two groups since all these factors have been previously found to influence outcomes.21-24 
At the same time, all remaining characteristics were not significantly different, showing 
that the indications for CCH and PNA were not substantially different at the participating 
sites. 
With the use of propensity scores, we were able to match 46 PNA patients to 84 
CCH patients who were similar in terms of their baseline degree of contracture and 
proportions of affected MCP joints (PNA, 34 degrees for 41 joints vs. CCH, 41 degrees for 
68 joints) and affected PIP joints (PNA, 30 degrees for 26 joints vs. CCH, 35 degrees for 
46 joints). All other characteristics were also similar between groups (Table 1. right).  
Among the matched treatment groups, the average degree of total extension 
deficit was 52 degrees. This corresponded to 93% of patients being graded as Tubiana I 
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(<45 degrees) or II (45-90 degrees), which indicated that the majority had mildly affected 
digits. Follow-up data was available for 91% of the primary outcome (degree of 
contracture), which was assessed at an average follow-up duration of 8 weeks (range 6-
12 weeks). There were no significant differences in baseline characteristics between 
those who did and did not have primary outcome data available (Supplementary Table 1).  
 
Supplemental Table. 1. Characteristics of the matched patients, divided by those with (respondent) and 
without data (non-respondents) available on the primary outcome (degree of contracture). 
 Respondent (N=118) Non-respondent (N=12) p  
Demographics 
 Age –yrs. 
 Male gender –% 
 Alcohol use –% 
 Current smoker –% 
 Epilepsy –% 
 
63±8 
75 
64 
17 
2 
 
64±5 
67 
67 
17 
0 
 
0.978 
0.562 
0.999 
0.999 
0.532 
Disease characteristics 
 Tubiana –% 
   Grade I  
   Grade II 
   Grade III or IV 
 Recurrent disease –% 
 Positive family history –% 
 
 
45 
50 
5 
21 
43 
 
 
50 
33 
17 
17 
67 
 
0.179 
 
 
 
0.999 
0.120 
Outcomes 
 Extension deficit –degrees† 
  Total 
  MCP joint level 
  PIP joint level 
  DIP joint level 
 
 
62±30 
39±23 
20±21 
3±9 
 
 
52±29 
29±24 
22±25 
1±4 
 
 
0.053 
0.010 
0.498 
0.063 
* Plus-minus values are means ±SD. 
† Values are reported for all joints. 
MCP, metacarpophalangeal; PIP, proximal interphalangeal; DIP, distal interphalangeal; SD, standard 
deviation.  
 
Sixty percent of PNA patients and 72% of CCH patients completed the MHQ to such an 
extent that the baseline overall score could be calculated. Of these, 64% in the PNA group 
and 76% in the CCH group had follow-up data available. We found no significant 
differences in the baseline characteristics between those with and without MHQ follow-
up data. 
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Change in angular correction  
For affected MCP joints, the improvement in contracture at follow-up was not 
significantly different among the matched treatment groups, in percentage correction 
and in absolute degrees (Figure 2. left and middle). The proportion of MCP joints reaching 
clinical improvement, defined as an improvement of >50 percent in the degree of 
contracture, was also similar between the treatment groups (Figure 2. right). 
 
	
Figure 2. Improvement in contracture for affected MCP joints (left and middle) and proportion of 
joints with clinical improvement (right) among the matched Collagenase Clostridium Histolyticum 
and percutaneous needle aponeurotomy groups at early follow-up.  
 
For affected PIP joints, improvement in contracture was also not significantly 
different among the matched treatment groups (Figure 3. left). Consistently, 
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(<45 degrees) or II (45-90 degrees), which indicated that the majority had mildly affected 
digits. Follow-up data was available for 91% of the primary outcome (degree of 
contracture), which was assessed at an average follow-up duration of 8 weeks (range 6-
12 weeks). There were no significant differences in baseline characteristics between 
those who did and did not have primary outcome data available (Supplementary Table 1).  
 
Supplemental Table. 1. Characteristics of the matched patients, divided by those with (respondent) and 
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Sixty percent of PNA patients and 72% of CCH patients completed the MHQ to such an 
extent that the baseline overall score could be calculated. Of these, 64% in the PNA group 
and 76% in the CCH group had follow-up data available. We found no significant 
differences in the baseline characteristics between those with and without MHQ follow-
up data. 
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Change in angular correction  
For affected MCP joints, the improvement in contracture at follow-up was not 
significantly different among the matched treatment groups, in percentage correction 
and in absolute degrees (Figure 2. left and middle). The proportion of MCP joints reaching 
clinical improvement, defined as an improvement of >50 percent in the degree of 
contracture, was also similar between the treatment groups (Figure 2. right). 
 
	
Figure 2. Improvement in contracture for affected MCP joints (left and middle) and proportion of 
joints with clinical improvement (right) among the matched Collagenase Clostridium Histolyticum 
and percutaneous needle aponeurotomy groups at early follow-up.  
 
For affected PIP joints, improvement in contracture was also not significantly 
different among the matched treatment groups (Figure 3. left). Consistently, 
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improvement in contracture in degrees was similar (Figure 3. left and middle). 
	
Figure 3. Improvement in contracture for affected PIP joints (left and middle) and proportion of joints 
with clinical improvement (right) among the matched Collagenase Clostridium Histolyticum and 
percutaneous needle aponeurotomy groups at early follow-up.  
 
The proportion of clinically improved PIP joints in the CCH group was not significantly 
different between groups (Figure 3. right).  
 
Adverse effects 
No serious adverse effects occurred in either of the matched treatment groups (Table 2).  
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Table 2. Adverse effects in the matched treatment groups, by severity grade.* 
Adverse effect PNA (N=46) CCH (N=84) 
Mild 
 Peripheral edema 
 Contusion 
  Mild 
  Severe 
 Pain 
 Blood blister 
 Axillary tenderness 
 Skin fissure 
 Sensory disturbance  
 Pruritus 
 Erythema 
 Lymphadenopathy 
 Scar sequelae 
 Wound healing problems 
Serious 
 Nerve laceration 
 Uncorrectable contracture  
 Wound infection  
 Arterial laceration 
 Tendon rupture 
 Cold intolerance 
 CRPS 
 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
4 
2 
n.a. 
n.a. 
n.a. 
0 
0 
 
0 
0 
0 
0 
0 
0 
0 
 
70 
62 
54 
8 
31 
11 
8 
8 
1 
4 
4 
1 
0 
0 
 
0 
0 
0 
0 
0 
0 
0 
* Values are percentages. 
PNA, Percutaneous needle aponeurotomy; CCH, Clostridium collagenase 
histolyticum; CRPS, complex regional pain syndrome. 
 
Three of the most common mild adverse effects in the CCH group were peripheral 
edema, contusion, and transient pain. The only events occurring in both treatment 
groups were skin fissures and sensory disturbances, which did not significantly differ in 
their relative incidence between groups (p=0.491 and p=1.000, respectively). 
 
Changes in hand function  
The overall MHQ score was similar at baseline in the matched PNA and CCH groups. At an 
average of 11 months follow-up, patients also reported a similar improvement in the 
overall score (PNA, 5.3 points vs. CCH, 4.9 points; p=0.912).  
There were, however, differences between the two groups in the extent to which 
several subdomain scores improved. PNA patients as compared with CCH patients 
reported, on average, larger improvements in the MHQ subscores of satisfaction (18 
points) and hand appearance (8 points), although only the difference in the satisfaction 
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improvement in contracture in degrees was similar (Figure 3. left and middle). 
	
Figure 3. Improvement in contracture for affected PIP joints (left and middle) and proportion of joints 
with clinical improvement (right) among the matched Collagenase Clostridium Histolyticum and 
percutaneous needle aponeurotomy groups at early follow-up.  
 
The proportion of clinically improved PIP joints in the CCH group was not significantly 
different between groups (Figure 3. right).  
 
Adverse effects 
No serious adverse effects occurred in either of the matched treatment groups (Table 2).  
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Table 2. Adverse effects in the matched treatment groups, by severity grade.* 
Adverse effect PNA (N=46) CCH (N=84) 
Mild 
 Peripheral edema 
 Contusion 
  Mild 
  Severe 
 Pain 
 Blood blister 
 Axillary tenderness 
 Skin fissure 
 Sensory disturbance  
 Pruritus 
 Erythema 
 Lymphadenopathy 
 Scar sequelae 
 Wound healing problems 
Serious 
 Nerve laceration 
 Uncorrectable contracture  
 Wound infection  
 Arterial laceration 
 Tendon rupture 
 Cold intolerance 
 CRPS 
 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
4 
2 
n.a. 
n.a. 
n.a. 
0 
0 
 
0 
0 
0 
0 
0 
0 
0 
 
70 
62 
54 
8 
31 
11 
8 
8 
1 
4 
4 
1 
0 
0 
 
0 
0 
0 
0 
0 
0 
0 
* Values are percentages. 
PNA, Percutaneous needle aponeurotomy; CCH, Clostridium collagenase 
histolyticum; CRPS, complex regional pain syndrome. 
 
Three of the most common mild adverse effects in the CCH group were peripheral 
edema, contusion, and transient pain. The only events occurring in both treatment 
groups were skin fissures and sensory disturbances, which did not significantly differ in 
their relative incidence between groups (p=0.491 and p=1.000, respectively). 
 
Changes in hand function  
The overall MHQ score was similar at baseline in the matched PNA and CCH groups. At an 
average of 11 months follow-up, patients also reported a similar improvement in the 
overall score (PNA, 5.3 points vs. CCH, 4.9 points; p=0.912).  
There were, however, differences between the two groups in the extent to which 
several subdomain scores improved. PNA patients as compared with CCH patients 
reported, on average, larger improvements in the MHQ subscores of satisfaction (18 
points) and hand appearance (8 points), although only the difference in the satisfaction 
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subscore reached significance (Figure 4). 
	
Figure 4. Change in MHQ scores in the matched Clostridium Collagenase Histolyticum and 
percutaneous needle aponeurotomy treatment groups.  
 
CCH patients, in turn, reported significantly larger improvements in the ADL subscore (4 
points). Further exploring these differences, all subdomain scores in absolute terms were 
similar between-groups at baseline and follow-up with the exception that the 
satisfaction and appearance subscores were an average of 7 and 9 points, respectively, 
lower in the PNA group than in the CCH group at baseline (p=0.204 and p=0.057, 
respectively). 
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Discussion 
Despite the large number of studies describing the outcomes of various treatments for 
Dupuytren’s contracture, scarce evidence is available to guide decision-making in the 
disease.26,27 The aim of this study involving multiple practice sites in the Netherlands was 
to assess the outcomes of PNA versus CCH in clinical practice. We found that, among 
patients with mildly contractures (93% Tubiana I or II), improvement in contracture with 
PNA as compared with CCH was similar for affected MCP and PIP joints. No major 
adverse effects occurred in any of the two treatment groups. Over time, the overall MHQ 
score also improved to a similar extent in both groups. 
As evidenced by both the relative improvement and in absolute degrees, the level 
of contracture correction achieved in our study at the MCP joint level after CCH was 
similar to that after PNA. Two previous clinical trials reported similar findings.8,9 In the 
present study, affected MCP joints improved by 31 and 26 degrees after CCH and PNA, 
respectively. This agrees well with the similar degree of improvement reported by 
Scherman and colleagues (46 and 47 degrees for CCH and PNA at 3 months, 
respectively)8 and by Strömberg and colleagues (48 and 46 degrees, respectively).9 The 
smaller improvement in contracture in absolute terms in our study can be explained by 
differences in baseline severity of contracture among the study samples as well as 
differences in assessment methods (passive versus active goniometry). Affected PIP 
joints in our study improved by 17 and 16 degrees after CCH and PNA, respectively. In 
comparison, Scherman and colleagues reported in their study that PIP joints also 
improved to a similar extent (8 and 11 degrees after CCH and PNA, respectively). Again, 
the difference in absolute improvement can be explained by slight differences in patient 
inclusion. Collectively, these findings show that the effectiveness of CCH at reducing 
contractures is similar to that of PNA in actual clinical practice, despite that decision-
making processes and compliance in this study probably differed from that in previous 
clinical trials. We therefore believe that they are an addition to the evidence-base 
available on CCH and PNA.  
We found no serious adverse effects following either treatments, which is 
consistent with what has previously been reported.9 Skin fissures and sensory 
disturbances were the only mild adverse effects that occurred after both CCH and PNA 
4Chapter 4	
	 76	
subscore reached significance (Figure 4). 
	
Figure 4. Change in MHQ scores in the matched Clostridium Collagenase Histolyticum and 
percutaneous needle aponeurotomy treatment groups.  
 
CCH patients, in turn, reported significantly larger improvements in the ADL subscore (4 
points). Further exploring these differences, all subdomain scores in absolute terms were 
similar between-groups at baseline and follow-up with the exception that the 
satisfaction and appearance subscores were an average of 7 and 9 points, respectively, 
lower in the PNA group than in the CCH group at baseline (p=0.204 and p=0.057, 
respectively). 
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Discussion 
Despite the large number of studies describing the outcomes of various treatments for 
Dupuytren’s contracture, scarce evidence is available to guide decision-making in the 
disease.26,27 The aim of this study involving multiple practice sites in the Netherlands was 
to assess the outcomes of PNA versus CCH in clinical practice. We found that, among 
patients with mildly contractures (93% Tubiana I or II), improvement in contracture with 
PNA as compared with CCH was similar for affected MCP and PIP joints. No major 
adverse effects occurred in any of the two treatment groups. Over time, the overall MHQ 
score also improved to a similar extent in both groups. 
As evidenced by both the relative improvement and in absolute degrees, the level 
of contracture correction achieved in our study at the MCP joint level after CCH was 
similar to that after PNA. Two previous clinical trials reported similar findings.8,9 In the 
present study, affected MCP joints improved by 31 and 26 degrees after CCH and PNA, 
respectively. This agrees well with the similar degree of improvement reported by 
Scherman and colleagues (46 and 47 degrees for CCH and PNA at 3 months, 
respectively)8 and by Strömberg and colleagues (48 and 46 degrees, respectively).9 The 
smaller improvement in contracture in absolute terms in our study can be explained by 
differences in baseline severity of contracture among the study samples as well as 
differences in assessment methods (passive versus active goniometry). Affected PIP 
joints in our study improved by 17 and 16 degrees after CCH and PNA, respectively. In 
comparison, Scherman and colleagues reported in their study that PIP joints also 
improved to a similar extent (8 and 11 degrees after CCH and PNA, respectively). Again, 
the difference in absolute improvement can be explained by slight differences in patient 
inclusion. Collectively, these findings show that the effectiveness of CCH at reducing 
contractures is similar to that of PNA in actual clinical practice, despite that decision-
making processes and compliance in this study probably differed from that in previous 
clinical trials. We therefore believe that they are an addition to the evidence-base 
available on CCH and PNA.  
We found no serious adverse effects following either treatments, which is 
consistent with what has previously been reported.9 Skin fissures and sensory 
disturbances were the only mild adverse effects that occurred after both CCH and PNA 
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but were rare. All other minor effects were unique to the CCH group among which 
peripheral edema, contusion and pain in the extremity were the three most common. We 
believe that these findings primarily highlight the different modes of action of the two 
treatments. 
  During the first year after treatment, we found that the overall MHQ score 
improved to a similar extent after PNA and CCH. This underscores the effectiveness of 
both treatments at improving hand function for patients, even for those with mild 
contractures. Interestingly, the subdomain scores of satisfaction and appearance 
showed larger improvements after PNA than after CCH at follow-up, while the scores in 
absolute terms were similar. We feel that this is due to the comparatively lower scores in 
these subdomains in the PNA group at baseline. Considering that both treatment groups 
were similar with respect to their baseline characteristics, including demographics and 
disease severity, this suggest less satisfaction and more concern with the appearance of 
their hands among those opting for PNA. Further research is warranted in this area, 
which we believe can address a knowledge gap regarding the concerns and needs that 
influence treatment decision-making among patients with Dupuytren’s disease.28-30 
 The resources required for CCH and PNA may also be important to consider when 
deciding between the two treatments, particularly considering that associated costs can 
differ substantially. Although these will vary depending on geographic region, the direct 
costs of CCH will be higher in most settings due to the low material costs of PNA. In 
addition, two visits are required with CCH whereas PNA requires only a single visit. CCH 
may therefore be regarded as the least cost-effective option of the two, which then 
ought to be justified by objective advantages (i.e. superior outcomes). To date, we are 
unaware of any study showing these advantages. Previous economic evaluations have, 
however, underlined the complexity in comparing the cost-effectiveness of different 
treatments in Dupuytren’s disease due to the lack and quality of existing literature.27,31 
The data presented in the current study allow for refining such economic models that 
help to identify treatment algorithms for Dupuytren’s contracture that are both cost-
effective and broadly applicable. 
Our study has several strengths. First, it used prospective data from 7 practice 
sites that were gathered as part of daily clinical practice, making it a comparative 
effectiveness study.32 The results from such studies, compared with strictly controlled 
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trials, may be more broadly generalizable because they better reflect the actual decision-
making processes, patient compliance, and, ultimately, the outcomes achieved in daily 
practice.10,32,33 Second, we examined the relative change in MHQ scores rather than a 
cross-sectional assessment, which enabled a comparison of the impact of CCH and PNA 
on different aspects of hand function.34 Other strengths include the relatively large 
sample analyzed, completeness of outcome data (91% primary outcome) and the use of 
propensity scores to minimize the risk of bias due to observed differences. Despite this 
study design, a potential limitation of this study is that propensity analyses cannot 
account for selection bias related to unmeasured characteristics (i.e. genetic 
constitution). A second limitation is that we could not reliably assess rates of recurrence, 
which may be as relevant to patients in treatment decision-making as early outcomes, 
because of the limited time-horizon of our study.30 Thirdly, only a subset of patients 
completed the MHQ. Although this might have influenced our results, the possibility for 
attrition bias seems small because there were no differences in the characteristics 
between those who did and did not complete the MHQ at follow-up. Finally, the rare 
incidence of adverse effects in both treatment groups precludes strong inferences to be 
made about the comparative risk profile of both treatments.  
In conclusion, we found that, among patients with mildly affected digits, CCH and 
PNA were similarly effective at improving contractures. Even among these patients, we 
found a significant and similar improvement in overall hand function, which reinforces 
the usefulness of both treatments as first-line treatments. Our findings also underscore 
the safety of both techniques in daily practice. Until longer-term studies are conducted 
that are urgently needed to better understand the durability of the outcomes of both 
treatments, we believe that these findings may help patients with Dupuytren’s disease, 
payers and providers decide between these two minimally invasive treatment options.  
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but were rare. All other minor effects were unique to the CCH group among which 
peripheral edema, contusion and pain in the extremity were the three most common. We 
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disease severity, this suggest less satisfaction and more concern with the appearance of 
their hands among those opting for PNA. Further research is warranted in this area, 
which we believe can address a knowledge gap regarding the concerns and needs that 
influence treatment decision-making among patients with Dupuytren’s disease.28-30 
 The resources required for CCH and PNA may also be important to consider when 
deciding between the two treatments, particularly considering that associated costs can 
differ substantially. Although these will vary depending on geographic region, the direct 
costs of CCH will be higher in most settings due to the low material costs of PNA. In 
addition, two visits are required with CCH whereas PNA requires only a single visit. CCH 
may therefore be regarded as the least cost-effective option of the two, which then 
ought to be justified by objective advantages (i.e. superior outcomes). To date, we are 
unaware of any study showing these advantages. Previous economic evaluations have, 
however, underlined the complexity in comparing the cost-effectiveness of different 
treatments in Dupuytren’s disease due to the lack and quality of existing literature.27,31 
The data presented in the current study allow for refining such economic models that 
help to identify treatment algorithms for Dupuytren’s contracture that are both cost-
effective and broadly applicable. 
Our study has several strengths. First, it used prospective data from 7 practice 
sites that were gathered as part of daily clinical practice, making it a comparative 
effectiveness study.32 The results from such studies, compared with strictly controlled 
PNA vs. CCH 
	
 79	
trials, may be more broadly generalizable because they better reflect the actual decision-
making processes, patient compliance, and, ultimately, the outcomes achieved in daily 
practice.10,32,33 Second, we examined the relative change in MHQ scores rather than a 
cross-sectional assessment, which enabled a comparison of the impact of CCH and PNA 
on different aspects of hand function.34 Other strengths include the relatively large 
sample analyzed, completeness of outcome data (91% primary outcome) and the use of 
propensity scores to minimize the risk of bias due to observed differences. Despite this 
study design, a potential limitation of this study is that propensity analyses cannot 
account for selection bias related to unmeasured characteristics (i.e. genetic 
constitution). A second limitation is that we could not reliably assess rates of recurrence, 
which may be as relevant to patients in treatment decision-making as early outcomes, 
because of the limited time-horizon of our study.30 Thirdly, only a subset of patients 
completed the MHQ. Although this might have influenced our results, the possibility for 
attrition bias seems small because there were no differences in the characteristics 
between those who did and did not complete the MHQ at follow-up. Finally, the rare 
incidence of adverse effects in both treatment groups precludes strong inferences to be 
made about the comparative risk profile of both treatments.  
In conclusion, we found that, among patients with mildly affected digits, CCH and 
PNA were similarly effective at improving contractures. Even among these patients, we 
found a significant and similar improvement in overall hand function, which reinforces 
the usefulness of both treatments as first-line treatments. Our findings also underscore 
the safety of both techniques in daily practice. Until longer-term studies are conducted 
that are urgently needed to better understand the durability of the outcomes of both 
treatments, we believe that these findings may help patients with Dupuytren’s disease, 
payers and providers decide between these two minimally invasive treatment options.  
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Abstract 
 
Background: This study examined patient satisfaction with hand function after 
fasciectomy for Dupuytren's contracture and determined which preoperative patient- 
and disease-specific factors predicted this satisfaction. 
 
Methods: Demographics and disease-specific factors were assessed from a prospective 
cohort of 194 patients who completed the Michigan Hand Outcomes Questionnaire 
preoperatively and underwent limited fasciectomy between 2011 and 2014 at six hand 
surgery practice sites. To evaluate satisfaction with hand function, patients were asked 
to complete the Michigan Hand Outcomes Questionnaire during the first year after 
fasciectomy. After patients were classified into a satisfied and an unsatisfied category 
using the question that specifically pertains to satisfaction with hand function, the 
authors applied multivariate logistic regression modeling to identify independent 
predictors of patient satisfaction. 
 
Results: At an average of 10 months (range, 6 to 12 months) after fasciectomy, 84 
percent (n = 163) of the patients were satisfied with their hand function. In multivariate 
analyses adjusting for the degree of postoperative residual contracture (p < 0.001) and 
complications (p < 0.001), a higher preoperative Michigan Hand Outcomes Questionnaire 
hand appearance subscore and male gender predicted a higher likelihood of becoming 
satisfied after fasciectomy. Other patient- and disease-specific factors did not show 
evidence for an association with patient satisfaction. 
 
Conclusion: The findings of this study suggest that providers should consider assessing 
concerns about the appearance of the hand in patients with Dupuytren's contracture. 
They also highlight the importance of complication prevention and full contracture 
correction from the patient's perspective. 
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Introduction 
Dupuytren’s disease is characterized by the development of cords that may contract and 
cause disfiguring flexion deformities.1 Surgical fasciectomy remains the standard against 
which the results of all other techniques ought to be compared.2 The technique 
effectively reduces contractures with acceptable complication rates and provides a 
relatively low risk of recurrence.3 However, outcomes that are good from a provider’s 
perspective do not necessarily satisfy patients. It is important to identify the factors that 
matter most to patients, in order to understand the patient perspective and maximize 
satisfaction rates.   
Patient satisfaction is a broad yet increasingly important construct, and may be 
subdivided into different domains, such as satisfaction with the provider, convenience of 
care, and functional outcomes. In general, satisfied patients better adhere to treatment 
regimens, and are more compliant and more loyal towards providers.4 Moreover, 
satisfaction data are increasingly used to judge the quality of surgical care.5,6 Although 
our knowledge of the factors influencing patient satisfaction remains incomplete, what is 
evident is that it not only depends on the treatment delivered but also on patient factors, 
such as demographics, functional status, and pretreatment expectations.7,8 Previous 
studies have reported variable satisfaction rates following fasciectomy9 but the factors 
contributing to this variation remain poorly understood.10,11  
The aim of the present study was to identify preoperative factors that influenced 
satisfaction with hand function after fasciectomy for Dupuytren’s contracture. 
Satisfaction with hand function is important, as the premise of the treatment is to 
restore hand function for patients. Preoperative factors were assessed because 
identification, prior to treatment, of those at risk of becoming unsatisfied may help 
providers to better address individual concerns or needs preoperatively, and prompt 
them to manage patients differently.  
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Methods 
Study sample 
After our local institutional review board approved our study protocol, we identified all 
patients who underwent fasciectomy for Dupuytren’s contracture between 2011 and 2013 
at 6 hand surgery practice sites using a prospectively maintained database that was 
designed for clinical and research purposes. Demographic and disease specific 
characteristics derived from this database were age, gender, occupational status, 
comorbidities, current tobacco and alcohol use, family history of Dupuytren’s disease, 
hand dominance, number of treated rays, bilateral disease, whether fasciectomy was 
performed for primary or recurrent disease, and the degree of contracture.   
We included all adult patients with a diagnosis of Dupuytren’s contracture who 
underwent fasciectomy and who had the ability to complete the study questionnaire. 
Patients were excluded if they had a diagnosis of a hand condition or underwent a 
concomitant intervention (e.g., carpal tunnel release) on the affected side that could 
confound patient satisfaction. Patients undergoing treatment for recurrent disease were 
included if they met the other eligibility criteria. 
 
Primary outcome: patient satisfaction with hand function 
The Michigan Hand Outcomes Questionnaire (MHQ) was mailed to all study participants 
before, and between 6 months and 1 year after surgery. The minimum 6 months follow-
period was decided upon based on previous research showing that the majority of 
patients are functionally recovered after fasciectomy at this time point.12 The MHQ is a 
thoroughly-developed and sensitive hand-specific instrument that assesses 6 domains of 
hand function: overall hand function, activities of daily living, pain, work performance, 
hand appearance, and patient satisfaction, with scores ranging from 0 (poorest function) 
to 100 (best function). The fact that the MHQ includes a scale that assesses hand 
appearance increases the scope of this instrument.13  
Satisfaction with hand function was assessed using one of the questions from the 
satisfaction domain of the MHQ that specifically asks patients about their satisfaction 
with overall hand function. Patients responded using a five-point Likert scale with the 
following possible answers: “Very satisfied”, “Somewhat satisfied”, “Neither Satisfied 
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Nor Dissatisfied”, “Somewhat Dissatisfied”, or “Very Dissatisfied”. We considered 
patients who selected “Very satisfied”, “Somewhat satisfied” as being satisfied with 
their hand function and all others as unsatisfied. Although dichotomization of ordinal 
data may result in some information loss, we decided upon this approach for two 
important reasons. First, our purpose was to specifically focus on the difference between 
patients who had at least some degree of satisfaction and those who reported no 
satisfaction at all. Second, previous other investigators have successfully used this 
approach to identify determinants of satisfaction in other hand conditions.14 Only the 
outcomes pertaining to the treated side were used. 
 
Clinical outcomes 
We anticipated that postoperative outcomes would influence patient satisfaction. To 
account for their possible influences, we assessed the occurrence of complications, 
whether a secondary procedure had been performed for recurrent contracture, and the 
degree of postoperative total residual contracture. The occurrence of complications and 
whether a revision procedure had been performed for recurrent disease within the 
follow-up period of the study was assessed through retrospective analyses of patients’ 
health records and office charts. Because it was assumed that any type of complication 
could impact patient satisfaction, we included all complications noted including 
neuropraxia, scar sequelae, wound healing problems, wound infection, hematoma, 
tenosynovitis, edema, cold intolerance, sympathetic dystrophy, persistent pain and nerve 
division, arterial injury. The degree of total residual contracture was assessed by certified 
hand therapists during visits occurring between 6 and 12 weeks after treatment by 
summing up the degree of active extension deficit at the MCP, PIP and DIP joint levels. 
Any hyperextension was converted to 0 degrees to prevent underestimation of the total 
degree of extension deficit. To improve the comparability between patients with a single 
affected versus those with multiple affected digits, we used the measurements 
pertaining to the most severely contracted digit. 
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Statistical analysis 
Descriptive statistics included means and standard deviations for continuous variables 
and numbers for categorical variables. A power analysis determined that a sample of 160 
patients would provide 80% power (alpha 0.05, beta 0.20) to detect a significant 
difference of 10 points in the MHQ overall hand function score between satisfied and 
unsatisfied patients and assuming a standard deviation of 18 points and a satisfied to 
unsatisfied ratio of 4:1.15 
Preliminary analyses examined possible bivariate relationships between patient 
satisfaction with hand function and a diverse set of demographic variables, clinical 
factors and the preoperative MHQ subdomain scores of overall hand function, ability to 
perform activities in daily life, work performance, satisfaction and hand appearance using 
Student t test’s for continuous variables and chi-square tests for categorical variables. 
Then, all factors showing a relationship (p<0.10) were included in multivariate logistic 
regression models (primary analyses) that accounted for the possible influences of 
postoperative outcomes on patient satisfaction to identify independent predictors of 
patient satisfaction. To explore possible mechanisms underlying the factors associated 
with satisfaction, interaction effects were assessed afterwards. Significance thresholds 
were set at P<0.05. 
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Results 
There were a total of 236 patients who underwent fasciectomy by one of the 16 hand 
surgeons from the participating sites. After excluding 42 patients based on our eligibility 
criteria, 194 patients remained to form our study sample. Of these, all patients completed 
the question pertaining to satisfaction with overall hand function. The mean age in our 
study sample was 63±9 years and 73% were men. At an average of 10 months (procedure 
to survey completion, range 6-12) after fasciectomy, 84% (N=163) of our study population 
were satisfied with their hand function while 16% (N=31) were unsatisfied. Satisfaction 
rates were not significantly different between the surgeons (P=0.777) and practice sites 
(P=0.291). The time from procedure to survey completion was similar between satisfied 
and unsatisfied patients (P=0.648).  
Table 1 shows the bivariate associations between preoperative characteristics and 
patient satisfaction with hand function.  
Table 1. Bivariate associations between demographics, clinical characteristics 
and self-reported outcomes at baseline with patient satisfaction with hand 
function during the first year after fasciectomy.* 
Variable Satisfied  
(N=163) 
Unsatisfied 
(N=31) 
P 
Age –yrs 
Male gender –% 
Occupational status –% 
Diabetes –% 
Smoking –% 
Alcohol –% 
Positive family history –% 
Bilateral disease –% 
Primary disease –% 
Dominant side treated –% 
No. of treated fingers 
Joint level affected 
 MP joint –% 
 PIP joint –% 
Total Extension deficit –degrees 
MHQ subdomain score (0-100) 
 Satisfaction 
 Activities in Daily Life 
 Overall Function 
 Appearance 
 Work Performance 
65 ± 9 
76 
42 
7 
4 
4 
50 
37 
70 
52 
1.7 
 
44 
79 
70 ± 24 
 
60 ± 24 
90 ± 14 
67 ± 16 
71 ± 19 
83 ± 24 
62 ± 9 
58 
36 
10 
10 
7 
42 
42 
55 
58 
1.8 
 
32 
87 
64 ± 36 
 
52 ± 20 
87 ± 13 
63 ± 13 
58 ± 16 
79 ± 21 
0.172 
0.038 
0.517 
0.712 
0.158 
0.616 
0.442 
0.635 
0.100 
0.731 
0.289 
 
0.218 
0.306 
0.248 
 
0.081 
0.368 
0.228 
0.001 
0.293 
* Plus-minus values are means ±SD. 
MP, metacarpophalangeal; PIP, proximal interphalangeal; SD, standard 
deviation; MHQ, Michigan Hand Outcomes Questionnaire. 
 
5Chapter 5	
	 90	
Statistical analysis 
Descriptive statistics included means and standard deviations for continuous variables 
and numbers for categorical variables. A power analysis determined that a sample of 160 
patients would provide 80% power (alpha 0.05, beta 0.20) to detect a significant 
difference of 10 points in the MHQ overall hand function score between satisfied and 
unsatisfied patients and assuming a standard deviation of 18 points and a satisfied to 
unsatisfied ratio of 4:1.15 
Preliminary analyses examined possible bivariate relationships between patient 
satisfaction with hand function and a diverse set of demographic variables, clinical 
factors and the preoperative MHQ subdomain scores of overall hand function, ability to 
perform activities in daily life, work performance, satisfaction and hand appearance using 
Student t test’s for continuous variables and chi-square tests for categorical variables. 
Then, all factors showing a relationship (p<0.10) were included in multivariate logistic 
regression models (primary analyses) that accounted for the possible influences of 
postoperative outcomes on patient satisfaction to identify independent predictors of 
patient satisfaction. To explore possible mechanisms underlying the factors associated 
with satisfaction, interaction effects were assessed afterwards. Significance thresholds 
were set at P<0.05. 
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More men were satisfied. Satisfied patients had, on average, higher preoperative 
MHQ hand appearance subscores as compared with those who were unsatisfied. All 
other subscores, preoperative patient factors, and disease specific characteristics, 
including occupational status, bilateral disease, recurrent disease, and the degree of 
preoperative contracture, showed no relationship with satisfaction.  
 As expected, postoperative outcomes influenced patient satisfaction. Satisfied 
patients had less residual total extension deficit (29 degrees vs. 18 degrees; P<0.001) and 
a lower rate of complications (20% vs. 52%; P<0.001; Table 2).  
 
Table 2. Complications, by patient satisfaction with hand 
function.* 
 Satisfied  
(N=163) 
Unsatisfie
d 
(N=31) 
P 
No complication † 
Neuropraxia 
Scar sequelae 
Wound infection 
Wound healing 
problems 
Edema 
Cold Intolerance 
Sympathetic dystrophia 
Persistent pain 
Stiffness 
Tenosynovitis 
Arterial injury 
Hematoma 
80 (131) 
9 (14) 
5 (8) 
2 (3) 
2 (3) 
1 (1) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
1 (1) 
1 (1) 
1 (1) 
48 (15) 
16 (5) 
10 (3) 
0 (0) 
10 (3) 
3 (1) 
3 (1) 
3 (1) 
3 (1) 
3 (1) 
0 (0) 
0 (0) 
0 (0) 
<0.001 
* Values are percentages (numbers).  
† There were no significant differences in the preoperative degree 
of contracture and joint levels involved between the two groups. 
 
Notably, the incremental change in the degree of contracture was not related to 
satisfaction (P=0.683). Within the follow-up period of this study, none of the patients 
underwent a secondary procedure for recurrent contracture, which precluded inclusion 
of this outcome as a possible predictor in further analyses.  
 The most parsimonious multivariate model that accounted for the influence of 
the degree of residual contracture (P=0.017) and complications (P=0.002) on patient 
satisfaction accounted for 32% of the variation in satisfaction response. In this model, the 
MHQ hand appearance subscore remained as the only significant preoperative predictor 
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of satisfaction with hand function, whereas gender approached significance (Table 3). 
More specifically, patients who had a higher preoperative hand appearance score of 10 
points were about 1.4 times as likely to be satisfied with their hand function. Men, as 
compared with women, were about 2.5 times as likely to be satisfied.  
 
Table 3. Preoperative predictors of satisfaction with hand function during the first year after 
fasciectomy from the final multivariable logistic regression model, with adjustment for the 
postoperative degree of total residual contracture and complications. 
Predictor OR (95% CI) P  
MHQ hand appearance subscore* (per 10 point 
incremental change) 
Male gender  
1.37 (1.12-1.62) 
2.54 (0.98-6.64) 
0.003 
0.056 
OR, Odds Ratio; CI, Confidence Interval; MHQ, Michigan Hand Questionnaire. 
 
 Further exploring the possible mechanisms underlying the effects of hand 
appearance on satisfaction, we found that the interaction effects between the 
preoperative hand appearance subscore and postoperative residual contracture 
(P=0.482) and complications (P=0.604) were not significant. The interaction effects 
between gender and residual extension deficit (P=0.645) and complications (P=0.202) on 
satisfaction were also not significant.  
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Discussion 
The present study examined satisfaction with hand function and its determinants in 
patients undergoing fasciectomy for Dupuytren’s contracture. Eighty-four percent of 
patients were satisfied during the first year after treatment. In light of the similar rates 
previously reported on fasciectomy9,11,12, this finding shows the effectiveness of 
fasciectomy from the patient perspective16 yet implies that the procedure may not be 
fully meeting patients’ needs.17 We found that a higher preoperative MHQ hand 
appearance score and male gender predicted a higher likelihood of becoming satisfied 
after adjusting for the influence of postoperative outcomes. We found no relations 
between satisfaction and other patient- and disease-specific factors.   
In this study, valuing appearance of the hand more positively before surgery was 
associated with higher satisfaction with hand function afterwards. This highlights the 
concern about the appearance of the hand patients with Dupuytren’s contracture may 
have as well as the detrimental impact of such concerns on satisfaction. After all, the 
hand is prominently visible and fulfills a crucial role in interaction with our environment, 
physical expression and social functioning.18,19 Dupuytren’s disease is characterized by 
the formation of contractures that may cause a variable degree of disfigurement and 
deformity11,20, which is further substantiated by the inverse correlation between the 
preoperative degree of contracture and the MHQ hand appearance subscore in the 
present study. Previous studies found that, among patients with other hand deformities, 
hand appearance significantly impacted their lifestyle due to feelings of anxiety, lowered 
self-esteem and negative self-perceptions.19,21-23 It may be that similar mechanisms 
contribute to the dissatisfaction in those who are concerned about the appearance of 
the hand in Dupuytren’s disease.20 In light of recent studies showing that hand 
appearance improves after fasciectomy24,25, it seems logical that, among those who have 
such concerns, satisfaction increases after their contractures and deformity have 
improved following the fasciectomy. We believe that these findings should raise 
awareness among hand surgeons for the concerns patients with Dupuytren’s disease 
may have about the appearance of the hand and possibly their need for restoration of a 
more normal hand appearance in addition to the unquestionable importance of 
functional restoration.  
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We found that men were about 2.5 times as likely to be satisfied as compared 
with women, which shows a gender disparity in satisfaction for which the underlying 
mechanisms are probably complex. Dupuytren’s disease occurs less frequently in 
women26, and it could be that they have different attitudes towards the disease and its 
consequences. The few studies examining gender differences in Dupuytren’s disease 
found primarily that clinical outcomes were better in men than women.27,28 Although this 
might explain why men were more satisfied, no such differences were found in the 
present study. Moreover, the negative interaction effect between gender and 
postoperative outcomes indicated that men and women were equally dissatisfied if a 
complication occurred or the degree of correction did not meet their expectation. As 
such, the forum is open for discussion as to why men were more satisfied after 
fasciectomy. Perhaps women experienced the impact of open fasciectomy more severely 
or they had higher expectations prior to the procedure. Future studies that are 
qualitative in nature may clarify these questions. Until then, however, the gender 
difference in satisfaction found in this study underscore the need for providers to 
consider adjusting for such differences before presenting satisfaction data in 
Dupuytren’s disease. 
 Less residual contracture was associated with higher rates of patient satisfaction, 
whereas the degree of contracture before and incremental change after surgery did not. 
This suggests that satisfaction depends more on the absolute postoperative result than 
the (potential) change in contracture. It also emphasizes the relevance of achieving full 
corrections from the patient perspective. Furthermore, our study reinforces the 
importance of the prevention of complications, as they also had a detrimental effect on 
patients’ satisfaction. The finding that other patient factors, such as recurrence, did not 
influence satisfaction suggests that patient satisfaction depends on how Dupuytren’s 
disease is experienced by each patient. 
 Strengths of this study include its prospective design and large sample size by 
virtue of the participation of 6 practice sites. This allowed for multivariate analyses to 
identify predictors of satisfaction, after taking into account the significant influences of 
postoperative outcomes. However, it also resulted in a high number of surgeons 
performing the procedures. 
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Although the satisfaction rates between the surgeons and practice sites involved did not 
differ significantly in the present study, the possibility exists for performance bias (i.e. 
bias due to performance variability between surgeons) to have influenced our findings.29.  
A second limitation is that patient satisfaction was assessed during the first year after 
fasciectomy whereas most contractures tend to recur after this time-horizon. As such, 
the extent to which levels of satisfaction change and its determinants remain similar over 
time remains unknown. Third, we only included patients undergoing fasciectomy, thus 
our findings may not apply to patients undergoing less invasive techniques. Fourth, we 
did not assess psychological factors, although these have been previously linked to 
patient-reported satisfaction30, which merits further research in this area.31 Finally, to 
increase the likelihood of finding predictors of patient satisfaction, we used the sensitive 
and well-validated hand-specific Michigan Hand Outcomes Questionnaire.4 However, the 
Unité Rhumatologique des Affections de la Main (URAM) is a more recently developed 
questionnaire specific to Dupuytren’s disease, which particularly focuses on the 
functional problems experienced by patients.32 Investigators should consider 
incorporating the URAM in future satisfaction studies as this would increase our 
understanding of what factors affect satisfaction in Dupuytren’s disease. 
 This study addresses a gap in knowledge regarding the determinants of patient 
satisfaction with hand function in Dupuytren’s disease, which is essential for 
understanding the patient perspective and improving satisfaction. Patient satisfaction 
was higher in patients who had higher self-rated hand appearance preoperatively, in 
men, and those who had better postoperative outcomes. These findings show that 
providers should consider assessing concerns about the appearance of the hand in 
patients with Dupuytren's contracture. They also highlight the relevance of full 
contracture corrections and the prevention of complications for patients.  
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Abstract 
 
Background: In the DuRo trial, a randomized clinical trial, percutaneous aponeurotomy 
with lipofilling (PALF) was as effective as limited fasciectomy (LF) in correcting primary 
Dupuytren’s contracture after 1-year follow-up. The purpose of the present study is to 
report the 5-year results of this trial, especially focusing on recurrence of contractures. 
 
Methods: We invited all patients who had undergone PALF or LF to participate in a post-
trial follow-up assessment. Thirty-one PALF patients and 21 LF patients were assessed by 
an independent examiner for the degree of contracture and whether patients had 
undergone a secondary procedure. The primary composite endpoint was recurrence 
rate, defined as either 20° or greater worsening in contracture (relative to week 3) or as 
having undergone a secondary procedure for a new or worsening contracture. 
 
Results: At 5 years, more joints in the PALF group than in the LF group had a recurrence 
(74% vs. 39%, p = 0.002). When re-defining recurrence as a worsening in total extension 
deficit of at least 30° for treated digits, this was 77% vs 32% (p = 0.001). Total extension 
deficit was also worse for PALF-treated digits (53 degrees vs. 31 degrees, p < 0.010).  
 
Conclusions: While we previously reported that PALF offers a shorter convalescence, 
fewer long-term complications but a similar degree of contracture correction, at 5 years, 
the corrections were less durable for PALF than for LF.  
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Introduction 
The standard of care for Dupuytren’s disease remains surgery, with open limited 
fasciectomy (LF) and percutaneous needle fasciotomy (PNF) being the two most 
established techniques.1 In comparison, PNF offers benefits because it is less invasive2, 
may be performed at the outpatient clinic, and is associated with a lower mild 
complication rate3 and a more rapid return to normal use of the hand.3,4 The largest 
drawback of PNF, however, is that its results may be less durable over time than for LF, 
with reported recurrence rates ranging from 50-85%4,5 while rates for LF range from 12-
39%.4,5 
In an attempt to improve the durability of the results of PNF, we developed an 
alternative treatment approach that relies on a more extensive percutaneous release 
than classical PNF, followed by subdermal autologous lipografting (Percutaneous 
Aponeurotomy with LipoFilling; PALF).6,7 Preclinical studies have demonstrated that the 
grafted lipoaspirate contains adipose-derived stem cells that may inhibit contractile 
myofibroblasts8, which are the cells primarily responsible for fibrosis and the 
pathogenesis of the contractures in Dupuytren’s disease. Although these studies imply a 
potential, long-term benefit of lipofilling in concurrence with aponeurotomy for 
Dupuytren’s disease, data from clinical studies are sparse.1,7  
The Dupuytren Rotterdam (DuRo) trial was originally designed to compare the 
efficacy and safety of PALF and LF in patients with primary disease.9 We found that 
during the first postoperative year, PALF corrected contractures as effective as LF while 
no significant difference in recurrence was found between both groups. In the current 
study, we report results after an extended follow-up period of 5 years in patients who 
previously participated in DuRo.  
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Methods 
Study design 
The design of the DuRo trial and the one-year follow-up data have been described 
previously (Dutch Trial Register NTR1692).9 In short, the study was a prospective, 
randomized, single-blind, clinical trial designed to compare PALF with LF at 1 year after 
treatment. Patients with primary Dupuytren’s disease and a flexion contracture of at 
least 20° at the MP joint and/or 30° at the PIP joint were eligible, while excluding patients 
with contractures affecting the thumb or patients using anticoagulant therapy.  
While we previously reported the data collected preoperatively and at 2 and 3 
weeks, 6 months and 1 year after treatment, this study compared the 5-year results 
between both groups. All surviving patients originally assessed at baseline in DuRo were 
considered eligible and contacted by phone.  
 
Treatments 
PALF and LF were performed under exsanguination by tourniquet and under regional or 
general anesthesia. Detailed descriptions of the techniques have been previously 
reported and a video demonstrating the PALF technique can be found in the Digital 
Content Supplementary.6,7 All patients were offered a comparable rehabilitation 
program under supervision of hand therapists and were instructed to use an extension 
splint at night for 6 months. 
 
Follow-up examinations 
The 5-year follow-up examination was performed by a single examiner (RW) who was not 
involved in the previous trial and, prior to assessment, was unaware of the treatment 
allocation. The degree of contracture was assessed using a goniometer after reaching a 
firm endpoint during passive extension of the digits at the MP, PIP and DIP joint levels. 
Total extension deficit was defined as the sum of the degree of extension deficit of MP, 
PIP and DIP joints and hyperextension at joint level was defined as 0 degrees to prevent 
underestimation of the total extension deficit. To increase comparability between 
patients who underwent treatment for a single digit and those treated for multiple 
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digits, we analyzed the digit most severely affected in patients with more than 1 affected 
digit.  
 
Primary and secondary outcome measures 
The primary endpoint was a composite measure of recurrence assessed at the level of 
affected joints. Recurrence was defined as either having undergone a secondary 
procedure for a new or worsening contracture, or as an increase in extension deficit of 
more than 20 degrees relative to week after treatment. The latter was based on a recent 
Delphi-based definition for recurrence of contracture that used a similar definition, 
although using one year as follow-up.10 To facilitate comparison with the randomized trial 
by van Rijssen et al comparing LF with NA without lipofilling, we also defined recurrence 
as an increase in total passive extension deficit of at least 30 degrees at the level of 
treated digits (relative to week 3).11  
To assess the patient perspective12, we asked patients who had not undergone a 
secondary procedure at the time of follow-up to complete the Disability of Arm Shoulder 
and Hand questionnaire (DASH) and a number of ad-hoc visual analogue scale (VAS) 
questions pertaining to the satisfaction with the overall treatment result, restoration of 
hand function, position of the fingers, appearance of the area treated of the hand, and 
whether patients’ expectations were met concerning the overall treatment result. 
 
Statistical Analysis 
The primary outcome analysis, assessing recurrence of contracture, was performed at 
the level of individual joints. The proportion of affected joints meeting this primary 
endpoint was compared between groups using the chi-square tests.  
To compare the degree of extension deficit between treatment groups, we used two-
sided Student’s t-tests. Since 5-year extension deficit was unavailable for patients who 
had undergone a secondary procedure at the time of follow-up, and since excluding 
these patients may underestimate degree of total extension deficit, we imputed the 
degree of extension deficit at 5 years using the pre-treatment degree of extension deficit 
in these patients.  
Uni- and multivariable logistic regression modeling were used to identify factors 
predicting recurrence at the level of treated digits. All baseline clinical factors showing 
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evidence for an association (p<0.100) in univariable analyses were included in 
multivariable models using a stepwise backward elimination approach.  
 
Results 
Study sample 
Between October 2015 and February 2016, 52 patients agreed to participate in the 
present 5-year study of whom 4 were bilaterally treated and assessed, resulting in a total 
of 56 treated hands (see Figure 1).  
 
	
Figure 1. Flow diagram of the complete study, for which we now report the 5-year results.  
PALF; extensive percutaneous needle aponeurotomy with lipofilling; LF; Limited Fasciectomy. 
 
Baseline characteristics were not significantly different between the treatment groups (Table 1). 
Respondents and non-respondents also did not differ in baseline characteristics, including 
diathesis factors (see Supplemental Table 1), with the exception that respondents more often 
had a family member with Dupuytren’s disease. The average follow-up duration for both 
treatment groups was similar (PALF 5.4 vs. LF 5.5 years, p=0.685).  
 
80 patients
40 patients / 45 hands
PALF
40 patients / 43 hands
LF
 39 patients / 44 hands
Baseline
 30 patients / 32 hands
Baseline
Primary endpoint
3 waiting list length
3 medical reasons
2 displeased about 
randomization result
1 reconsideration of 
decision to be treated
1 family circumstances
31 patients / 34 hands
Year 5
21 patients / 22 hands
Year 5
Randomization
1 fear of surgery
37 patients / 42 hands
Year 1
27 patients / 30 hands
Year 1
3 unreachable
2 unwilling to participate
1 deceased
3 deceased
2 unreachable
1 unwilling to participate
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Table 1. Baseline characteristics of the study sample, divided by treatment group.* 
  PALF (31 patients / 34 
hands) 
LF (21 patients / 22 
hands) 
p  
Patient characteristics 
 Age –yrs. 
 Male gender –% 
 Diabetes –% 
 Alcohol –units per week 
 
62±9 
82 
9 
2 
 
62±7 
82 
9 
2 
 
0.103 
0.959 
0.973 
0.741 
Disease-specific variables 
 Positive family history –% 
 Ectopic disease –% 
 Ledderhose’s disease –% 
 Peyronie’s disease –% 
 No. rays treated 
  1 –% 
  >1 –% 
 
59 
29 
21 
 12  
 
52 
48 
 
67 
19 
14 
10 
 
69 
31 
 
0.561 
0.391 
0.556 
0.796 
0.253 
 
Outcomes 
Extension deficit –degrees 
  Total flexion deformity 
  MP joints 
   No. affected MP joints 
  PIP joints 
   No. affected PIP joints 
 
 
61±34 
21±26 
18 
39±28 
28 
 
 
58±35 
26±25 
15 
31±29 
16 
 
 
0.772 
0.488 
0.258 
0.311 
0.391 
* Plus-minus values are means ±SD. 
PALF, Extensive Percutaneous Needle Aponeurotomy with Lipofilling; LF, Limited 
Fasciectomy; MP, metacarpophalangeal; PIP, proximal interphalangeal; DASH, Disability 
of Arm Shoulder and Hand; SD, standard deviation.  
 
The mean age was 62 years in the overall group and 82% were men. The majority of the 
digits analyzed were Tubiana grade I (36%) or II (46%) before surgery. Our primary outcome 
analyses were based on 77 affected joints; 46 in the PALF group and 31 in the LF group.  
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Extension deficit –degrees 
  Total flexion deformity 
  MP joints 
   No. affected MP joints 
  PIP joints 
   No. affected PIP joints 
 
 
61±34 
21±26 
18 
39±28 
28 
 
 
58±35 
26±25 
15 
31±29 
16 
 
 
0.772 
0.488 
0.258 
0.311 
0.391 
* Plus-minus values are means ±SD. 
PALF, Extensive Percutaneous Needle Aponeurotomy with Lipofilling; LF, Limited 
Fasciectomy; MP, metacarpophalangeal; PIP, proximal interphalangeal; DASH, Disability 
of Arm Shoulder and Hand; SD, standard deviation.  
 
The mean age was 62 years in the overall group and 82% were men. The majority of the 
digits analyzed were Tubiana grade I (36%) or II (46%) before surgery. Our primary outcome 
analyses were based on 77 affected joints; 46 in the PALF group and 31 in the LF group.  
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Supplemental Table 1. Baseline characteristics, divided by patients who were able and willing to 
participate (respondent) with the present study and those who were unable or unwilling to 
participate (non-respondent). 
 Respondent  
(52 patients / 56 hands) 
Non-respondent  
(17 patients/ 20 hands) 
p  
Patient characteristics 
 Age –yrs. 
 Male gender –% 
 Diabetes –% 
 Alcohol –units per week 
 
62±8 
82 
9 
2±2 
 
64±9 
80 
20 
2±2 
 
0.599 
0.832 
0.188 
0.896 
Disease-specific variables 
 Positive family history –% 
 Ectopic disease –% 
 Ledderhose’s disease –% 
 Peyronie’s disease –% 
 No. rays treated 
 
62 
26 
18 
11 
1.6±0.9 
 
30 
15 
10 
5 
1.4±0.5 
 
0.015 
0.339 
0.393 
0.437 
0.430 
Outcomes 
Extension deficit –degrees† 
  Total  
  MP joint 
  PIP joint 
DASH score –points 
 
 
60±34 
23±25 
36±28 
14±14 
 
 
64±35 
16±24 
46±21 
17±20 
 
 
0.612 
0.287 
0.092 
0.631 
* Plus-minus values are means ±SD. 
† Values are reported for all joints. 
MP, metacarpophalangeal; PIP, proximal interphalangeal; DASH, Disability of Arm Shoulder and Hand; 
SD, standard deviation.  
 
Recurrence rate and residual contracture 
While at one year after surgery the recurrence rate was not significantly different between 
groups, more affected joints in the PALF group (74%) than in the LF group (39%) had a recurrence 
at 5 years, based on our composite outcome endpoint analysis of either having undergone a 
secondary procedure or having an increase in extension deficit of more than 20 degrees relative 
to week after treatment (see Figure 2). 	
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Figure 2. Recurrence rates in the percutaneous aponeurotomy with lipografting (PALF) and the 
limited fasciectomy (LF) groups based on the composite endpoints at 1 and 5 years after surgery.  
 
When defining recurrence as an increase in total passive extension deficit of at least 30 
degrees (relative to week 3) for treated digits, following van Rijssen et al., we also find 
that more digits in the PALF group (77%) met the definition for recurrence at 5 years than 
in the LF group (32%; p=0.001). At 5 years postoperatively, the estimated degree of total 
passive extension deficit was also significantly worse for PALF than LF treated digits (53 
degrees vs 31 degrees; see Figure 3). 
 
Figure 3. Estimated total passive extension deficit (TPED) in both groups preoperatively and at all 
recorded follow-up visits. The p-value corresponds to the difference between both groups at 5 years 
after surgery. 
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When analyzing MP and PIP joints separately, for MP, the proportion of joints with a 
recurrence based on the composite endpoint analysis at 5 years in the PALF group was 
higher than in the LF group but was not significant (61% vs. 33%, p=0.166). The estimated 
degree of extension deficit was also higher for affected MP joints after PALF than after 
LF (24 degrees vs. 11 degrees, Figure 4). 
 
 	
Figure 4. Estimated extension deficit for affected MP joint in both treatment groups preoperatively 
and at all recorded follow-up visits. The p-values correspond to the differences between both groups 
at 5 years after surgery.  
 
For PIP, however, more affected joints in the PALF group met the primary endpoint than 
in the LF group (82% vs. 44%, p=0.017). The estimated degree of extension deficit was also 
higher for affected PIP joints after PALF than after LF (47 degrees vs. 28 degrees, Figure 
5). 
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Figure 5. Estimated extension deficit for affected PIP joints in both treatment groups preoperatively 
and at all recorded follow-up visits. The p-values correspond to the differences between both groups 
at 5 years after surgery.  
 
Patient-reported outcomes 
A total of 18 PALF treated patients and 17 LF-treated patients, i.e., the patients who had 
not yet undergone a revision procedure, completed the study questionnaires at 5 years 
after surgery. Among this subset of patients, 5-year DASH scores were not significantly 
different between groups (PALF, 10.5 points; LF, 9.3 points; see Figure 6).  
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Figure 6. DASH scores in both groups preoperatively and at all recorded follow-up visits. The p-value 
corresponds to the difference between both groups at 5 years after surgery. 
 
Satisfaction was also not significantly different between groups (Table 2). 
 
Table 2. Satisfaction scores using a Visual Analogue Scale from 0-10 in the PALF and LF subgroups at 5 
years after surgery. 
Question PALF 
(n=18) 
LF 
(n=17) 
p 
Are you satisfied about the overall result of the surgical 
procedure? 
Does the overall result of the surgical procedure meet your 
expectations?  
How satisfied are you about the position of your fingers? 
How satisfied are you about the extent to which your hand 
function was restored?  
How satisfied are you about the way your hand/operated area 
looks?  
Would you choose the same surgical procedure again? (%) 
Would you recommend the same surgical procedure to friends, 
family, and acquaintances? (%) 
7.1±3.1 
 
7.3±3.1 
 
6.5±3.3 
7.0±3.1 
 
7.8±2.8 
 
83 
89 
8.5±2.1 
 
8.0±2.8 
 
7.6±2.8 
8.4±2.2 
 
8.2±2.5 
 
77 
88 
0.138 
 
0.495 
 
0.316 
0.130 
 
0.643 
 
0.691 
0.952 
PALF, Extensive Percutaneous Needle Aponeurotomy with Lipofilling; LF, Limited Fasciectomy; MP, 
metacarpophalangeal; PIP, proximal interphalangeal; DASH, Disability of Arm Shoulder and Hand; SD, 
standard deviation.  
 
Risk factors for recurrence  
Significantly more patients with an affected PIP joint had a recurrence at 5 years. All 
other baseline characteristics, including ectopic disease, family history of the disease, 
diabetes, epilepsy were unrelated. 
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In multivariable analysis (Table 3), we found that the presence of an affected PIP joint 
remained to show a trend for an independent association with a higher likelihood of 
developing a recurrence. 
 
Table 3. Baseline independent risk factors for 5-year recurrence at the level of 
treated digits from the final multivariable logistic regression model. 
Risk factor OR 95% CI p 
Treatment type* 
Affected PIP joint  
0.16 
4.08 
0.04-0.54 
0.92-18.2 
0.002 
0.065 
*Values are reported for LF with PALF as the reference group. 
OR, odds ratio; CI, Confidence Interval. 
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Discussion 
Long-term results of treatments are highly relevant to patients with Dupuytren’s disease, 
as recurrence rate was recently found to be among the most important attributes for 
patients in making treatment choices.13 Attempting to reduce the relatively high 
recurrence rate of traditional needle aponeurotomy for Dupuytren’s contracture, we 
developed an alternative approach using an extensive and fundamentally different 
percutaneous release technique and subsequent autologous lipografting (PALF). The 
purpose of the present study was to assess the 5-year results of a randomized controlled 
trial comparing this treatment with standard limited fasciectomy (LF) for primary 
Dupuytren’s contracture. We found that at 5 years follow-up significantly more joints in 
the PALF group than in the LF group had a recurrence (74% versus 39%, p < 0.001), based 
on either having undergone a secondary procedure or having an increase in extension 
deficit of more than 20 degrees. In line with this finding, the degree of total extension 
deficit was significantly worse after PALF than after LF. Extension deficit was worse for 
PIP joints compared with MP joints, and for PIP joints the difference in extension deficit 
between both treatment groups was also larger than for MP joints. No differences were 
found in patient-reported outcomes.  
In this study, PALF-treated digits had a recurrence rate that was 35% higher than 
that of LF-treated digits at 5 years after treatment (74% versus 39%). This finding is in line 
with the previously reported higher rate for conventional needle aponeurotomy. A 
question that remains is whether the recurrence of PALF is better than for conventional 
needle fasciotomy. Comparison with previous literature requires caution because 
differences in definitions can importantly influence recurrence rate.14,15 In addition, 
factors such as patient selection can influence outcome in different studies. Having said 
this, when we compare our results with the only other randomized study comparing 
fasciectomy and needle fasciotomy for Dupuytren’s disease to date, using a comparable 
TPED-based definition for recurrence, the 45% difference found in the present study (32% 
vs 77%) is smaller than the previously reported 64% higher recurrence rate of traditional 
needle aponeurotomy (PNF) as compared with LF at 5 years (21% versus 85%).11 Without a 
direct head to head comparison of traditional needle aponeurotomy and PALF, 
PALF vs. LF RCT: 5-year results 
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accounting for baseline differences and using similar outcome measurements, however, 
it can not be concluded whether this difference is statistically significant.  
The inferior recurrence rate of PALF is particularly evident at the PIP joint level, as 
indicated by the larger between-treatment group differences in 5-year recurrence rates 
and extension deficit for affected PIP joints (38% and 19 degrees) than for MP joints (28% 
and 14 degrees). This finding confirms the general observation that PIP contractures are 
more difficult to treat and, as a result, have comparatively poorer results. It also suggests 
that PALF may be more valuable for patients with affected MP joints than for PIP joints, 
since MP joints generally have a smaller change of a recurrent contracture.  
This study has a number of limitations. A first limitation is the loss-to-follow-up. Reasons 
for this were diverse and are inherent to this Dupuytren population, such as a number of 
patients who deceased or who were not in sufficient health to participate in the long-
term follow-up. Despite this, baseline characteristics were similar between the treatment 
groups included in the 5-year follow-up. A second limitation is that our study included a 
relatively high proportion of patients with diathesis factors, which limits the 
generalizability of the results. This may also have contributed to the relatively high 
recurrence rates of LF (i.e., 21% in Van Rijssen et al. compared to 32% when applying a 
similar definition in our study). A third limitation is that we estimated the degree of 
extension deficit for those patients who had underwent a secondary procedure at the 5-
year follow-up examination using their preoperative contracture. This assumed that 
patients’ threshold for undergoing treatment remains unchanged over time, which may 
not always be correct. Despite of this, this allowed us to estimate extension deficits for 
patients while without this analysis; only patients with limited recurrence would have 
been included. Fourth, we used a composite endpoint of recurrence that does not take 
into account when in time patients who had underwent a revision procedure reached 
this endpoint. Future studies may take this individual variation into consideration in order 
to allow for time-to-event type analyses to predict longer-term outcomes, such as risk of 
recurrence, at the individual patient level. Finally, we had limited power to assess the 
long-term outcomes separately for affected MP and PIP joints due to the small sample 
size, which may have precluded us from finding significant differences at the MP joint 
level.  
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 In conclusion, we found that among patients with primary Dupuytren’s disease, 
percutaneous needle aponeurotomy and lipofilling provided less durable corrections as 
compared with LF at 5 years follow-up, although the 35% higher rate may be lower than 
previously has been reported for traditional PNF. After LF, convalescence is typically 
long, impeding an early return to work or daily manual activities.16,17 In contrast, patients 
treated with PALF returned to normal use of the hand after an average of 9 days as 
compared with an average 17 days for LF patients in our previous study.9 This highlights 
the less-invasive nature of the technique. In addition, both contracture correction and 
recurrence after PALF is better for MP joints than for PIP joints. Taken together, when 
comparing both techniques in primary disease, PALF provides good short term outcome 
with quick convalescence and less complications when compared with LF, while LF offers 
straighter fingers at 5-year follow-up. 
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 In conclusion, we found that among patients with primary Dupuytren’s disease, 
percutaneous needle aponeurotomy and lipofilling provided less durable corrections as 
compared with LF at 5 years follow-up, although the 35% higher rate may be lower than 
previously has been reported for traditional PNF. After LF, convalescence is typically 
long, impeding an early return to work or daily manual activities.16,17 In contrast, patients 
treated with PALF returned to normal use of the hand after an average of 9 days as 
compared with an average 17 days for LF patients in our previous study.9 This highlights 
the less-invasive nature of the technique. In addition, both contracture correction and 
recurrence after PALF is better for MP joints than for PIP joints. Taken together, when 
comparing both techniques in primary disease, PALF provides good short term outcome 
with quick convalescence and less complications when compared with LF, while LF offers 
straighter fingers at 5-year follow-up. 
PALF vs. LF RCT: 5-year results 
	
 117	
References 
1. Eaton C. Evidence-based medicine: Dupuytren contracture. Plastic and reconstructive surgery. May 
2014;133(5):1241-1251. 
2. van Rijssen AL, Gerbrandy FS, Ter Linden H, Klip H, Werker PM. A comparison of the direct 
outcomes of percutaneous needle fasciotomy and limited fasciectomy for Dupuytren's disease: a 6-week 
follow-up study. The Journal of hand surgery. May-Jun 2006;31(5):717-725. 
3. Zhou C, Selles RW, Slijper HP, et al. Comparative Effectiveness of Percutaneous Needle 
Aponeurotomy and Limited Fasciectomy for Dupuytren's contracture: A Multicenter Observational Study. 
Plastic and reconstructive surgery. Jun 8 2016. 
4. Rodrigues JN, Becker GW, Ball C, et al. Surgery for Dupuytren's contracture of the fingers. The 
Cochrane database of systematic reviews. 2015;12:CD010143. 
5. Chen NC, Srinivasan RC, Shauver MJ, Chung KC. A systematic review of outcomes of fasciotomy, 
aponeurotomy, and collagenase treatments for Dupuytren's contracture. Hand. Sep 2011;6(3):250-255. 
6. Hovius SE, Kan HJ, Smit X, Selles RW, Cardoso E, Khouri RK. Extensive percutaneous 
aponeurotomy and lipografting: a new treatment for Dupuytren disease. Plastic and reconstructive surgery. 
Jul 2011;128(1):221-228. 
7. Hovius SE, Kan HJ, Verhoekx JS, Khouri RK. Percutaneous Aponeurotomy and Lipofilling (PALF): A 
Regenerative Approach to Dupuytren Contracture. Clinics in plastic surgery. Jul 2015;42(3):375-381, ix. 
8. Verhoekx JS, Mudera V, Walbeehm ET, Hovius SE. Adipose-derived stem cells inhibit the 
contractile myofibroblast in Dupuytren's disease. Plastic and reconstructive surgery. Nov 2013;132(5):1139-
1148. 
9. Kan HJ, Selles RW, van Nieuwenhoven CA, Zhou C, Khouri RK, Hovius SE. Percutaneous 
Aponeurotomy and Lipofilling (PALF) versus Limited Fasciectomy in Patients with Primary Dupuytren's 
Contracture: A Prospective, Randomized, Controlled Trial. Plastic and reconstructive surgery. Jun 
2016;137(6):1800-1812. 
10. Kan HJ, Verrijp FW, Hovius SER, van Nieuwenhoven CA, Dupuytren Delphi G, Selles RW. 
Recurrence of Dupuytren's contracture: A consensus-based definition. PloS one. 2017;12(5):e0164849. 
11. van Rijssen AL, ter Linden H, Werker PM. Five-year results of a randomized clinical trial on 
treatment in Dupuytren's disease: percutaneous needle fasciotomy versus limited fasciectomy. Plastic and 
reconstructive surgery. Feb 2012;129(2):469-477. 
12. Zhou C, Hovius SE, Slijper HP, et al. Predictors of Patient Satisfaction with Hand Function after 
Fasciectomy for Dupuytren's Contracture. Plastic and reconstructive surgery. Sep 2016;138(3):649-655. 
13. Kan HJ, de Bekker-Grob EW, van Marion ES, et al. Patients' Preferences for Treatment for 
Dupuytren's Disease: A Discrete Choice Experiment. Plastic and reconstructive surgery. Jan 2016;137(1):165-
173. 
14. Kan HJ, Verrijp FW, Huisstede BM, Hovius SE, van Nieuwenhoven CA, Selles RW. The consequences 
of different definitions for recurrence of Dupuytren's disease. Journal of plastic, reconstructive & aesthetic 
surgery : JPRAS. Jan 2013;66(1):95-103. 
15. Werker PM, Pess GM, van Rijssen AL, Denkler K. Correction of contracture and recurrence rates of 
Dupuytren contracture following invasive treatment: the importance of clear definitions. The Journal of 
hand surgery. Oct 2012;37(10):2095-2105 e2097. 
16. Zhou C, Hovius SE, Pieters AJ, Slijper HP, Feitz R, Selles RW. Comparative effectiveness of 
percutaneous needle aponeurotomy and Collagenase injection for Dupuytren's contracture: A multicenter, 
propensity-matched observational study. Plastic and reconstructive surgery. Global open. 2017;Accepted. 
17. Zhou C, Hovius SE, Slijper HP, et al. Collagenase Clostridium Histolyticum versus Limited 
Fasciectomy for Dupuytren's Contracture: Outcomes from a Multicenter Propensity Score Matched Study. 
Plastic and reconstructive surgery. Jul 2015;136(1):87-97. 
 
 
		 118	
 
	
 119	
 
 
 
 
 
 
Part IV 
VOLUME AND OUTCOMES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		 118	
 
	
 119	
 
 
 
 
 
 
Part IV 
VOLUME AND OUTCOMES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		 120	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surgeon Volume and Outcomes 
	
 121	
 
7 
Surgeon Volume and The Outcomes Of 
Dupuytren's Surgery: Results From A Dutch 
Multicenter Study 
C.	Zhou	MD,	I.	Ceyisakar	MSc,	S.E.R.	Hovius	MD	PhD,	R.	Feitz	MD,	H.P.	Slijper	
PhD,	H.F.	Lingsma	PhD,	R.W.	Selles	PhD		
	
	
	
	
 
	
 
 
 
Plast Reconstr Surg. 2018 Jul. 
 
 
 
 
 
 
 
 
 
From the Departments of Plastic, Reconstructive, and Hand Surgery, Rehabilitation 
Medicine and Public Health, Erasmus MC University Medical Center; and Hand and Wrist 
Surgery, Xpert Clinic.
		 120	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surgeon Volume and Outcomes 
	
 121	
 
7 
Surgeon Volume and The Outcomes Of 
Dupuytren's Surgery: Results From A Dutch 
Multicenter Study 
C.	Zhou	MD,	I.	Ceyisakar	MSc,	S.E.R.	Hovius	MD	PhD,	R.	Feitz	MD,	H.P.	Slijper	
PhD,	H.F.	Lingsma	PhD,	R.W.	Selles	PhD		
	
	
	
	
 
	
 
 
 
Plast Reconstr Surg. 2018 Jul. 
 
 
 
 
 
 
 
 
 
From the Departments of Plastic, Reconstructive, and Hand Surgery, Rehabilitation 
Medicine and Public Health, Erasmus MC University Medical Center; and Hand and Wrist 
Surgery, Xpert Clinic.
Chapter 7	
	 122	
	
Abstract  
 
Objective: For a number of major complex surgical procedures, the outcomes are better 
when performed by surgeons with higher procedure volumes. The purpose of this study 
was to examine the relations between surgeon procedure volume and the outcomes of 
Dupuytren’s surgery. 
Design: Observational study from 2011-14 
Setting: Consortium of 6 dedicated hand surgery practice sites in The Netherlands 
Participants: 588 patients who underwent surgery for Dupuytren’s contracture by one of 
the 16 surgeons from the participating sites. 
Main exposure variable: Annual surgeon volume 
Main outcome measures: The degree of residual contracture, full release rate and any 
postoperative adverse event examined within 3 months of surgery. 
Results: Mean annual surgeon volume was 51 among the 16 surgeons, and ranged from 4 
to 86 procedures. The majority of patients had primary Dupuytren’s contracture (79%) 
and underwent open fasciectomy (74%). Multivariable regression analyses showed that 
surgeon volume was linearly related to all three outcomes, and identified no optimal 
volume threshold. Performing 10 additional procedures per year was independently 
associated with nearly 0.8 degree less residual contracture (p=0.002), 9% higher odds of 
attaining a full release (p=0.037), and 11% lower odds of experiencing an adverse event 
(p<0.001). Nonetheless, patient-related factors had larger impacts on all three clinical 
outcomes than surgeon volume. 
Conclusion and relevance: In this study of practicing hand surgeons, surgeon volume 
varied widely, and a higher volume was associated with less postoperative residual 
contracture, higher full release rates, and fewer adverse events. These findings imply 
that increasing surgeon procedure volume provides an opportunity for improving the 
outcomes of Dupuytren’s surgery. 
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Introduction 
For certain major high-risk surgical procedures, associated outcomes are better for 
surgeons performing a large number of such procedures.1-3 For example, lower mortality 
rates have been consistently linked to a higher procedure volume for various complex 
oncologic and cardiovascular procedures.4-9 Such findings are important because they 
provide the premise on which surgical training and specialization is based. They have also 
prompted recent recommendations for the centralization of complex surgical care.10 
Whether such volume-outcome relations exist for common relatively minor surgical 
procedures remains less well understood.11,12  
Dupuytren’s disease is a very common, progressive fibromatosis of the hand.13 It 
begins with the formation of nodules and scar-like tissue underneath the palmar skin. 
Over time, cords typically develop that extend, thicken and contract, causing flexion 
contractures of the affected finger joints. Contractures typically involve the 
metacarpophalangeal (MCP) and/or the proximal-interphalangeal (PIP) joint. The ring 
and little fingers are most times affected. As a result, hand function may be impaired and 
quality of life diminished.14-16 Although it occurs among people from all ethnicities, global 
prevalence rates range from 3 to 6% in Caucasians.17-19 The exact cause remains 
incompletely understood, but there is a strong genetic component.20 
Surgery is the mainstay of treatment for Dupuytren’s contracture, which aims to 
improve contractures to restore function. Two of the most common techniques are open 
fasciectomy, in which the pathologic tissue is surgically removed, and needle fasciotomy, 
in which cords are only transected through the skin.19,21-23 However, the outcomes of 
both treatments vary widely across individual patients, depending on patient-, and 
disease-specific characteristics.24 For example, contractures at the level of the MCP joint 
typically have more favorable prognosis than those of the PIP joint.25-28 On the other 
hand, outcomes may depend as much on the surgeons’ experience and how often he/she  
performs both procedures, with higher volume surgeons being more likely to attain 
successful outcomes and attaining fewer adverse events.  
Using data from a consortium of 6 practice sites in the Netherlands, we sought to 
clarify the relation between surgeon procedure volume and the outcomes of 
Dupuytren’s surgery. Our specific aim was to quantify the magnitude of effect of surgeon 
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volume on three objective clinical outcomes – the degree of residual contracture, the 
probability of a full contracture release, and the risk of any type of adverse event – 
relative to other clinical predictors.  
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Methods 
Study design and patients 
This study was based on an analysis of data from a consortium of 6 dedicated hand 
surgery practice sites in the Netherlands of all patients undergoing a surgical procedure 
for Dupuytren’s contracture between November 2011 and February 2014.  
All participating sites submitted the data into a registry including a wide range of 
information on patient demographics, disease characteristics and treatment 
characteristics. Patient factors derived from the database were patients’ age, gender and 
coexisting conditions. Disease characteristics included the severity of contracture, the 
number of digits treated, bilateral disease, which fingers and joint levels were affected, 
and family history of Dupuytren’s disease. Treatment characteristics included the type of 
surgical procedure and whether patients had recurrent disease. Trained hand-therapists 
prospectively gathered the data as part of standard clinical practice and used it to direct 
therapy, ensuring the completeness and accuracy of the data. 
We included all adult patients with a diagnosis of Dupuytren’s disease who 
underwent open fasciectomy or needle fasciotomy. We excluded patients with an 
isolated MCP contracture of less than 20 degrees and those undergoing concomitant 
surgery (e.g. carpal tunnel release) on the treated side that could confound outcome 
assessments. Patients with recurrent disease were accepted if they met the other 
eligibility criteria.  
Our local institutional review board approved this study, which was performed in 
accordance with STROBE guidelines.29 
 
Primary and secondary outcomes 
The primary outcome for this study was the degree of total residual contracture. 
Certified hand-therapists examined the degree of active extension deficit at baseline and 
at visits occurring between 6 weeks and 3 months of surgery using a finger goniometer 
for each affected finger. Specifically, extension deficit was examined at the MCP, PIP and 
DIP joint levels for each finger, and summed to obtain the total degree of residual 
contracture. To allow for comparison between patients with single versus multiple-digit 
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involvement, we used the data from the digit most severely affected at baseline (e.g., 
highest total extension deficit). 
Secondary outcomes were the probability of a full release, defined as less than 10 
degrees of total extension deficit, and the occurrence of an adverse event assessed up 
until the same time point. Adverse events included sensory disturbances, scar sequelae, 
wound-related problems, infection, edema, cold intolerance, neurovascular problems, 
loss of hand strength, hematoma, tenosynovitis, skin fissures, flare reaction, thenar 
atrophy, and skin flap necrosis. The outcomes chosen in this paper were influenced by 
the findings from a previous study from our group examining the preferences patients 
with Dupuytren’s disease have regarding their treatment.33 Moreover, we decided on 
early outcomes because we assumed that they would better reflect the proficiency of a 
surgeon than longer-term outcomes, such as recurrence, which may depend more on 
patient factors30-32. 
 
Main exposure variable: surgeon volume 
Our main exposure variable, surgeon procedure volume, was examined at the surgeon-
level. For each procedure, the identity of the treating surgeon was obtained from the 
database or, in case data were missing, from electronic health records. Providers who 
had no knowledge of this study entered the identity of the surgeon at the first 
preoperative consultation but had the opportunity to change the identity at subsequent 
time-points in case someone other than the original surgeon performed the procedure. 
Surgeon volume was defined as the average number of surgical procedures per year 
each participating surgeon performed for Dupuytren’s contracture during the study 
period. For statistical modeling and inferences, all outcomes were examined at the 
patient-level.  
 
Analysis 
First, we categorized surgeons into volume strata according to tertiles and summarized 
the unadjusted outcomes among these strata using descriptive statistics. Continuous 
variables were reported as means±SD and categorical variable using frequencies. 
 We used multivariable linear and logistic regression models to examine possible 
relations between surgeon procedure volume and the degree of total residual 
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contracture, the probability of a full release, and the risk of any type of adverse event. 
Since the factors affecting each outcome may differ, we adjusted for a separate set of 
covariates for each of the outcomes that were determined using a backward stepwise 
selection approach, a systematic search of literature using the QUIPS tool34 (unpublished 
data), and based on clinical validity. The final linear regression model for the degree of 
residual contracture ultimately included patients’ age, gender, the joint levels affected, 
number of digits treated, bilateral disease, primary or recurrent disease, pre-treatment 
degree of extension deficit, surgical technique and surgeon experience (the number of 
years in practice of the operating surgeon) as covariates. The logistic regression model 
for the incidence of full release included patients’ age, gender, diabetes, whether a PIP 
joint was affected, the number of digits treated, primary or recurrent disease, pre-
treatment degree of extension deficit, surgical technique, and surgeon experience. The 
logistic regression model for the incidence of an adverse event included patients’ age, 
gender, diabetes, whether a PIP joint was affected, the number of digits treated, primary 
or recurrent disease, pre-treatment degree of extension deficit, surgical technique, and 
surgeon experience. To assess the general form of the relationships between volume 
and outcomes, we tested for non-linearity by assessing whether non-linear models fitted 
the data significantly better than the linear models. In addition, we used receiver-
operating curves relating various thresholds for surgeon volume to the clinical outcomes 
to identify optimal volume-thresholds associated with improved outcomes.35 Based on 
the abovementioned regression models, we plotted the adjusted outcomes against 
surgeon volume to illustrate the effect of surgeon volume on the three outcomes. To 
assess the relative magnitude of effect of surgeon volume as compared with clinical 
predictors, we created forest plots with the beta-coefficients and log-odds of volume 
and clinical factors that were significantly associated with each of the outcomes of 
interest. 
 The sample of our study population of nearly 600 cases was based on the data 
available and insights regarding the number of factors associated with outcomes.21,36 As 
a general rule, each independent covariate requires about 10-20 cases when using linear 
regression,37 indicating an adequate sample size. 
The probability of Type1 error was set at 0.05 for all analyses. All analyses were 
performed with SPSS(version 22.0) and RStatistical software(version 3.3.0). 
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Results 
Patient and surgeon characteristics 
We identified a total of 666 patients undergoing a surgical procedure for Dupuytren’s 
disease between 2011 and 2014. After applying our eligibility criteria, 588 patients 
remained to form our study sample (Figure 1). The majority were men and had primary 
Dupuytren’s disease. Seventy-four percent underwent open fasciectomy and 26% 
underwent needle fasciotomy. Table 1 details demographic and clinical characteristics of 
our sample.  
Table 1. Demographic and disease-specific characteristics of the study sample (n=590). 
Variable  
Age, years. 
Male gender, % 
Diabetes, % 
63 ± 10 
77 
11 
Recurrent disease, % 
Bilateral disease, % 
Family history of disease, % 
N treated digits 
Tubiana grade 
  I, % 
  II, % 
  III, % 
  IV, % 
29 
60 
48 
1.7 ± 0.8 
 
30 
45 
20 
5 
Baseline extension deficit, degrees 
Total† 
   MCP joint level 
   PIP joint level 
   DIP joint level 
 
70 ± 36 
27 ± 25 
37 ± 27 
6 ± 12 
Plus-minus values are means ± SD.  
†Both affected and unaffected joints are included in these values. 
Figure. 1. Selection of patients for inclusion 
in the study. 
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A total of 16 surgeons performed all procedures at 6 different practice sites. They were 
trained at 7 different institutions, and their mean experience (number of years in 
practice) was 9.7 years (range, 6 months to 29 years). Twenty-five percent of the 
surgeons were female. Mean annual surgeon volume was 51 and ranged from 4 to 86 
procedures. Surgeons differed in terms of the proportions of primary cases (p=0.027), 
bilateral cases (p<0.001), patients with affected MP joints (p=0.009), and the mean 
number of digits (p<0.001) they treated, indicating a need to adjust for these factors.  
Follow-up data was available for the primary outcome (residual contracture) for 
93% (n=547) of patients. All patients had follow-up data available for adverse events. 
Patients who lacked data on the primary outcome were not significantly different from 
those with data available in terms of baseline characteristics with the exception that 
those with follow-up data were treated for more digits (Suppl.Table 1).  
 
Suppl. Table 1. Demographic and disease-specific characteristics compared between patients 
with and without data available on the primary outcome (total residual contracture). 
Variable Data available 
(n=547) 
Data unavailable 
(n=41) 
p 
Age, years. 
Male gender, % 
Diabetes, % 
63 ± 9 
77 
11 
62 ± 12 
76 
12 
0.512 
0.843 
0.812 
Recurrent disease, % 
Bilateral disease, % 
Family history of disease, % 
No. treated digits 
30 
60 
47 
1.7 ± 0.8 
20 
61 
59 
1.3 ± 0.8 
0.143 
0.917 
0.160 
0.002 
Total extension deficit, degrees† 70 ± 37 62 ± 29 0.128 
Plus-minus values are means ± SD.  
†Both affected and unaffected joints are included in these values. 
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Clinical outcomes 
Overall, the average degree of total contracture improved from 70 degrees from baseline 
to 24 degrees residual total contracture at follow-up. About one-fourth of digits were 
fully released. (Figure 2). Forty-seven percent (n=278) of patients experienced at least 
one adverse event.  
 
The three most common adverse events were sensory disturbances, scar sequelae and 
wound-healing problems (Table 2).  
 
Table 2. Adverse events in the study sample (n=590). 
Sensory disturbances 
Scar sequelae 
Wound healing 
Edema 
Wound infection 
Cold intolerance 
Circulatory problems 
Nerve injury 
Subjective loss of hand strength 
Hematoma 
TVS 
Skin fissure 
Flare reaction 
Necrosis skin flap 
Thenar atrophy 
12 (72) 
12 (71) 
8 (47) 
4 (25) 
3 (18) 
2 (10) 
2 (9) 
1 (7) 
1 (7) 
1 (6) 
1 (4) 
1 (3) 
1 (3) 
1 (3) 
0 (1) 
Values are percentages (numbers). 
 
Figure 2. Percentage change in the degree of total 
contracture (active extension deficit) at follow-up from 
baseline and the rate of full release in the study sample 
(n=547). 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Surgeon volume and outcomes 
Figure 3 shows that the unadjusted clinical outcomes among the three volume strata 
improved with increasing volume.  
	
Figure 3. The unadjusted degree of residual contracture (A), probability of a full release (B), and the 
risk of at least one postoperative adverse effect (C) among three surgeon volume strata. 
	
For none of the outcomes (degree of residual contracture, full release and adverse 
events), non-linear models were a significantly better fit compared to the linear models 
(p=0.053, p=0.517, and p=0.517, respectively). This indicated that the relation was linear 
for all three outcomes, which was further substantiated by the receiver-operating curves 
showing no obvious optimal volume thresholds (Suppl.Figure 1). Therefore, we analyzed 
surgeon volume as a linear term.    
 
 
Suppl. Figure. 1. The influence of 
various surgeon volume-thresholds 
(at 10, 20, 30, 40, 50, 60, 70, 80 
surgical procedures per year) on the 
ability of the multivariable models to 
distinguish (area under the curve 
statistic) between patients with and 
without a full release (dotted line) 
and patients who had at least 1 
postoperative adverse event and 
those who did not (continued line). 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In multivariable regression analyses, surgeon volume was significantly and inversely related to 
the degree of residual contracture at follow-up (beta coefficient=0.8, p=0.002). Hence, with 
every 10 additional procedures per year the degree of residual contracture improved by 0.8 
degrees (Figure 4).  
 
 
Figure 4. The relation between surgeon volume (mean number of surgical procedures performed for 
Dupuytren’s disease per year) and the degree of postoperative residual contracture, adjusted for 
patient factors, treatment characteristics, and number of years in practice. Each dot represents 1 of 
the 16 participating surgeons. The size of each dot corresponds to the relative contribution of each 
surgeon to the multivariable model. The thin lines represent 95% confidence intervals. 
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As compared with other clinical predictors, such as an affected proximal-interphalangeal joint, 
and type of procedure, however, this magnitude of effect of surgeon volume was relatively small 
(Figure 5).  
	
Figure 5. Plot showing clinical factors that were significantly associated with the degree of residual 
contracture from the final multivariable regression model that also adjusted for age, gender, 
primary or recurrent disease, and the number of years in practice. The corresponding horizontal 
lines represent the 95% confidence intervals. 	
	
Surgeon volume was also directly related to the probability of attaining a full release 
(odds ratio=1.09, p=0.037): with every 10 additional procedures per year, the odds of a 
full release increased with 9% (Figure 6). Again, this magnitude of effect was small in 
comparison with other clinical predictors (Figure 7).	 
	
Figure 6. The relation 
between surgeon volume 
(mean number of surgical 
procedures performed for 
Dupuytren’s disease per 
year) and the probability of 
a full release, adjusted for 
patient factors, treatment 
characteristics, and number 
of years in practice. The 
thin lines represent 95% 
confidence intervals. 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Figure 7. Plot showing clinical factors that were significantly associated with the probability of a full 
release from the final multivariable regression model that also adjusted for age, gender, primary or 
recurrent disease, diabetes, and the number of years in practice. The corresponding horizontal lines 
represent the 95% confidence intervals.  
 
Lastly, the odds of any type of adverse event decreased with increasing surgeon volume 
(odds ratio=0.89 p<0.001; Figure 8); with every 10 additional procedures the odds 
decreased by 11%. Again this effect was smaller than that of the two other significant 
predictors (the number of treated digits and type of procedure) in the model (Figure 9). 
 
	
Figure 8. The relation between surgeon volume (mean number of surgical procedures performed for 
Dupuytren’s disease per year) and the probability of any adverse effect, adjusted for patient factors, 
treatment characteristics, and number of years in practice. The thin lines represent 95% confidence 
intervals. 
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Figure 9. Plot showing clinical factors that were significantly associated with the risk of any adverse 
effect from the final multivariable regression model that also adjusted for age, gender, preoperative 
contracture, diabetes, affected PIP joint, type of procedure, and the number of years in practice. The 
corresponding horizontal lines represent the 95% confidence intervals. 
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Discussion	
In this study involving 16 practicing surgeons from 6 hand surgical practice sites in the 
Netherlands, we examined whether the number of surgical procedures they performed 
annually for Dupuytren’s contracture was related to the subsequent outcomes. We 
found that surgeon volume varied widely, and that a higher volume was an independent 
predictor of three objective clinical outcomes: less residual contracture, a higher odds of 
a full release, and a lower odds of an adverse event. 
In this study, performing 10 additional procedures per year was associated with 
nearly 1 degree less residual contracture. From a functional perspective, this finding may 
be of limited value. However, each 10 additional procedures per year was also 
independently associated with 9% higher odds of attaining a full release and 11% lower 
odds of experiencing an adverse event, both of which are of greater importance 
considering the tendency of contractures to recur after treatment and the burden of a 
required reintervention over time and adverse events. Notably, the general form of the 
relations remained linear up to over 80 procedures per year. This is similar to what has 
been reported for several major complex surgical procedures2,38,39, such as abdominal 
aortic aneurysm repair and lung cancer resection, but differs from the behavior of the 
volume-outcome association found in, for example, groin hernia repair, another relatively 
minor, although quite different, surgical procedure.40 We believe that these findings 
underscore the technical difficulty of achieving a full release for patients with 
Dupuytren’s contracture while simultaneously minimizing the risk of any type of adverse 
event.  
For all three outcomes, the impact of surgeon volume on outcomes was relatively 
small compared to a variety of clinical characteristics. Although only few high quality 
prognostic studies have specifically assessed the predictors of outcomes of Dupuytren’s 
treatment and, to our knowledge, none previously considered surgeon volume as a 
factor, this finding may not be surprising. Many clinicians will surely recognize the poor 
prognosis associated with certain clinical factors such as PIP joint involvement.25,41,42 We 
feel that the strong and independent associations between patient factors and all three 
outcomes emphasizes the importance of deciding when to intervene in Dupuytren’s 
contracture. Furthermore, the range of independent predictors of outcomes identified in 
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this study may be used to better design future prognostic studies as well as to more 
accurately counsel patients about their expected surgical outcomes. For example, we 
found that 10 degrees of worse contracture preoperatively corresponds to 29% lower 
odds of a full release whereas each additional digit treated increases the risk of an 
adverse event by 47%. 
Finally, our findings may have direct implications for those responsible for 
assessing the quality of surgical care delivered to Dupuytren’s disease patients.  The 
limitations of the current methods for ensuring a surgeon’s competence and proficiency, 
such as continuing medical education initiatives, are well acknowledged as they are not 
directly linked with actual outcomes or performance standards..43,44 As clinical registries 
similar to the one used in the present study become more widely available, we expect 
that outcomes-based assessment of surgeons will become more feasible.45 The link 
between higher procedure volume and improved outcomes in this study shows that 
tracking the number of procedures a surgeon performs for Dupuytren’s disease may 
provide a much more direct way of assessing his or her proficiency in treating this 
condition. 
Current understanding of volume-outcome relations is limited to a large extent to 
major complex surgery.40 By virtue of quality data from the participating sites, we were 
able to examine whether such relations hold true for Dupuytren’s surgery using three 
objective outcomes. These data were complete (93% primary outcome) and 
prospectively gathered by independent hand-therapists. Moreover, it allowed for a 
rigorous adjustment for a wide range of clinical characteristics. Some, however, may 
question the decision to only include fasciectomy and needle aponeurotomy in 
determining surgeon volume. By doing so, we did not take into account the potential 
volume-effects of other, perhaps similar, procedures in the hand and assumed that the 
magnitude of effect was equal for needle and open Dupuytren’s surgery. However, when 
assessing whether there is a link between volume and outcomes for a previously 
unexplored surgical procedure, one has to manage with the data available. After 
identifying these associations, a next step could be to examine the extent to which they 
are mediated by type of procedure and/or other surgeon characteristics. Another 
limitation is that we only had access to data from trained, practicing surgeons who 
operated at dedicated hand surgical practice sites. Our findings may therefore not apply 
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this study may be used to better design future prognostic studies as well as to more 
accurately counsel patients about their expected surgical outcomes. For example, we 
found that 10 degrees of worse contracture preoperatively corresponds to 29% lower 
odds of a full release whereas each additional digit treated increases the risk of an 
adverse event by 47%. 
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operated at dedicated hand surgical practice sites. Our findings may therefore not apply 
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to those working in a different context. Finally, although we observed clear associations 
between surgeon volume and outcomes, we cannot prove causality. Higher volume 
surgeons may have had better outcomes because they were more proficient as a result 
of performing more procedures (practice-makes perfect hypothesis) or they may have 
already more proficient and therefore attracted more patients (selective-referral 
hypothesis).1 In the Netherlands, patients with Dupuytren’s disease, however, are mostly 
referred by family practitioners, and we believe referrals to depend more on proximity of 
services rather than the recognition of surgeon’s outcomes, making the first explanation 
more likely. 
Surgical outcomes and how often a surgeon performs a procedure will always 
vary.10 In this study among fully trained practicing surgeons performing Dupuytren’s 
surgery, surgeon volume varied widely, and a higher volume was associated with less 
residual contracture, a higher probability of a full release, and a lower risk of adverse 
events. These findings imply that increasing a surgeon’s procedure volume provides an 
opportunity for improving their outcomes in Dupuytren’s surgery.  The insights about the 
relative extent to which procedure volume affects outcomes is also critical to informing 
the discussions concerning optimization of provider-related factors and the proposed 
pros and cons of regionalization of Dupuytren’s disease care.  
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to those working in a different context. Finally, although we observed clear associations 
between surgeon volume and outcomes, we cannot prove causality. Higher volume 
surgeons may have had better outcomes because they were more proficient as a result 
of performing more procedures (practice-makes perfect hypothesis) or they may have 
already more proficient and therefore attracted more patients (selective-referral 
hypothesis).1 In the Netherlands, patients with Dupuytren’s disease, however, are mostly 
referred by family practitioners, and we believe referrals to depend more on proximity of 
services rather than the recognition of surgeon’s outcomes, making the first explanation 
more likely. 
Surgical outcomes and how often a surgeon performs a procedure will always 
vary.10 In this study among fully trained practicing surgeons performing Dupuytren’s 
surgery, surgeon volume varied widely, and a higher volume was associated with less 
residual contracture, a higher probability of a full release, and a lower risk of adverse 
events. These findings imply that increasing a surgeon’s procedure volume provides an 
opportunity for improving their outcomes in Dupuytren’s surgery.  The insights about the 
relative extent to which procedure volume affects outcomes is also critical to informing 
the discussions concerning optimization of provider-related factors and the proposed 
pros and cons of regionalization of Dupuytren’s disease care.  
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Overview 
This thesis addressed a number of controversial questions and gaps in our knowledge on 
the treatment and outcomes in Dupuytren’s disease. We did so according to 4 specific 
aims. The first aim was to examine the comparative effectiveness of CCH (Clostridium 
Collagenase Histolyticum) injections, PNA (percutaneous needle aponeurotomy) and LF 
(limited fasciectomy) in daily clinical practice. The second aim was to examine the extent 
to which patients were functionally satisfied after LF and determine what predicts this 
satisfaction. The third aim was to evaluate the long-term efficacy of PALF (extensive 
percutaneous needle aponeurotomy with lipofilling) versus LF. The fourth and last aim 
was to clarify the extent to which the operating surgeon, in particular how many 
procedures performed per year, was related to outcomes.  
Hence, we structured this thesis into 4 Parts: 1. comparative effectiveness, 2. 
patient satisfaction, 3. Long-term comparative efficacy of PALF, and 4. volume and 
outcomes. In this chapter, we summarize and discuss each part, followed by a general 
discussion and future perspectives. 
 
Part I. Comparative effectiveness  
The myriad of existing treatment options for Dupuytren’s contracture highlight the lack 
of a single, optimal, treatment technique that fully meets the needs of every patient.1 
Each technique has proposed unique pros and cons. What defines optimal varies from 
patient to patient, depending on clinical disease manifestation, functional limitations, 
and their needs and expectations.2 Given the uncertainty about the effectiveness of all 
existing treatments relative to eachother, an evaluation of the results of the most 
popular techniques (LF, PNA and CCH) was urgently needed to clarify this issue.3 
 
PNA versus LF 
In Chapter 2, we compared the results between PNA and LF.4 Outcomes assessed 
included the degree of total residual contracture, MHQ scores, and complications. To 
account for differences in baseline characteristics between treatment groups we applied 
inverse-probability weighing. This novel statistical approach eliminates selection bias due 
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to such differences by weighing each patient based on their probability of receiving PNA 
or LF given known cofactors.5 This probability is expressed as a propensity score.  
  After propensity score-based inverse probability weighing, 78 PNA and 103 LF 
patients who were very similar at baseline remained for the outcome comparison. The 
degree of total residual contracture at follow-up (6-12 weeks) was not significantly 
different (PNA, 21 degrees; LF, 18 degrees). However, the PNA group showed a lower 
mild complication rate (PNA, 5.2 percent; LF, 24.3 percent) and reported significantly 
larger increases in the MHQ scores of satisfaction, work performance, ADL, and overall 
hand function. 
 The authors of the only randomized clinical trial comparing the efficacy of LF and 
PNA suggested the appropriateness of PNA for mild contractures.6 The findings of our 
study, which are based on data gathered as part of standard practice, reinforce that, for 
such cases, PNA can be as effective as LF at reducing contractures in the short-term – at 
a lower risk of complications.  
  
CCH versus LF 
Large, placebo-controlled studies have demonstrated the efficacy and safety of 
injectable CCH for Dupuytren’s contracture.7-12 In some countries, CCH is now increasingly 
accepted as an alternative to surgery in select patients.13 To assess the comparative 
effectiveness of CCH in actual practice, we designed a study (Chapter 3) assessing the 
treatment versus LF – the current surgical standard.14 Outcomes assessed included the 
degree of residual contracture, MHQ scores, and complications assessed at 6-12 weeks 
after surgery or the last injection. In this study, we analyzed affected MCP joints 
separately from PIP joints because the latter tend to have poorer outcomes. Prior to 
these outcome comparisons, we applied propensity score analysis to account for 
differences between the two treatment groups.  
In the 132 matched patients who underwent treatment (n = 66 CCH or n=66 LF), 
we found that the degree of residual contracture for affected MCP joints was not 
significantly different (13 degrees versus 6 degrees; p = 0.095). Affected PIP joints 
showed worse residual contracture in the CCH group as compared with LF group (25 
degrees versus 15 degrees; p = 0.010). However, CCH was associated with fewer serious 
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effectiveness of CCH in actual practice, we designed a study (Chapter 3) assessing the 
treatment versus LF – the current surgical standard.14 Outcomes assessed included the 
degree of residual contracture, MHQ scores, and complications assessed at 6-12 weeks 
after surgery or the last injection. In this study, we analyzed affected MCP joints 
separately from PIP joints because the latter tend to have poorer outcomes. Prior to 
these outcome comparisons, we applied propensity score analysis to account for 
differences between the two treatment groups.  
In the 132 matched patients who underwent treatment (n = 66 CCH or n=66 LF), 
we found that the degree of residual contracture for affected MCP joints was not 
significantly different (13 degrees versus 6 degrees; p = 0.095). Affected PIP joints 
showed worse residual contracture in the CCH group as compared with LF group (25 
degrees versus 15 degrees; p = 0.010). However, CCH was associated with fewer serious 
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complications and larger improvements in the MHQ scores of satisfaction, ADL, and work 
performance.  
In this study comparing CCH to LF for Dupuytren’s contracture, the short-term 
contracture correction achieved was similar among the treatment groups. Hand function 
recovers faster after CCH. CCH therefore requires consideration for patients as a 
treatment alternative to LF, particularly for those who seek a minimally invasive 
treatment option and a more rapid return to use of their hand.  
 
CCH versus PNA 
In Chapter 4, we report the results of CCH compared with PNA, which remains the most 
popular minimally invasive treatment for Dupuytren’s contracture.15 Because relative 
changes in outcomes may be more meaningful to patients than absolute outcomes, we 
assessed the extent both treatments improved outcomes.16 In addition to early objective 
outcomes, we also assessed the change in MHQ scores through 1 year-follow-up.17,18  
Among the 130 patients (93% Tubiana I or II) who were matched based on their 
propensity scores (n=46 PNA and n=84 CCH), post-intervention improvement in 
contracture was similar: 26 degrees (65% improvement from baseline) for PNA vs. 31 
degrees (71%) for CCH for affected MCP joints (p = 0.163). For affected PIP joints, this 
improvement was 16 degrees (50% improvement) vs. 17 degrees (42%; p = 0.395), 
respectively. No serious complications were noted in either of the two treatment groups. 
Of the mild adverse effects, only skin fissures and sensory disturbances were seen in 
both groups. Through 1-year follow-up, patients reported similar improvements in the 
overall MHQ score (PNA, 5.3 points vs. CCH, 4.9 points; p = 0.912). 
 In Tubiana grade I or II patients (mild cases), CCH and PNA appeared equally 
effective at reducing contractures. Both treatments improve overall hand function, 
which was maintained through 1-year follow-up.  
 
Part 2. Patient satisfaction  
Most surgeons continue to regard open LF as the surgical standard of care, particularly in 
cases of PIP joint involvement and advanced cases. The previous chapters confirm that 
LF effectively reduces contractures at an reasonable complication rate. Yet outcomes 
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that seem good from a clinician’s perspective may not necessarily satisfy patients. In 
Chapter 5, we examined patient satisfaction with hand function after LF, and identified 
preoperative factors that predicted this satisfaction.19  
 Demographics and disease-specific factors were assessed from a prospective 
cohort of 194 patients treated with LF. After patients were classified into a satisfied vs. 
unsatisfied category using the question of the MHQ pertaining to satisfaction with hand 
function, multivariate regression modeling identified predictors of patient satisfaction. 
At a mean 10 months (range, 6 to 12) after fasciectomy, 84 percent were satisfied with 
their hand function. In multivariate analyses adjusting for the significant effects of the 
degree of postoperative residual contracture (and complications, a higher preoperative 
hand appearance subscore and male gender was associated with a higher likelihood of 
becoming satisfied after fasciectomy. Other demographic- and clinical factors were not 
independently predictive of patient satisfaction.  
The independent relations between objective outcomes and patient satisfaction 
identified in this study emphasize the importance of complication prevention and full 
releases from the patient perspective. The finding that the extent patients value the 
appearance of their hand predicts satisfaction shows that restoration of a normal hand 
appearance may be important to Dupuytren’s disease patients. 
 
Part 3. Long-term comparative efficacy of PALF 
Attempting to improve on existing treatment options for Dupuytren’s contracture, 
Hovius and Khouri introduced extensive percutaneous needle aponeurotomy with 
lipofilling (PALF) in 2011.20 In this hybrid technique, a more elaborate PNA technique is 
applied where multiple to hundreds of 1-2 mm deep perforations through the skin are 
made with a needle. These then disrupt the structural integrity of the underlying fascial 
structures, allowing them to lengthen under tension. In contrast to the few discrete 
transverse fasciotomies in classical aponeurotomy, the large number of perforations and 
cuts creates a mesh that is permissive to fat grafting in addition to releasing the cords. 
Autologous lipoaspirate is then grafted into the subcutaneous dissection plane.21  
The initial results of a single-blinded, multicenter, randomized clinical in which this 
PALF is compared with standard limited fasciectomy have been published previously.22 
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treatment option and a more rapid return to use of their hand.  
 
CCH versus PNA 
In Chapter 4, we report the results of CCH compared with PNA, which remains the most 
popular minimally invasive treatment for Dupuytren’s contracture.15 Because relative 
changes in outcomes may be more meaningful to patients than absolute outcomes, we 
assessed the extent both treatments improved outcomes.16 In addition to early objective 
outcomes, we also assessed the change in MHQ scores through 1 year-follow-up.17,18  
Among the 130 patients (93% Tubiana I or II) who were matched based on their 
propensity scores (n=46 PNA and n=84 CCH), post-intervention improvement in 
contracture was similar: 26 degrees (65% improvement from baseline) for PNA vs. 31 
degrees (71%) for CCH for affected MCP joints (p = 0.163). For affected PIP joints, this 
improvement was 16 degrees (50% improvement) vs. 17 degrees (42%; p = 0.395), 
respectively. No serious complications were noted in either of the two treatment groups. 
Of the mild adverse effects, only skin fissures and sensory disturbances were seen in 
both groups. Through 1-year follow-up, patients reported similar improvements in the 
overall MHQ score (PNA, 5.3 points vs. CCH, 4.9 points; p = 0.912). 
 In Tubiana grade I or II patients (mild cases), CCH and PNA appeared equally 
effective at reducing contractures. Both treatments improve overall hand function, 
which was maintained through 1-year follow-up.  
 
Part 2. Patient satisfaction  
Most surgeons continue to regard open LF as the surgical standard of care, particularly in 
cases of PIP joint involvement and advanced cases. The previous chapters confirm that 
LF effectively reduces contractures at an reasonable complication rate. Yet outcomes 
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that seem good from a clinician’s perspective may not necessarily satisfy patients. In 
Chapter 5, we examined patient satisfaction with hand function after LF, and identified 
preoperative factors that predicted this satisfaction.19  
 Demographics and disease-specific factors were assessed from a prospective 
cohort of 194 patients treated with LF. After patients were classified into a satisfied vs. 
unsatisfied category using the question of the MHQ pertaining to satisfaction with hand 
function, multivariate regression modeling identified predictors of patient satisfaction. 
At a mean 10 months (range, 6 to 12) after fasciectomy, 84 percent were satisfied with 
their hand function. In multivariate analyses adjusting for the significant effects of the 
degree of postoperative residual contracture (and complications, a higher preoperative 
hand appearance subscore and male gender was associated with a higher likelihood of 
becoming satisfied after fasciectomy. Other demographic- and clinical factors were not 
independently predictive of patient satisfaction.  
The independent relations between objective outcomes and patient satisfaction 
identified in this study emphasize the importance of complication prevention and full 
releases from the patient perspective. The finding that the extent patients value the 
appearance of their hand predicts satisfaction shows that restoration of a normal hand 
appearance may be important to Dupuytren’s disease patients. 
 
Part 3. Long-term comparative efficacy of PALF 
Attempting to improve on existing treatment options for Dupuytren’s contracture, 
Hovius and Khouri introduced extensive percutaneous needle aponeurotomy with 
lipofilling (PALF) in 2011.20 In this hybrid technique, a more elaborate PNA technique is 
applied where multiple to hundreds of 1-2 mm deep perforations through the skin are 
made with a needle. These then disrupt the structural integrity of the underlying fascial 
structures, allowing them to lengthen under tension. In contrast to the few discrete 
transverse fasciotomies in classical aponeurotomy, the large number of perforations and 
cuts creates a mesh that is permissive to fat grafting in addition to releasing the cords. 
Autologous lipoaspirate is then grafted into the subcutaneous dissection plane.21  
The initial results of a single-blinded, multicenter, randomized clinical in which this 
PALF is compared with standard limited fasciectomy have been published previously.22 
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Eighty patients were randomly assigned to each treatment group. Through 1-year follow-
up of this, almost full release of affected MCP joints was obtained in both groups, 
whereas some residual contracture remained at the level of the PIP joint. Patients 
undergoing PALF resumed normal use of the hand more rapidly. In Chapter 6, we report 
the 5-year results of this study, focusing on long-term recurrence rates. Thirty-one PALF 
and 21 LF patients participated in this extended post-trial follow-up assessment. At 5 
years, more affected joints in the PALF group than in the LF group met our primary 
composite endpoint for recurrence (74% vs. 39%, p = 0.002).  
Hence, we conclude that PALF is safe, provides a quick full recovery with mild 
complications, effectively reduces contractures, and has a good 1-year recurrence rate. 
However, the technique unfortunately does not provide as durable corrections over time 
as does LF. 
 
Part 4. Volume and outcomes 
Practice makes perfect; Luft and colleagues first highlighted this common concept by 
demonstrating that the number of procedures a surgeon performs (surgeon  
procedure volume) affected his or her outcomes.23 For a variety of major complex 
surgical procedures, such relations between volume and outcomes are now 
established24-29, which have had substantial policy and clinical implications.30 In Chapter 7, 
we examined whether similar volume-outcome relations existed for Dupuytren’s surgery 
in practicing hand surgeons.  
Using data from 6 hand surgical practice sites in the Netherlands, we clarified the 
relations between surgeon volume and three clinical outcomes in 588 patients who 
underwent a surgical intervention (PNA or LF) for Dupuytren’s contracture. Annual 
procedure volume ranged from 4-86 procedures per year, and was related to all three 
outcomes in a linear fashion. After rigorous adjustment for a wide range of patient- and 
treatment factors, performing 10 additional procedures per year was associated with 
nearly 0.8 degrees of less residual contracture (p=0.002), 9% higher odds of attaining a 
full release (p=0.037), and 11% lower odds of experiencing an adverse event (p<0.001). 
Compared with patient-related factors, the effect of surgeon volume on clinical 
outcomes was relatively small, however. 
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In conclusion, the number of procedures performed for Dupuytren’s surgery per 
year varied among practicing surgeons. Higher procedure volume was independently 
associated with improved clinical outcomes, that is, with less residual contracture, a 
higher probability of a full release, and a lower risk of adverse events. However, the 
effect of procedure volume on outcomes was smaller than that of a variety of patient 
factors. 
 
General discussion, limitations, and future perspectives  
Considering the studies in Part 1 (Comparative Effectiveness of CCH, PNA and LF) 
together, the primary finding was that while certain outcomes differed across the three 
techniques others did not.4,14,15 For both functional recovery and complications, CCH and 
PNA were superior to LF in the short-term. As compared with LF, CCH resulted in fewer 
serious complications and larger improvements in the MHQ scores of satisfaction, ADL, 
and work performance examined within 3 months of treatment. PNA also resulted in 
larger improvements in the same MHQ scores and had a lower mild complication rate 
than LF. In contrast, the degree of short-term contracture correction achieved in daily 
practice was comparable for all three treatments with the exception that affected PIP 
joints had a relatively small but significantly worse residual contracture after CCH than 
after LF. These results underline the usefulness of CCH and PNA for less advanced cases, 
in particular for those seeking the benefits of a minimally invasive treatment.  
In Part 2, we focused on patient satisfaction after LF and the influence of initial 
correction, complications, and preoperative factors on this satisfaction.19 The majority of 
patients (84%) were satisfied with their hand function after surgery. We found, after 
accounting for the positive effect of better correction and avoidance of complications on 
patient satisfaction, that a higher preoperative MHQ hand appearance score and male 
gender predicted a higher level of satisfaction. The link between patient satisfaction with 
the degree of correction and complications highlights the importance of these two 
objective outcomes from the patient perspective as well as provides some reassurance 
regarding the validity of patient satisfaction as an outcome in Dupuytren’s disease. The 
independent link between hand appearance and satisfaction suggests that restoration of 
a normal hand appearance may be relevant to patients. After all, the hand is considered 
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than LF. In contrast, the degree of short-term contracture correction achieved in daily 
practice was comparable for all three treatments with the exception that affected PIP 
joints had a relatively small but significantly worse residual contracture after CCH than 
after LF. These results underline the usefulness of CCH and PNA for less advanced cases, 
in particular for those seeking the benefits of a minimally invasive treatment.  
In Part 2, we focused on patient satisfaction after LF and the influence of initial 
correction, complications, and preoperative factors on this satisfaction.19 The majority of 
patients (84%) were satisfied with their hand function after surgery. We found, after 
accounting for the positive effect of better correction and avoidance of complications on 
patient satisfaction, that a higher preoperative MHQ hand appearance score and male 
gender predicted a higher level of satisfaction. The link between patient satisfaction with 
the degree of correction and complications highlights the importance of these two 
objective outcomes from the patient perspective as well as provides some reassurance 
regarding the validity of patient satisfaction as an outcome in Dupuytren’s disease. The 
independent link between hand appearance and satisfaction suggests that restoration of 
a normal hand appearance may be relevant to patients. After all, the hand is considered 
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to be the most visible part of the body only second to the face, and fulfils a crucial role in 
social interaction, functioning, physical expression.31,32 These findings highlight that 
providers should not only assess the detrimental impact flexion deformities can have on 
the physical well-being of Dupuytren’s disease patients, but also their possible impact on 
patients’ psychological well-being. 
In part 3, we compared the long-term efficacy of PALF versus LF and found that at 
5-years significantly more affected joints after PALF had a recurrent contracture than 
after LF (PALF, 74% vs. LF, 39%). Given the earlier results of this RCT, we concluded that 
PALF is safe and effective at reducing contractures and has a reasonable long-term 
recurrence rate. The recurrence rate for PALF seems lower than what has previously 
been reported for classical PNA (85%) by van Rijssen and Werker et al. but was not as 
good as anticipated. Given these findings, we feel that this technique holds a unique 
position among the other available treatment options in being most suited for patients 
who seek a fast recovery, low risk of complications and a long-term recurrence rate that 
lies between that of LF and classical PNA, while it can be used to treat multiple rays at 
once. 
 In all previously mentioned studies, it became evident that objective clinical 
outcomes varied widely across individual patients independent from the treatment 
technique used. In Part 4, we sought to clarify whether the number of procedures a 
surgeon performs per year (surgeon volume) could explain this variation in individual 
patient outcomes. Surgeon volume varied considerably, and a higher volume was 
associated with three objective clinical outcomes. Performing 10 additional procedures 
per year was associated with nearly 1 degree less residual contracture, 9% higher odds of 
attaining a full release, and 11% lower odds of experiencing a complication. Given the 
higher risk of early recurrence in patients with a poor initial correction ref, these findings 
may have significant long-term clinical implications for patients. The independent link 
between volume and complications suggests an opportunity for surgeons to minimize 
their complications by increasing their surgical volume. However, the impact of surgical 
volume on these three outcomes was smaller than that of various patient characteristics. 
This emphasizes the importance of proper patient selection and adequate timing of 
treatment in achieving optimal outcomes in Dupuytren’s disease.  
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 The studies in this thesis have limitations that are worth considering. First, 
treatment assignment in the comparative effectiveness studies in Part 1 was not random. 
This leaves the possibility of confounding by indiciation bias, which could have influenced 
our results. However, to minimize the risk of bias due to non-random treatment 
assignment, we applied propensity score analyses.33 This approach also allowed us to use 
data that were gathered as part of standard practice to make valid comparisons of 
treatments using one of the largest cohorts of Dupuytren’s disease patients studied. Our 
findings may therefore be more externally valid (i.e. more broadly generalizable) than 
those obtained from strictly controlled clinical trials. In Part 2, we focused specifically on 
satisfaction with hand function, whereas patient satisfaction may be subdivided in other 
subdomains such as satisfaction with proximity of services, the actual treatment given, 
or the clinicians involved. We decided upon satisfaction with hand function because the 
primary goal of treatment in Dupuuytren’s disease is to restore hand function. 
Nevertheless, all other domains of satisfaction may be important in judging the quality of 
Dupuytren’s disease care, and the extent to which they are related to objective clinical 
outcomes is an important future research topic. Third, the follow-up duration in nearly all 
our studies (with the exception of Part 3) did not allow for reliable assessment of long-
term results of the treatments examined while long-term outcomes may be just as 
important to patients as short-term outcomes when considering treatments.34 Our 
studies therefore do not provide evidence on the long-term comparative effectiveness of 
CCH, PNA and LF. Fortunately, several clinical trials are currently underway that aim to 
address this knowledge gap.35,36 Finally, our volume-outcome study in Part 4 only 
investigated the relations between surgeon procedure volume and three provider-
oriented outcomes. Clarification of the possible relations between procedure volume 
more subjective outcomes may provide us with unique perspectives and opportunities 
on how we can optimize Dupuytren’s disease care from the patient perspective. 
 
Future perspectives 
The need for more comparative studies is clear, in particular RCT’s that help to further 
establish the comparative effectiveness of current treatments for Dupuytren’s disease. 
However, the person who plans to undertake such a trial is bound to face practical, 
8Chapter 8	
	 148	
to be the most visible part of the body only second to the face, and fulfils a crucial role in 
social interaction, functioning, physical expression.31,32 These findings highlight that 
providers should not only assess the detrimental impact flexion deformities can have on 
the physical well-being of Dupuytren’s disease patients, but also their possible impact on 
patients’ psychological well-being. 
In part 3, we compared the long-term efficacy of PALF versus LF and found that at 
5-years significantly more affected joints after PALF had a recurrent contracture than 
after LF (PALF, 74% vs. LF, 39%). Given the earlier results of this RCT, we concluded that 
PALF is safe and effective at reducing contractures and has a reasonable long-term 
recurrence rate. The recurrence rate for PALF seems lower than what has previously 
been reported for classical PNA (85%) by van Rijssen and Werker et al. but was not as 
good as anticipated. Given these findings, we feel that this technique holds a unique 
position among the other available treatment options in being most suited for patients 
who seek a fast recovery, low risk of complications and a long-term recurrence rate that 
lies between that of LF and classical PNA, while it can be used to treat multiple rays at 
once. 
 In all previously mentioned studies, it became evident that objective clinical 
outcomes varied widely across individual patients independent from the treatment 
technique used. In Part 4, we sought to clarify whether the number of procedures a 
surgeon performs per year (surgeon volume) could explain this variation in individual 
patient outcomes. Surgeon volume varied considerably, and a higher volume was 
associated with three objective clinical outcomes. Performing 10 additional procedures 
per year was associated with nearly 1 degree less residual contracture, 9% higher odds of 
attaining a full release, and 11% lower odds of experiencing a complication. Given the 
higher risk of early recurrence in patients with a poor initial correction ref, these findings 
may have significant long-term clinical implications for patients. The independent link 
between volume and complications suggests an opportunity for surgeons to minimize 
their complications by increasing their surgical volume. However, the impact of surgical 
volume on these three outcomes was smaller than that of various patient characteristics. 
This emphasizes the importance of proper patient selection and adequate timing of 
treatment in achieving optimal outcomes in Dupuytren’s disease.  
Summary and Discussion 
	
 149	
 The studies in this thesis have limitations that are worth considering. First, 
treatment assignment in the comparative effectiveness studies in Part 1 was not random. 
This leaves the possibility of confounding by indiciation bias, which could have influenced 
our results. However, to minimize the risk of bias due to non-random treatment 
assignment, we applied propensity score analyses.33 This approach also allowed us to use 
data that were gathered as part of standard practice to make valid comparisons of 
treatments using one of the largest cohorts of Dupuytren’s disease patients studied. Our 
findings may therefore be more externally valid (i.e. more broadly generalizable) than 
those obtained from strictly controlled clinical trials. In Part 2, we focused specifically on 
satisfaction with hand function, whereas patient satisfaction may be subdivided in other 
subdomains such as satisfaction with proximity of services, the actual treatment given, 
or the clinicians involved. We decided upon satisfaction with hand function because the 
primary goal of treatment in Dupuuytren’s disease is to restore hand function. 
Nevertheless, all other domains of satisfaction may be important in judging the quality of 
Dupuytren’s disease care, and the extent to which they are related to objective clinical 
outcomes is an important future research topic. Third, the follow-up duration in nearly all 
our studies (with the exception of Part 3) did not allow for reliable assessment of long-
term results of the treatments examined while long-term outcomes may be just as 
important to patients as short-term outcomes when considering treatments.34 Our 
studies therefore do not provide evidence on the long-term comparative effectiveness of 
CCH, PNA and LF. Fortunately, several clinical trials are currently underway that aim to 
address this knowledge gap.35,36 Finally, our volume-outcome study in Part 4 only 
investigated the relations between surgeon procedure volume and three provider-
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financial, and even ethical challenges. One of the biggest challenges in recruitment, in 
our experience, is that patients are usually reluctant to participate in a trial if they risk 
randomisation to an entirely different technique (e.g. injection with Collagenase versus 
surgical fasciectomy). The studies in Part I underscored propensity score analyses as a 
useful tool in assessing the comparative effectiveness of different treatment techniques 
for Dupuytren’s disease. Considering the ever-expanding number of treatment strategies 
and questions about their effectiveness, we believe that future studies that make 
appropriate use of such statistical techniques and observational, real-world data will be 
of increasing importance.  
Disease manifestation in Dupuytren’s disease is very heterogeneous. One of the 
problems encountered in practice as a result of this is the difficulty of applying averaged 
study results to individual patients. For example, using the findings in Chapter 4 to 
counsel patients who are considering CCH and PNA by stating that, on average, MCP 
contractures improve by 71% after CCH as compared with 65% for PNA is probably the 
best we can do from an evidence based medicine perspective. However, this may be 
quite inaccurate in many cases. A critical question that remains is whether the 
performance of more comparative studies provides the most effective approach of 
solving this issue of applying global evidence (“average treatment effects” measured as 
population means) to individual cases (individual patients who may differ from the 
population mean).  
Clinicians are obviously aware that the same procedure can have different effects 
on different patients, and take multiple patient factors into account when counselling 
patients about possible outcomes. However, they do so in a largely, subjective and, 
mostly implicit, manner. Prognostic research has the potential to change the way this is 
done by proving tools that allow for a more objective, accurate estimation of the 
probability of certain outcomes. In contrast to comparative studies that focus on the 
effect of a single factor (difference between two treatments) on outcomes, prognostic 
studies aim to accurately predict outcomes from multiple factors. The previously 
mentioned tools have been given various names such as prediction model, prediction 
rule and prognostic models.37-39 Many of such tools are now ingrained in the daily 
practice of providers across various medical and surgical specialties because of the 
prognostic value they provide. The Adjuvant! Online prediction model for breast cancer 
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recurrence is perhaps one of the best examples of how such a tool can fundamentally 
change and improve the way pretreatment consultations and decision making processes 
take place.40-42 If efforts are undertaken to formalize outcome-prediction in Dupuytren’s 
disease, we are confident that the same can be achieved for this population. Future 
investigators who plan to travel this road are recommended to use the secondary 
findings from Chapter 8 in their study design. 
It seems that Collagenase, needle aponeurotomy, fat grafting, and fasciectomy 
will all have a role in the future treatment of Dupuytren’s disease. Fortunately, 
investigators will be able to rely on both traditional and newer study designs to help 
unravel the best indications of each technique. Our findings support the value of 
Collagenase injection and needle aponeurotomy as first-line treatments in less advanced 
cases. Starting with these two minimally invasive techniques in such cases is an 
appropriate approach because of similar early outcomes in comparison with open 
surgery. Fasciectomy seems best reserved for advanced cases (i.e. severe diathesis, long-
standing PIP contractures, multiray and/or recurrent disease) and/or those who seek the 
most durable corrections. Ultimately, each patient is unique and has his or her own 
concerns, needs, and expectations from treatment.  Which treatment is most 
appropriate probably depends as much on these subjective factors as on similarities or 
differences in clinical outcomes. Until we find a cure for this chronic disease, the quest 
for more effective and safer treatment strategies continues – as it has for many decades.  
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Dit proefschrift addresseert een aantal controversiele vraagstukken over de behandeling 
van de ziekte van Dupuytren. We hebben dit gedaan aan de hand van een viertal 
doelstellingen. Het eerste doel was om de relatieve effectiviteit van Collagenase injecties 
(CCH), percutane naaldfasciotomie (PNA) en selectieve fasciëctomie (LF) te beoordelen 
in de dagelijkse praktijk (Deel 1). Als tweede hebben wij de mate waarin patiënten na LF 
tevreden zijn bepaald én welke factoren hierop van invloed waren onderzocht (Deel 2). 
Onze derde doelstelling was om de lange termijn resultaten van extensieve percutane 
naaldaponeurotomie met lipofilling (PALF) te onderzoeken (Deel 3). Ons vierde en 
laatste doel was om te verhelderen in welke mate de chirurg, in het bijzonder hoeveel 
ingrepen hij of zij per jaar uitvoert voor Dupuytren, van invloed is op klinische 
behandeluitkomsten (deel 4). 
De huidige behandelingen voor de ziekte van Dupuytren bieden bepaalde voor en 
nadelen. In hoofdstuk 2 vergeleken we PNA en LF op basis van de mate van 
restkromstand, verbetering in handfunctie (beoordeeld met de MHQ) en complicaties na 
behandeling. We maakten gebruik van propensity score-gebaseerde inverse probility 
weighing (IPW) om te corrigeren voor eventuele selectiebias. Na IPW bleven er 78 PNA 
en 103 LF vergelijkbare patiënten over. Deze twee groepen hadden geen significante 
verschillen in restkromstand na 6-12 weken follow-up (PNA, 21 graden LF, 18 graden). 
PNA had minder complicaties en resulteerde in significant grotere toenames in de MHQ 
scores van tevredenheid, werkprestaties en algemene hand functie. Deze resultaten 
laten zien dat PNA, op korte termijn, net zo effectief kan zijn als LF in het corrigeren van 
contracturen bij geselecteerde patiënten terwijl het risico op complicaties kleiner is. 
In hoofdstuk 3 vergeleken we CCH met LF. In sommige landen wordt CCH in 
toenemende mate als alternatief op chirurgie gezien. We vergeleken beide 
behandelingen op basis van dezelfde uitkomsten als in het vorige hoofdstuk. Ook hier 
maakten we gebruik van propensity score analyses om te corrigeren voor baseline 
verschillen in beide groepen voor de behandeling. Bij de 132 propensity-score 
gematchede patienten (N=66 CCH en N=66 LF) vonden we dat de mate van 
restkromstand voor aangedane MCP gewrichten tussen beide behandelingen niet 
significant verschillend was (13 graden vs 6 graden, p=0.095). Aangedane PIP gewrichten 
in de CCH groep hadden echter meer restkromstand dan die in de LF groep (25 graden vs 
15 graden, p=0.010). CCH resulteerde in minder ernstige complicaties en meer toename in 
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de tevredenheid, ADL en werkprestatie subdomein scores van de MHQ. Deze resultaten 
laten zien dat CCH een effectief alternatief kan zijn voor LF, met name voor patienten 
met een aangedaan MCP gewricht én de voordelen van een minder invasieve ingreep 
zoeken.  
In hoofdstuk 4 vergeleken we CCH met PNA – waarschijnlijk de meest gebruikte 
minimaal invasieve behandeling op dit moment voor de ziekte van Dupuytren. Onder de 
130 (93% Tubiana I of II) patiënten die vergelijkbaar waren (N=46 PNA vs N=84 CCH) was 
na behandeling de mate van verbetering in kromstand vergelijkbaar in beide groepen 
(65% verbetering voor PNA versus 71% voor CCH) voor MCP contracturen. Dit was ook het 
geval voor PIP contracturen (50% voor CCH versus 42% voor PNA). We vonden geen 
ernstige complicaties, en patiënten rapporteerden een vergelijkbare verbetering in de 
MHQ totaal score gedurende 1 jaar follow-up. Deze resultaten laten zien dat CCH en PNA 
vergelijkbaar zijn wat betreft hun effectiviteit in het corrigeren van de kromstand, 
verbeteren van hand functie en complicaties. 
In hoofdstuk 5 bepaalden we patiënttevredenheid met hand functie na LF, en 
onderzochten wij welke preoperatieve factoren hierop van invloed waren. Nadat 
patiënten gecategoriseerd waren als tevreden of ontevreden met behulp van het 
specifieke item van de MHQ vragenlijst die over tevredenheid met handfunctie gaat, 
hebben we multivariabele regressie gebruikt om de voorspellende factoren te 
identificeren. Van alle patiënt was 84% tevreden met hun hand functie. Rekening 
houdend met de significante invloed van de mate van restkromstand én het optreden 
van een complicatie op tevredenheid, vonden we dat een hogere preoperatieve 
waardering voor het uiterlijk van de hand en het mannelijk geslacht gerelateerd waren 
aan een hogere kans om tevreden te zijn. Deze resultaten suggeren dat het herstel van 
het uiterlijk van de hand bij de ziekte van Dupuytren belangrijk is voor patienten. Ook 
helpt het inschatten in welke mate het legitiem is om patiënttevredenheid als 
uitkomstmaat voor kwaliteit te gebruiken bij de ziekte van Dupuytren. 
In hoofdstuk 6 onderzochten wij lange termijn resultaten van PALF in een RCT. In 
totaal werden 80 patienten gerandomiseerd naar PALF of LF. Op 5-jaar vonden wij dat 
significant meer aangedane gewrichten in de PALF groep dan in de LF groep voldeden 
aan onze samengestelde primaire uitkomstmaat voor recidief (PALF 74% versus 39%). Wij 
beschouden PALF als een innovatieve en veilige techniek die leidt tot een snel herstel 
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aan onze samengestelde primaire uitkomstmaat voor recidief (PALF 74% versus 39%). Wij 
beschouden PALF als een innovatieve en veilige techniek die leidt tot een snel herstel 
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tegen een laag complicatierisico. De lange termijn-resultaten van PALF zijn echter wat 
teleurstellender dan gehoopt. 
In hoofdstuk 7 onderzochten we of er een relatie bestaat tussen hoeveel ingrepen 
een chirurg op jaarbasis uitvoert voor de ziekte van Dupuytren en de 
behandeluitkomsten. Voor veel verschillende algemeen chirurgische ingrepen is 
ondertussen een sterk verband aangetoond. Voor Dupuytren chirurgie is dit echter niet 
eerder onderzocht en onbekend. We hebben dit bij 588 patiënten onderzocht. Na 
rekening te houden met een diversiteit aan patient-factoren, vonden we dat het 
uitvoeren van 10 extra ingrepen op jaarbasis leidt tot bijna 1 graad minder restkromstand, 
9% meer kans op een volledige release, én 11% minder kans op complicaties. De invloed 
van operatief volume is echter klein ten opzichte van de effecten van patiënt-factoren op 
deze uitkomsten.  
De bevindingen van de studies in Deel 1 laten zien dat CCH, PNA en LF - bij 
patienten die geschikt zijn voor alle drie de behandelingen - even goede verbetering van 
de kromstand kan worden bereikt op korte termijn. Hand functie herstelt sneller na CCH 
en PNA in vergelijking tot LF, en ernstige complicaties komen minder vaak voor bij beide 
minimaal invasieve behandelingen.  De resultaten in Deel 2 laten zien dat objectieve 
uitkomstmaten zoals restkromstand of complicaties van invloed zijn op de tevredenheid 
met de hand functie, maar dat deze patiënttevredenheid ook afhangt van hoe iemand 
zijn of haar aangedane hand eruit vindt zien.  De hand is tenslotte, na het gezicht, het 
meest zichtbare lichaamsdeel en vervult een cruciale rol in het dagelijks functioneren en 
sociale interactie. Dit suggereert dat flexiecontracturen niet alleen functioneel 
beperkend zijn maar ook een negatieve invloed kunnen hebben op de psychische 
gesteldheid van patiënten met de ziekte van Dupuytren.  De resultaten in Deel 3 laten 
zien dat PALF veilig en effectief is en geassocieerd is met een acceptabele lange-termijn 
recidiefkans. De recidiefkans van 74% lijkt lager dan dat van traditionele naaldfasciotomie 
technieken. Derhalve zijn we van mening dat PALF een unieke plek in de behandeling van 
de ziekte van Dupuytren inneemt.  De resultaten van Deel 4 laten zien dat individuele 
patiëntuitkomsten erg uiteenlopen, en daarnaast dat hoe vaak een chirurg Dupuytren 
opereert van invloed is op zowel de mate van contractuurcorrectie als complicaties. Deze 
bevinding laat zien dat het verhogen van het operatief volume een strategie kan zijn om 
uitkomsten te verbeteren, zelfs bij ervaren gecertificeerde handchirurgen. Patiënt 
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factoren hebben echter een nog grotere impact op deze uitkomsten wat het belang van 
zorgvuldige patiëntselectie en timing van een operatie benadrukt. 
De studies in dit proefschrift hebben tekortkomingen. Onze vergelijkende studies 
waren niet gerandomiseerd waardoor er risico is op zogenaamde “verborgen bias” (bias 
door factoren die je niet hebt gemeten die wel van invloed zijn op uitkomsten). We 
hebben niet onderzocht in welke mate operatief volume van invloed is op patient-
gerapporteerde uitkomsten wat ons zou helpen het patientperspectief beter te 
begrijpen. Daarnaast was de follow-up duur in de meeste studies kort, waardoor we 
geen uitspraak kunnen doen over de lange-termijn effectiviteit van behandelingen.  
Het is duidelijk dat we meer vergelijkende studies nodig zullen hebben, in het 
bijzonder RCT’s met een lange follow-up duur. Tegelijkertijd zal de onderzoeker die dit 
wil doen geconfronteerd worden met praktische, financiële en ethische kwesties. Wij 
verwachten derhalve een grotere rol voor observationale studies die slim gebruik maken 
van nieuwe statistische methodes en de steeds groter wordende datasets die verzameld 
zijn in de dagelijkse praktijk. De vraag is echter in welke mate inzichten van RCTs en 
dergelijke vergelijkende studies betere zorg voor de individuele patiënt te leveren. Hoe 
de ziekte van Dupuytren zich uit verschilt enorm van patiënt tot patiënt. Het is de vraag 
in welke mate de gemiddelde resultaten van dergelijke studies in de praktijk van 
toepassing zijn op individuele patiënten.  
In tegenstelling tot vergelijkende studies die zich richten op het effect van 1 factor 
op uitkomsten (verschil tussen behandelingen) beogen prognostische studies 
uitkomsten te voorspellen op basis van meerdere factoren. Dergelijke studies kunnen 
tools leveren om artsen helpen accurater en objectiever een inschatting te maken van de 
uitkomsten bij een bepaalde patient. Zulke tools heten ook wel een predictiemodel, 
predictieregel of een prognostisch model. Er zijn legio voorbeelden te geven uit andere 
medische velden waar dergelijke studies de manier waarop patienten worden 
geinformeerd en keuzes worden gemaakt hebben getransformeerd. Wij zijn ervan 
overtuigd dat hetzelfde kan worden bereikt bij de ziekte van Dupuytren. Toekomstige 
onderzoekers die van plan zijn dergelijke initiatieven te ondernemen worden sterk 
geadviseerd de nevenbevindingen van hoofdstuk 8 te gebruiken in hun studieontwerp.  
Het lijkt erop dat Collagenase, fasciotomie, lipofilling én open chirurgie allemaal 
een rol zullen blijven spelen in de behandeling van de ziekte van Dupuytren. Diverse 
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onderzoeksontwerpen zullen nodig zijn om de indicaties van iedere techniek verder te 
verscherpen. De resultaten van dit proefschrift suggereren een aanpak waarin eerst CCH 
of PNA worden geprobeerd, met name bij patiënten met minder ernstige contracturen. 
Hoewel fasciëctomie de minste kans op recidieven geeft is deze behandeling ook het 
meest invasief en risicovol. Open chirurgie kan dus waarschijnlijk het beste worden 
bewaard voor patienten die minder geschikt zijn voor minimaal invasieve behandelingen. 
Uiteindelijk is iedere persoon met de ziekte van Dupuytren uniek met zijn of haar eigen 
zorgen en verwachtingen ten aanzien van een behandeling. Wij hopen dat de beschreven 
resultaten in dit proefschrift patiënten en clinici zal helpen bij het maken van keuzes in de 
behandeling.   
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